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Abstract 
 
Community pharmacies in England provide a variety of services including 
essential services such as the dispensing of medicines, advanced services 
such as Medicine Use Reviews, and enhanced and locally commissioned 
services, for example the minor ailments scheme.  In October 2011 a new 
advanced service called the New Medicine Service (NMS) was introduced.  It 
aimed to improve adherence to newly prescribed medicines for patients with 
certain long term conditions and reduce medicines wastage.  
This thesis aims to evaluate the implementation of the NMS by exploring how 
the service was developed and implemented, identifying both potential and 
actual barriers and facilitators to NMS implementation, investigating the 
proportion of prescription items that are eligible for the service, and 
examining the uptake and provision of the service.   
In order to achieve this several studies were carried out.  Interviews were 
conducted with stakeholders LQYROYHG LQ WKH VHUYLFH¶V development and 
implementation.  Focus groups were conducted with community pharmacists 
complimented by interviews with superintendent pharmacists both before and 
after the introduction of the NMS.  Data regarding the number of prescription 
items eligible for the service were collected in community pharmacies, and an 
analysis of service records for a large national chain of pharmacies was 
carried out. 
The studies determined that there were four stages to the development and 
implementation of the NMS; pre-negotiation, negotiations, the launch phase, 
and post-implementation.  Both community pharmacists and superintendent 
pharmacists were enthusiastic about the potential of the service prior to the 
introduction of the service and anticipated good uptake of the service which 
was confirmed by post-implementation results.  Several barriers were 
identified prior to implementation, the most important of which was the 
payment structure.  Post-implementation results confirmed that the payment 
structure had affected NMS implementation, and direct observations in 
pharmacies, that the opportunity rate to provide the service was nearly half of 
WKHSD\PHQWVWUXFWXUH¶VWKHRUHWLFDOUate.  Analysis of service data showed the 
uptake of the NMS was greater than the uptake of MURs in 2005. 
The findings of this thesis provide policy makers, pharmacy stakeholders, 
community pharmacists, and researchers with knowledge of how pharmacy 
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services are developed. It also provides insights about factors that can 
facilitate or hinder service provision, including pharmacist attitudes towards a 
service, certain service and pharmacy characteristics (such as the ability to 
carry out telephone consultations), company encouragement to provide the 
service, the experience of conducting other pharmacy services, pharmacist 
workload, the accreditation procedure, and the services payment structure.  
These insights can be used to improve IXWXUH SKDUPDF\ VHUYLFHV¶
implementation. 
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Chapter 1: Introduction 
 
The provision of advanced clinical services by community pharmacists is a 
relatively recent development with the first advanced service, Medicine Use 
Reviews (MURs), having been introduced in 2005.  The introduction of MURs 
required pharmacists to get to grips with the new concept of providing formal 
NHS consultations as part of the community pharmacist role.  With the MUR 
service being established and the change in pharmacist role accepted, the 
introduction of the New Medicine Service (NMS) provided an opportunity to 
understand how pharmacy services are implemented without the impact of 
culture change. This can be used to inform future service implementation.  
The introduction of the new service also allows us to see how culture within 
pharmacy has changed since the introduction of MURs and to compare the 
implementation of the two services. 
When examining the implementation of a service it is helpful to identify 
barriers and facilitators to the process.  Doing so means that barriers can be 
addressed and facilitators optimised to help the implementation of the 
service.  Many barriers and facilitators to MUR provision and implementation 
have been published and it was thought interesting to find out what the 
pharmacy profession has learned from it and whether the same barriers and 
facilitators have affected the introduction of the NMS. 
Whilst much research has been conducted examining the provision of MURs, 
there is still a lack of information about how services are developed. The 
introduction of a new pharmacy service is an opportunity to understand the 
process of service implementation.  By understanding how services are 
developed and introduced, and what is important to stakeholders involved in 
commissioning new services, research can be focused on providing the 
evidence most valued by commissioners for future services. 
In this chapter the background to community pharmacy services and the 
different tiers of services is set out.  Adherence to medicines and medicines 
wastage are then introduced, focusing in particular on how to measure them, 
interventions that aimed to improve adherence and wastage, and the 
problems caused by non-adherence.  I then examine the different models of 
health behaviour change and how they relate to non-adherence and the New 
Medicine Service (NMS).  The NMS is then introduced, including the structure 
of the service and the research that underpins it.  The existing body of 
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research that has looked at the NMS is described, as is research conducted 
concerning the implementation of the Medicine Use Review (MUR) service.  I 
look at current research into the implementation of clinical services in order to 
identify facilitators and barriers to service implementation.  I then consider 
different theories of service evaluation and relate them to evaluating the NMS.  
The different ways in which the NMS could be evaluated are described 
including descriptions of the different methods available.  Finally the aims and 
objectives of this thesis are detailed. 
1.1 National Health Service community pharmacy services  
In England, community pharmacy services are not directly provided by the 
NHS but through an NHS contract with community pharmacies.  This NHS 
contract has changed over time to move from being primarily based on 
prescription dispensing to one where pharmacies are paid for providing more 
clinical services in addition to the volume of dispensing.  This report is 
concerned with community pharmacies only, therefore when this report refers 
to pharmacies, it refers to community pharmacies.  Pharmacy businesses can 
be grouped by size.  In this thesis pharmacies have been categorised using 
the definitions used by PwC in their cost of service inquiry for community 
pharmacy. Independent pharmacies are chains of 1-5 pharmacies, small chain 
pharmacies have 6 or more pharmacies (but do not including the 10 largest 
pharmacy chains in England), and larger chains are defined as being the 10 
largest pharmacy chains in England.1 
3KDUPDFLVWV VSHDNDERXW µ7KH 3KDUPDF\&RQWUDFW¶KRZHYHU WKHUH LVQRRQH
document that is the contract.  Instead, what is required of a community 
pharmacist in England is outlined in several documents namely: (i) The 
National Health Service Act 1977, (ii) The National Health Service 
(Pharmaceutical Services) Regulations 20052, (iii) The Pharmaceutical 
Services (Advanced and Enhanced) (England) Directions 20053, and (iv) The 
Pharmaceutical Services (Advanced Services) (Appliances) (England) 
Directions 20094. 
The contents of these documents differ in focus and hence appear to serve 
different purposes.  The National Health Service Act 1977 provides a 
background for understanding the Pharmacy Contract.  On the other hand The 
National Health Service (Pharmaceutical Services) Regulations No.641 2005 
and The Pharmaceutical Services (Advanced and Enhanced) (England) 
Directions 2005 are useful consultation tools detailing what the NHS expects 
of a community pharmacy. The more recent publication, The Pharmaceutical 
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Services (Advanced Services) (Appliances) (England) Directions 2009, adds 
additional services that a community pharmacy can provide under the NHS. 
There are three levels of services that pharmacies provide.  These include (i) 
essential services, (ii) advanced services, and (iii) enhanced services and 
locally commissioned services; these are discussed in the sections that follow. 
Pharmacies are remunerated for the services they provide via the NHS-
Business Services Authority Prescription Pricing Division (PPD). 
1.1.1 Essential Services 
Essential services are the core services that all pharmacies must provide.  
These first level services include; 
x Dispensing of medicines ± the supply of medicines against NHS 
prescriptions 
x Repeat dispensing ± the supply and management of medicines against 
repeat prescriptions 
x Additional essential service requirements linked to the supply of 
appliances ± for example, the measuring and fitting of stockings 
x Waste management  - collection and appropriate disposal of medicines 
returned by patients 
x Public health ± participation in health promotion and the provision of 
advice 
x Signposting ± directing customers to other sources of help and support 
x Support for self-care ± providing advice and supplying medicines over 
the counter 
x Clinical governance ± ensuring appropriate procedures and safety 
mechanisms are in place within the pharmacy. 
1.1.2 Advanced Services 
The second level of services is advanced services.  They are nationally 
commissioned services and can only be provided by accredited pharmacists 
from premises that have been approved by the local Clinical Commissioning 
Group (CCG) or Local Area Team (LAT).  One of the requirements for having a 
premises approved is that there is a consultation room where the services can 
be provided in private.  The first advanced service to be introduced was 
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medicine use reviews (MURs), and the prescription intervention service in 
2005.  Since then two more advanced services have been implemented; 
appliance use reviews (AURs) and stoma appliance customisation services, 
although they are not widely provided.  The latest advanced service to be 
introduced is the New Medicine Service (NMS) implemented in October 2011 
and it is the implementation of this service that this thesis concerns. 
085V DLP WR DGGUHVV SDWLHQWV¶ XVH RI WKHLU PHGLFLne and to improve their 
knowledge of the pharmaceutical treatments they are undergoing.3 AURs are 
reviews for patients who use appliances (e.g. catheters) and so aim to 
LPSURYHWKHSDWLHQWV¶NQRZOHGJHDQGXVHRIWKHLUDSSOLDQFHV.4  Stoma services 
are different from the other two advanced services and are provided by far 
fewer pharmacists.  The stoma service provides custom fitting of stoma 
appliances for patients to ensure proper fitting and correct use as well as 
prolonging the duration of use of the stoma appliance and therefore reducing 
wastage.4  Prior to the introduction of the New Medicine Service (NMS), 
advanced services have aimed to improve knowledge and use of medications 
and appliances and to reduce wastage of them.  This contrasts with the NMS 
which was introduced explicitly to address patient adherence to medicines. 
The most widely established advanced service is the MUR and prescription 
intervention service, therefore the majority of data available about uptake of 
advanced services are about MURs.  The uptake of MURs was slow with 67% 
of pharmacies in England providing the service in 2009/10, four years after 
they were introduced.5   Previous studies have found that the uptake of MURs 
was much greater by larger chains than by independent pharmacies.6   
With over 1.8 million MURs conducted between April 2010 and February 2011 
it is important to consider how acceptable the service is to both pharmacists 
conducting the service and patients that are experiencing it.  Pharmacists 
have been found to have a positive attitude towards MURs and advanced 
services in general, with many seeing them as an opportunity to extend their 
role using their existing professional skills.7 In general patients have been 
found to be positive about their MUR experience, although it should be noted 
that few patients had heard of MURs before receiving one, therefore their 
expectations were not high.8  Patients are positive about the idea of 
pharmacists helping them to manage their medicines suggesting potential 
support for advanced services.9 
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1.1.3 Enhanced Services 
The third level of services is enhanced and locally commissioned services.  In 
the past they have been commissioned by Primary Care Trusts (PCTs) but 
changes to the NHS in the last few years mean that this has changed.  There 
are now several ways these services can be commissioned.  The 
Pharmaceutical Services (Advanced and Enhanced) (England) Directions 2012 
set out 20 enhanced services that can be commissioned by NHS England Area 
Teams.10  Examples of such services include needle and syringe exchange and 
the minor ailments service.  Services can also be commissioned by Clinical 
Commissioning Groups (CCGs) and local authorities through NHS standard or 
local contracts.  In addition, if CCGs or local authorities would like a service 
listed in the 2012 directions to be commissioned as a pharmaceutical service 
in their area, they can request it to be commissioned by the NHS England 
Area Team.11 
1.2 Non-Adherence and Medicines Wastage 
1.2.1 Adherence  
There are three terms used to describe medicine taking.  The different terms 
do have subtly different meanings however they are often confused.  The first 
term is compliance.  It has been defined as; µ7KHH[WHQW WRZKLFKWKHSDWLHQW¶V
EHKDYLRXUPDWFKHVWKHSUHVFULEHU¶VUHFRPPHQGDWLRQV¶.12  This term is seen as 
paternalistic and has fallen out of favour despite being commonly used until 
relatively recently.  The second term that has been widely adopted in 
preference to compliance is adherence.  Adherence has been defined as: µ7KH
H[WHQW WR ZKLFK WKH SDWLHQW¶V EHKDYLRXU PDWFKHV DJUHHG UHFRPPHQGDWLRQV
IURPWKHSUHVFULEHU¶.13 
Both of the above terms are about the patient following a health care 
SURIHVVLRQDO¶V UHFRPPHQGDWLRQ  $ PRUH SDWLHQW-centred approach is 
concordance.  It has been defined as: µ$Q DJUHHPHQW UHDFKHG DIWHU
negotiation between a patient and a health care professional that respects the 
beliefs and wishes of a patient in determining whether, when and how 
PHGLFLQHV DUH WR EH WDNHQ¶.13  Concordance therefore describes a process 
rather than an outcome. 
Therefore, although concordance is the newest and most patient-centred term 
to describe medicine taking behaviour, it is adherence that is most widely 
used.  It is the term used by the NHS, and the term that is referred to in the 
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service specification from the NMS.  Therefore this is the term that will be 
used throughout this project. 
In 2009 The National Institute for Health and Clinical Excellence (NICE) 
published guidelines regarding adherence to medicines.  The existence of 
these guidelines demonstrates how important improving adherence is to the 
NHS.  In the guidelines, NICE defines adherence to medicine as µWKHH[WHQWWR
ZKLFK WKH SDWLHQW¶V DFWLRQ PDWFKHV WKH DJUHHG UHFRPPHQGDWLRQV¶.14  The 
guidelines explain the reason for the importance of improving adherence by 
stating that poor adherence (or non-adherence) leads to negative 
consequences for the patient, the NHS and society in general. 
a) Cost to the individual patient; 
Non-adherence is closely linked to treatment failure.15  For example, if a 
patient with diabetes does not adhere to their treatment, their blood glucose 
levels will not reduce and this increases the risk of long-term complications.  
b) Cost to the NHS; 
It has been estimated that between 30% and 60% of medicines are not taken 
as recommended13, costing the NHS £36m-£196m in hospital admissions that 
could be avoided.14  In addition to the cost of hospital admissions, there is 
also the considerable cost of wasted medicine and a poorer quality of life for 
patients. 
c) Cost to society  
Society is also impacted by individuals not being adherent.  There is evidence 
to support the idea that non-adherence contributes to the emergence and 
increase of drug resistant organisms within society.15  An example of this is 
Tuberculosis treatment which requires strict levels of adherence to be 
effective16 and a failure to complete the treatment course can lead to relapse 
and drug resistant pathogen strains emerging.17  Society is also affected by 
employees missing work due to sickness contributed to by non-adherence. 
1.2.2  Non-adherence 
According to the definition accepted by NICE, anything less than a 100% 
PDWFK EHWZHHQ WKH SDWLHQW¶V DFWLRQV DQG WKH DJUHHG UHFRPPHQGDWLRQV LV
classed as non-adherence.  Non-adherence can be intentional or non-
intentional.  Intentional non-adherence is where a patient makes a decision 
not to take their medicine as prescribed.  Non-intentional non-adherence is 
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where the non-adherence is not as a result of a conscious decision the patient 
has made, for example where a patient is forgetful. 
There are many reasons for non-adherence, both intentional and non-
intentional.  The risk factors for poor adherence fall into three groups; 
(i) Medicine-related factors: 
These can be the patient experiencing distressing side effects or 
having complex regimens for taking the medicine.18-20  Claxton, 
Cramer and Pierce found that µWKHSUHVFULEHGQXPEHURIGRVHVSHU
GD\LVLQYHUVHO\UHODWHGWRDGKHUHQFH¶.21 
(ii) Emotional or physical factors such as beliefs the patient holds 
about their disease or the treatment and disabilities that may affect 
WKHSDWLHQW¶VDELOLW\WRWDNHtheir medicine. 
(iii)  Clinical or social factors such as co-morbidities or lifestyle.22 
It has been suggested that 30-60% of all medicines prescribed for long 
term conditions are not taken as prescribed.13,23  Adherence appears to 
vary with; 
x Age ± Adherence seems to improve with age24 however the 
relationship is not a simple one as there is higher prevalence of 
cognitive problems with increasing age13.  The least adherent age 
group is adolescents.24 
x Gender ± Women appear to be less adherent to medicine 
regimens.25,26 
x Marital status ± There may be a correlation between being single and 
low levels of adherence although the evidence for this is not strong.27 
x Ethnicity ± There seems to be a connection between ethnicity and 
levels of adherence.  The differences between ethnic groups seem to 
be based on cultural differences in beliefs about medicines and there is 
variation within groups.13 
x Education ± Higher levels of educational attainment seem to be 
associated with higher levels of adherence.27 
x Social support ± It has been suggested that social support can help 
some patients in overcoming barriers to adherence.  However little is 
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known about what types of support are likely to be helpful to different 
individuals.13 
x Presence of depression or a level of cognitive impairment ± Kessels 
declared that recalling medicine-taking instructions accurately is 
necessary for adherence.28  Therefore anything that impairs the 
recollection of instructions will reduce adherence.  The link between 
depression and poor adherence is unclear, however depressed patients 
are three times more likely to be non-adherent than patients who are 
not depressed.13 
It is important to note that these characteristics are viewed as factors 
influencing behaviour rather than explaining adherence or a lack thereof.13 
 
1.2.3  Adherence in different medical conditions 
Adherence levels tend to differ according to the nature of D SDWLHQW¶V 
condition.  Patients with acute conditions, such as a bacterial infection, tend 
to adhere to pharmaceutical treatments.  Patients with long term conditions 
tend to have lower adherence, with some evidence finding that there is a 
significant drop in adherence after 6 months of taking a medicine.29,30  It is 
also worth noting that there are no widely agreed acceptable levels of 
adherence.30  There is also considerable variation in adherence rates in 
different long term conditions.  Some conditions are associated with high 
adherence rates, such as HIV antiviral treatment (>80%)31, whereas other 
conditions tend to have much lower adherence rates, such as asthma (around 
50%).32   
1.2.4  Measuring Adherence 
Studies have used a variety of methods to measure or calculate adherence to 
medicine.  The methods can be indirect or direct ways of measuring 
adherence.  Adherence is difficult to measure because if the patient is aware 
that their adherence is being measured, adherence is likely to increase.  
Despite the large body of research into adherence, there is no gold standard 
for measuring it.33  The different methods include; 
x Self-report - This method involves the patient recalling how often they 
have taken their medicine.  Self-report often over-estimates levels of 
adherence, however it has been found to be a good indicator of 
14 
 
adherence.34   One such self-report method is the Morisky scale35; a 
validated questionnaire that is widely used to measure adherence. 
x Doctors judgement - This method is not an accurate way of 
determining adherence as it has been found that doctors overestimate 
WKHLU SDWLHQW¶V DGKHUHQFH36  Consequently this method is not 
commonly used. 
x Pill counts ± this involves counting the number of pills left after a 
period of time to estimate how many tablets the patient has taken 
during that time.  This method makes the assumption that the pills 
that are not in the container at the end of the time period have been 
taken rather than wasted. 
x Prescriptions - This method involves looking at either GP records to 
find the dates prescriptions have been written, or pharmacy records to 
find the date prescriptions have been dispensed.  Calculating the 
intervals between prescriptions being written or dispensed (known as 
the prescription possession ratio) can be used as an estimate of 
adherence.  This method does make the assumption that when a 
prescription has been written or dispensed the patient has taken the 
medicine as directed. 
x Electronic measurement devices - This method involves an electronic 
GHYLFH EHLQJ DVVRFLDWHG ZLWK WKH FRQWDLQHU FRQWDLQLQJ D SDWLHQW¶V
medicines e.g. Medication Event Monitoring System (MEMS).37  The 
device notes when the container has been opened or activated and the 
GDWDJDLQHGFDQEHXVHGWRFUHDWHDSLFWXUHRIWKHSDWLHQW¶VPHGLFLQH
taking habits.  This method makes the assumption that when the 
container is opened or activated the patient is taking a dose, and 
seems to give the most accurate adherence measurements, although 
there is the risk that patient awareness of being monitored could lead 
to an overestimate of adherence.38  
x Outcome measures ± These are the desired outcomes of successful 
treatment and are not a reliable way of estimating adherence as there 
is not necessarily a clear relationship between an outcome measure 
and adherence.  It is based on the assumption that the improving 
adherence increases the likelihood of the desired outcome measures 
being achieved. 
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x Measuring blood serum levels or urinary excretion of the drug - This 
method allows the monitoring of whether or not a patient has taken 
any of the drug prescribed.  It does not show how the patient takes 
their medicine, nor the frequency or quantity taken.  This method is 
most commonly used to monitor long term adherence to a therapy.  
For example measuring glycated haemoglobin (HbA1c) levels (a long 
term measure of diabetic control) over time gives an indication of 
adherence to anti-diabetic therapy.  
x Observation - This involves the patient attending a pharmacy or clinic 
to be observed taking their medicine.  This method is an accurate way 
of ensuring adherence, however it is very inconvenient for the patient 
who must attend the pharmacy or clinic daily.   This method is usually 
used to increase adherence rather to measure adherence.  Observation 
has been used for methadone administration and anti-tuberculosis 
treatment.   
 
1.2.5 Interventions to Improve Adherence  
Measures to improve adherence to medicine aim to improve patient 
outcomes, reduce the financial burden on the NHS, and slow the increase in 
drug resistant strains of micro-organisms.  Therefore there have been many 
attempts to develop interventions particularly for patients with long term 
conditions.  In a review of interventions for enhancing medicine adherence, 
Haynes et al. found that the majority of studies of adherence interventions 
have very small sample sizes, reducing the likelihood of statistically significant 
findings.39  Despite this studies have found that interventions can improve 
adherence.  These interventions have at least one of the following 
characteristics; 
x Improved convenience of care 
x More information, including about the risk of experiencing side effects40 
x Reminders to take the medicine(s) 
x Self-monitoring by the patient 
x Counselling by a health care professional 
x Including the family in education about the therapy 
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x Telephone follow-up by pharmacists40 
x 6XSSRUWLYHFDUHWUHDWPHQWDLPLQJWR LPSURYHSDWLHQWV¶TXDOLty of life 
by preventing, controlling or relieving complications and side effects 
from medicines). 39,42 
Much research has looked at targeting interventions to patients with specific 
conditions.  One of these is HIV/AIDS, where high adherence rates are very 
important, 95% adherence or more is required to give the maximum effect of 
the antiretroviral therapy.43  High levels of adherence in patients with 
HIV/AIDS are associated with lower levels of disease progression, 
hospitalisation and mortality.44  In a review of support and education services 
provided to patients to promote adherence to antiretroviral therapy, several 
features were identified as related to improved adherence; 
x Providing the service at an individual level compared with a group 
setting, 
x Providing the service over an extended period (more than 12 weeks), 
x Services aimed at improving practical medicines management skills.45 
Another long term condition that has been widely researched with regards to 
improving adherence is type 2 diabetes mellitus, in particular aiming to 
reduce HbA1c levels.  Interventions that have been shown to reduce HbA1c 
levels include a nurse-led telephone intervention46, a comprehensive care 
model provided by pharmacists47 and an intervention where pharmacists were 
able to make treatment adjustments48.  
Research has also been carried out in patients with psychological illness, 
chronic heart disease, dyslipidemia, and other chronic conditions such as 
asthma but relatively little research has been carried out with participants 
with multiple morbidities.39  In a study carried out by Clifford et al a patient 
centred telephone-based intervention was found to improve adherence in 
patients who were 75 years old or over, and patients who have certain long 
term conditions (stroke, coronary heart disease, asthma, diabetes and 
rheumatoid arthritis), who were prescribed a new medicine.  The intervention 
focused on providing information to patients about their new medicines and 
addressing any problems they may have encountered when taking them.  The 
interventions were conducted from a central location by two pharmacists who 
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had received specific training.41  This study is examined in further detail in 
section 1.4.1. 
It has been suggested by Elliott that improving access to health care and 
encouraging interventions that are effective at promoting sustained behaviour 
change should be a priority for policy makers.49  The research discussed 
above suggests that when designing an intervention to improve adherence, 
some characteristics associated with successful interventions should be 
incorporated to increase the likelihood of the service improving adherence.   
1.2.6 Medicines Waste 
7KH WHUP µPHGLFLQHVZDVWH¶ UHIHUV WRPHGLFLQH WKDW KDV EHHQ GLVSHQVHG EXW
that has not been and will not be taken.  Medicines waste may be returned to 
a pharmacy or dispensing GP practice, disposed of via household waste, or 
retained in the home.  Medicines waste can be divided into potentially 
avoidable waste and unavoidable waste.  In good quality pharmaceutical care 
there is a level of inevitable waste, for example, a medicine may be stopped 
SUHPDWXUHO\ LI D SDWLHQW¶V FRQGLWLRQ GRHV QRW UHVSRQG WR LW  7KHUH DUH DOVR
components of medicines waste that are avoidable and it is here where 
savings can be made. However it has been argued that the most serious 
consequence of medicines waste is not the financial implications, but the loss 
of therapeutic benefit to patients.50 
In 2004, 600 tonnes of unused medicines were returned to pharmacies to be 
destroyed.48  In addition, a recent audit of community pharmacies found that 
returned medicines had a value of around £100 million, with half of that figure 
considered to be avoidable waste.50 These figures represent conservative 
estimates of general medicines waste as excess medicines may be disposed of 
informally (e.g. via household waste) and so the exact figure is unknown.  In 
a tough economic environment where savings need to be made, the NHS 
would be wise to look at affordable strategies to reduce medicines wastage, 
despite WKH 8.¶V PHGLFLQHV ZDVWH SUREOHP EHLQJ QR JUHDWHU WKDQ LQ
comparable countries.47 An economic evaluation found that £100-150 million 
could be saved for the NHS by reducing medicines waste.50 
Medicines waste is often talked about in relation to adherence, however they 
are two different concepts.  Whilst non-adherence may (or may not) lead to 
some waste, it is not the main cause of medicines waste.50  Risk factors for 
waste fall into several categories; 
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x Individual level factors - These factors are the same as those for non-
adherence and include lack of knowledge, experience of side effects 
and beliefs about medicines.  Put simply, if the patient is non-adherent 
they are more likely to produce waste. 
x Process and system causes - Included in this group are; complex 
treatment regimes, long prescription durations, and changes in 
treatment.   
x Patient group and condition specific causes - Medicines waste tends to 
vary between different groups of patients and patients with different 
conditions.50 
As discussed above, there is a level of inevitable waste involved in good 
pharmaceutical care.  However there are significant savings to be made by 
reducing waste that is not inevitable.  A public survey conducted by the York 
Health Economics Consortium and the University of London School of 
Pharmacy found that the most common reason for patients not completing a 
course of medicine (and therefore producing waste) was the disappearance of 
symptoms.  The second most common reason was a change in medicine by 
the GP or consultant.  Only 6.9% of participants reported not wanting to take 
the medicine as the reason for not completing a course of medicine.50 
An audit of medicines returned to community pharmacies was carried out by 
the same group as the public survey described above.  This audit recorded 
reasons for the medicine being returned.  The most common reason was 
death (26.5%) with the second most common reason being that the medicine 
was stopped (25.0%).  Only 4.78% of returned medicines were recorded as 
being due to non-adherence.50 
 
1.2.7 Interventions to reduce wastage 
There have been several interventions that aim to reduce medicines waste.  
They include restricting prescription length, medicine reviews, repeat 
dispensing schemes, and awareness campaigns.  These are described below. 
Restricting prescription lengths 
One intervention used within the NHS to reduce medicines wastage was the 
recommendation from PCTs to reduce prescription lengths.  Most commonly 
prescribers restrict their prescribing to only 28 days of medicines for patients.  
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Whilst this intervention may reduce the amount of unnecessary medicines 
prescribed, it may also cause additional problems.  The majority of 
prescriptions written are repeat prescriptions for long term conditions.  These 
medicines tend to be essential and missing doses can be potentially harmful.  
Reducing the prescription length for these essential medicines increases the 
likelihood of a patient running out of medicine, which may have the potential 
to impact on their condition. 
In addition to a potential reduction in treatment benefit in patients with long 
term conditions, restricting prescription length reduces the payment per 
prescription dispensed for pharmacies as the fixed funding for pharmacy 
means that an increase in the number of prescriptions reduces the 
remuneration per prescription.  Researchers in the US concluded that 
restricting the length of prescription was not a cost effective method of 
reducing waste because the increase in cost in pharmacy charges would 
outweigh the savings made by reducing waste.51  However this does not 
necessarily mean that restricting prescription length is not cost effective in the 
UK as the US and the UK have different models for remuneration. 
Medicine Reviews  
One of the aims of conducting medicine reviews is to reduce medicines waste.  
Studies have found that pharmacists carrying out MURs can reduce the 
number of repeat medicines ordered and reduce the number of uncollected 
prescriptions at GP surgeries, thus reducing waste.52,53  However these 
studies were highly structured with the pharmacists conducting the MURs 
adhering to pre-defined standards.  In reality the quality of service provision 
varies with the ability of the pharmacist to conduct MURs, the accuracy of the 
SDWLHQW¶VUHSHDWPHGLFLQHUHFRUGVDQGWKHUHODWLRQVKLSWKHSKDUPDF\KDVZLWK 
WKH SDWLHQW¶V *3 SUDFWLFH54  This could affect the likelihood of the MUR 
effecting change in medicines waste. 
A review carried out on medicine reviews in a wider sense (i.e. differing 
interventions carried out by various health care practitioners) found no firm 
evidence that medicine reviews had a positive effect on reducing medicines 
wastage.55   
Repeat dispensing schemes 
Around 70% of all prescriptions written in primary care are repeat 
prescriptions for items to treat long term conditions.50  A method of 
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pharmacist managed repeat dispensing has been introduced where a 
pharmacy holds batches of prescriptions for a patient who can come into the 
pharmacy to collect regular medicines, usually on a 28 day basis.  The 
pharmacist confirms with the patient exactly what medicine is needed.  This 
system should reduce waste by reducing the amount of unnecessary 
medicines collected by patients. 
The repeat dispensing scheme is described by the 2008 white paper, 
Pharmacy in England, as being a proven method of reducing medicines 
waste.55  However the paper also acknowledged that repeat dispensing 
prescriptions only make up 1.5% of all prescriptions issued in primary care.  
This poor uptake of the scheme, mainly driven by a lack of GP engagement, 
means that the service has not realised its potential to reduce waste and it 
has not been possible to assess the cost effectiveness of the service.47,56 
Awareness campaigns 
There have been many campaigns run by PCTs highlighting the cost of 
medicines waste.  These campaigns often include the use of posters and 
leaflets in GP surgeries as well as community pharmacies.  There is anecdotal 
evidence that these campaigns do reduce the amount of medicine waste 
within PCTs.57   Oxfordshire PCT found that the awareness campaign they ran 
halved the amount of medicines returned to pharmacies.58  This suggests that 
media campaigns explaining the cost of medicines waste to local health care 
are an effective method of reducing waste. 
1.2.8  Why Non-Adherence and Associated Wastage is Still a 
Prevailing Problem 
The Evaluation of the Scale, Causes and Costs of Waste Medicines report 
demonstrates that there is still concern regarding medicine wastage in the 
NHS, despite interventions having been introduced to reduce waste.50  The 
interventions may have failed to reduce waste across the NHS due to the 
localised nature of the interventions.  Another possible drawback to some of 
WKH LQWHUYHQWLRQV LVWKDWWKH\GLGQ¶W IRFXVVSHFLILFDOO\RQZDVWHUHGXFWLRQ $
report and action plan produced by the steering group on improving the use 
of medicines for better outcomes and reduced waste was published in October 
2012.59  The report detailed possible ways to address the problems identified 
in the Evaluation of the Scale, Causes and Costs of Waste Medicines report 
including targeted MURs and the provision of the NMS.  Whilst levels of non-
adherence and medicines waste in the UK is no higher than in other 
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countries49, the publishing of the action plan suggests that non-adherence and 
associated medicines waste is a priority for the Department of Health. 
 
Despite many attempts to improve the situation, the NHS still has a problem 
with patients being non-adherent to their medicine and producing waste.  A 
reduction in non-adherence and waste production could lead to significant 
savings for the NHS in a time when funding is stretched.  It has been 
suggested by Elliott that improving access to health care and encouraging 
interventions that are effective at promoting sustained behaviour change 
should be a priority for policy makers.49   
 
Increasing levels of adherence requires behaviour change in those taking 
medicines.  Therefore in the next section models of behaviour change are 
discussed. 
 
1.3 Models of Health Behaviour Change 
When considering how WRFKDQJHSHRSOH¶VPHGLFLQHWDNLQJEHKDYLRXULWFDQEH
useful to look at models of individual behaviour change.  In this section some 
of the most widely accepted models of individual behaviour change will be 
examined including; the Health Belief Model, the Transtheoretical Model, and 
the theories of Reasoned Action and Planned Behaviour, in an effort to 
understand how they might relate to adherence to medicines and the NMS.  
Models of social change have not been discussed here as they do not apply to 
changing an LQGLYLGXDOSDWLHQW¶VPHGLFLQHWDNLQJEHKDYLRXU 
 
1.3.1 The Health Belief Model  
There is evidence that a patient is more likely to stop taking a medicine if he 
or she has doubts about the importance of the illness.60  How these factors 
are linked and affect a patients action is summarised by the Health Belief 
Model.  Figure 1.1 shows the model in pictorial form. 
The Health Belief Model was developed by Becker in 1974 and is a way to 
SUHGLFWDSDWLHQW¶VEHKDYLRXU62  It acknowledges that there are many factors 
WKDW LQIOXHQFH D SDWLHQW¶V GHFLVLRQ PDNLQJ SURFHVV DQG WKDW XOWLPDWHO\ WKH
patient chooses whether or not to take action according to the balance 
between how the patient thinks the action will benefit them, and the barriers 
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they face when taking action.  There are four variables: individual 
perceptions, likelihood of action, cues to action, and modifying factors. 
 
Figure 1.1:  The Health Belief Model adapted from Janz and Becker 63 
 
Individual perceptions 
$QLQGLYLGXDO¶VSHUFHSWLRQVDUHGHWHUPLQHGE\WKHVHYHULW\RIWKHGLVHDVHDQG
how susceptible they believe they are to it.  The combination of these factors 
is known as the perceived threat of the disease.   
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Likelihood of action 
The likelihood that the individual will take action is determined by the balance 
between the perceived benefits associated with taking action and the 
perceived barriers to behaviour change. 
Cues to action 
The model suggests that an individual needs a cue before they will take action 
to change their behaviour.  This can vary from reading a newspaper article 
encouraging behaviour change or a mass media campaign, to the illness of a 
family member. 
Modifying factors 
The health belief model acknowledges that there are factors that can modify 
DQ LQGLYLGXDO¶VEHOLHIVDQGWKHSHUFHLYHGWKUHDWRI WKHGLVHDVH, and so affect 
WKHLUOLNHOLKRRGRIDFWLRQ7KHVHPRGLI\LQJIDFWRUVLQFOXGHWKHLQGLYLGXDO¶VDJH
gender and socio-economical background as well as their personality and 
education. 
The health belief model can be applied to medicine taking behaviour.  It 
suggests that ideas about the possible benefits of a medicine versus the 
barriers to taking it are affected by how the patient sees their condition and 
what concerns they have about the treatment.  Horne and Weinman describe 
this as the necessity-concerns differential, where the patient weighs up how 
necessary they believe the medicine is, against what concerns they have 
about taking it.61  If the necessity score is greater than the concerns the 
patient holds, they are likely to take the medicine.  If the concerns outweigh 
how necessary the patient believes the medicine is, they are unlikely to take 
it.  These concerns may be specific to the medicine, for example; regarding 
possible side effects or developing dependence to the medicine, or they might 
be more general concerns about taking the medicine or the importance or 
severity of the disease. This is supported by a study carried out by Elliott et 
al. who found that a patient was more likely to stop taking a medicine if they 
did not believe that the illness was important.60  From this we can see that 
the views a patient holds regarding his or her illness and the medicine they 
are taking can have a consLGHUDEOHLQIOXHQFHRQWKHSDWLHQW¶VPHGLFLQHWDNLQJ
behaviour. 
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Janz and Becker write that patients µQHHGWRKDYHVRPHNLQGRI FXH WR WDNH
DFWLRQ¶.  They suggest that this prompt may be a conversation with a 
µVLJQLILFDQWSHUVRQ¶.63  In the case of the NMS, the pharmacist would hope to 
EHWKHµVLJQLILFDQWSHUVRQ¶FDXVLQJWKHSDWLHQWWRWDNHDFWLRQ7KHKHDOWKEHOLHI
PRGHO ZRXOG VXJJHVW WKDW WKH VHUYLFH VKRXOG DGGUHVV D SDWLHQW¶V FRQFHUQV
about the new medicine as well as emphasising the potential benefits in order 
to improve adherence.  The model does acknowledge, however, that whether 
or not to be adherent is ultimately WKH SDWLHQW¶V GHFLVLRQ DQG ZKLOVW WKH
pharmacist providing the service can hope to influence the decision by 
altering the beliefs the patient holds, there will be other factors outside of the 
pharmacists influence. 
The health belief model can be used to explain both adherent and non-
adherent behaviour.  The model would suggest that adherent behaviour 
results from the individual viewing the threat of disease as significant and 
deciding that the potential benefits of taking the medicine outweigh the 
perceived barriers.  Non-adherence could be explained by the individual 
perceiving the threat from the disease as low and the barriers to becoming 
adherent as greater than the potential benefits to taking the medicine. 
A major criticism of the model is that there is a lack of clarity regarding the 
definitions of the factors and the relationships between them, making the 
model difficult to apply.  This results in the model having weak predictive 
power.64,65  Zimmerman and Vernberg conducted a review that found that the 
health belief model had a lower predictive power than the theory of reasoned 
action and concluded that the health belief model is really a list of variables 
affecting behaviour.66  Another review of the health belief model found that as 
the model has such weak predictive power with factors difficult to define, it 
should not be used to inform the structure of new interventions being 
developed.65  The implication for the NMS is that if the service is found to 
improve adherence, it is unlikely to be the result of the health belief models 
influence on the development of the service. 
The health belief model takes social, economic and environmental factors as 
well as cognitive factors into account. However, past use of this model to 
examine the relationships between factors has often not included social, 
economic or environmental factors, therefore the relationships between these 
factors and the likelihood of behaviour change is largely unknown.65  
Yarbrough and Braden found that the predictive power of the model was 
improved by including an LQGLYLGXDO¶V VRFLR-economic background.67  
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Therefore, when applying the health belief model to the NMS, it may help 
increase the likelihood of imSURYLQJ D SDWLHQW¶V DGKHUHQFH LI SKDUPDFLVWV 
consider the social, economic and environmental situation of the patient and 
how these factors may affect their perception of the threat of disease, the 
benefits of and barriers to medicine adherence. 
There is some evidence that emotional reactions can be a predictor for 
behaviour change68, however the health believe model does not take 
emotions into account; it assumes that health behaviour is rational.  It is 
possible that by FKDQJLQJ WKH PRGHO WR LQFOXGH DQ LQGLYLGXDO¶V HPRWLRQDO
response, the power of the health belief model to predict behaviour could be 
increased.  Whilst there is no scope in the model to include emotions, there is 
potential for pharmacists conducting the 106 WR WDNH SDWLHQWV¶ IHHOLQJs into 
account in order to help them overcome perceived barriers to becoming more 
adherent to their medicines. 
Whilst the predictive power of the health belief model is weak and is unlikely 
to facilitate the NMS in causing behaviour change, it is possible that 
pharmacists may be able to use some of the factors described in the model to 
improve the likelihood of a patient changing their medicine taking behaviour.  
It may be helpful for pharmacists to understand what the patients believe are 
barriers to medicine taking, and by addressing these barriers influence 
patients to be more likely to become adherent. 
1.3.2  The Transtheoretical Model and Stages of Change 
The transtheoretical model was developed after comparing the leading 
theories of psychotherapy and behavioural change.69   It takes the processes 
and principles of the major theories of intervention and integrates them into 
stages of change.  The model views behaviour change as a process involving 
5 stages. 
Stage 1: Pre²contemplation 
At this stage people are not planning to change their behaviour.  They 
typically avoid reading, talking or thinking about the behaviour such medicine 
taking. 
Stage 2: Contemplation 
At the contemplation stage people are considering changing the behaviour 
and are weighing up the pros and cons of changing.   
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Stage 3: Preparation 
At the preparation stage people are planning to change their behaviour in the 
immediate future and may be making preparations to do so, for example they 
may make an appointment with their GP to discuss the action they wish to 
take. 
Stage 4: Action 
This stage is characterised by people having made changes in their lifestyle 
within the last six months.  Not all behaviour changes count as action in this 
model.  In order for the change to class as action the individual must reach 
the standard agreed by health professionals as sufficient to reduce the risk.  
For example, adherence to HIV medicines must be greater than 95% in order 
for them to be most effective.43 
Stage 5: Maintenance 
At this stage people have made the behaviour changes and are working to 
prevent relapse to the undesirable behaviours. 
There is a sixth stage that applies to some behaviours.  This stage is called 
termination and at this stage people are no longer tempted to return to the 
old behaviours.  This stage does not apply to non-adherent patients becoming 
adherent to their medicines. It has been suggested that as a rule of thumb in 
a population displaying the undesirable behaviour 40% will be in the pre-
contemplation stage, 40% will be in the contemplation stage and 20% will be 
in the action stage.69 
The transtheoretical model points out that when a person is considering 
changing an undesirable behaviour they will weigh up the pros and cons of 
making that change before coming to a decision.  Research suggests that to 
progress from pre-contemplation to contemplation the pros of the behaviour 
change must increase, and to progress from contemplation to action the cons 
of the behaviour change must decrease.70  The model also sets out activities 
that people use to move through the stages of change by altering the balance 
of pros and cons.  These activities are called processes of change.  The ten 
processes that have the most support from research are69: 
x Consciousness raising:  this is where the person is made aware of the 
consequences of the undesirable behaviour. 
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x Dramatic relief: this activity is one that provokes an emotional 
experience that can be reduced by taking appropriate actions providing 
a sense of relief. 
x Self re-evaluation: this activity involves the person assessing how they 
view themselves with and without the undesirable behaviour. 
x Environmental re-evaluation: this activity involves the person 
assessing the impact of the presence or absence of the undesirable 
behaviour on the people around them.  
x Self-liberation:  this is the belief that the person can change and has 
the commitment to do so. 
x Helping relationships:  relationships between the person wishing to 
change a behaviour and the people around them can support the 
individual in changing their behaviour. 
x Counter-conditioning:  this activity involves replacing the undesirable 
behaviour with a healthy behaviour. 
x Contingency management:  this is where consequences to making 
progress toward changing the undesirable behaviour are introduced.  
They can be rewards or punishments. 
x Stimulus control:  This activity involves the person removing cues to 
the undesirable behaviour and introducing prompts for the healthy 
behaviour. 
x Social liberation:  this involves increasing social opportunities or 
alternatives available to the individual. 
7KH WUDQVWKHRUHWLFDO PRGHO SURSRVHV ZD\V RI FKDQJLQJ DQ LQGLYLGXDO¶V
undesirable behaviour and therefore could only be useful for patients that the 
NMS identifies as non-adherent.  Whilst the model may not apply to adherent 
patients, by using the model to establish whether an individual is prepared to 
change their medicine taking behaviour and by using some of the processes of 
change to increase aQLQGLYLGXDO¶VUHDGLQHVVWRFKDQJHSDWLHQWVLGHQWLILHGE\
the NMS as non-adherent could be encouraged to become more adherent to 
their medicine.  There are, however, several concerns that should be 
considered. 
Whilst the transtheoretical model has enjoyed popularity, there have been 
several criticisms made.  It has been suggested that applying the stages of 
change to complex behaviours is particularly difficult because there maybe a 
variety of specific behaviours within a complex behaviour and an individual 
may be in different stages of change for each specific behaviour.71  Adherence 
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to medicines could be seen as a complex behaviour as individuals are often 
taking multiple medicines and have varying levels of adherence to the 
different medicines.  For example, people are more likely to have higher levels 
of adherence to acute treatments compared with long term preventative 
medicines.  The transtheoretical model would suggest that the NMS avoids 
this pitfall because it focuses on adherence to an individual medicine but that 
WKH106ZRXOGQRWQHFHVVDULO\LPSURYHDQLQGLYLGXDO¶VDGKHUHQFHWRDOOWKHLU
medicines and therefore potentially have a lower impact on the desired 
outcome of the medicines.   
In addition, it has been suggested that the pre-contemplation stage actually 
contains two separate groups of individuals who would benefit from being 
treated differently; aware pre-contemplators and unaware pre-contemplators.  
Aware pre-contemplators know that their behaviour is undesirable but do not 
intend to change, whereas unaware pre-contemplators do not know that their 
behaviour is undesirable so see no need to change.72   This would suggest 
that when conducting the NMS with an individual in the pre-contemplation 
stage, a pharmacist needs to establish whether the patient is aware of how 
they should be taking their medicines to determine whether they are an 
aware pre-contemplator or an unaware pre-contemplator, in order to know 
how best to encourage the patient to change their medicine taking behaviour.   
There are also criticisms made regarding the algorithms for determining which 
stage of change individuals are in.  The algorithms are often based on self-
assessment which is a problem because studies have shown that people 
believe they are far more compliant with behavioural recommendations than 
their behaviour demonstrates.72,73  In addition, as there is no accepted 
method of comparing different staging algorithms, the validity of the 
algorithms has not been demonstrated.  It has also been suggested that there 
could be problems with the reliability of staging algorithms because transition 
between stages of change are common and can occur over a very short period 
of time.74,75  The structure of the NMS does not include an algorithm for 
GHWHUPLQLQJDSDWLHQW¶VVWDge of change, however if this was included it would 
be based on self-assessment and pharmacists would need to be aware that 
patients may be less compliant with recommendations than their answers 
would suggest. 
Whilst the transtheoretical model is not appropriate for all patients who 
receive the NMS, I believe that some aspects of the model could help 
pharmacists encourage non-adherent patients to change their medicine taking 
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behaviour.  The idea that some people are more prepared to change their 
behaviour than others and the ways suggested by this model to encourage 
people to become more ready to change could be utilised by pharmacists 
when conducting the NMS in its current structure. 
 
1.3.3  The Theory of Reasoned Action and The Theory of Planned 
Behaviour 
The Theory of Reasoned Action (TRA), set out in Figure 1.2, was developed in 
order to understand the relationship between attitudes and behaviour.  The 
WKHRU\ VWDWHV WKDW WKDW DQ LQGLYLGXDO¶V EHKDYLRXUDO LQWHQWLRQ LV WKH ELJJHVW
predictor of their behaviour.  
 
$QLQGLYLGXDO¶VEHKDYLRXUDOLQWHQWLRQLVGHWHUPLQHGE\WKHLUDWWLWXGHWRZDUGV
the behaviour and the subjective norm associated with the behaviour.  In turn 
WKHLQGLYLGXDO¶VDWWLWXGHWRZDUGVWKHEHKDYLRXULVGLFWDWHGE\WKHLUEHKDYLRXUDO
beliefs and their evaluation of the outcomes associated with the behaviour. 
The subjective norm is determined by the opinions of people important to the 
inGLYLGXDOWRZDUGVWKHEHKDYLRXUDQGWKHLQGLYLGXDO¶VPRWLYDWLRn to comply 
with their opinions. 
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Figure 1.2: The theory of reasoned action, adapted from 
Health Behaviour and Health Education 
69
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The theory of planned behaviour (TPB) (Figure 1.3) is a development of the 
75$LQDQHIIRUWWRDFFRXQWIRUIDFWRUVWKDWPD\DIIHFWDSHUVRQ¶VLQWHQWLRQDQG
behaYLRXUEXWDUHRXWVLGHRIWKHSHUVRQ¶VFRQWURO7KHWKHRU\LQWURGXFHVWKH
LGHDRISHUFHLYHGFRQWUROWKDWLVGHWHUPLQHGE\WKHSHUVRQ¶VEHOLHIVDERXWWKH
presence or absence of factors that could facilitate or inhibit the behaviour, 
and the power of such factors to facilitate or inhibit the behaviour.66 
 
For the theories of reasoned action and planned behaviour the model 
components and the relationships between them are clearly defined and can 
have mathematical values assigned in order to determine the impact of the 
FRPSRQHQWRQDQ LQGLYLGXDO¶VEHKDYLRXU76  This clarity results in the models 
having a greater predictive power than the health belief model.66 
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Figure 1.3 The Theory of planned behaviour adapted from 
Health Behaviour and Health Education 
69
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The theories of reasoned action and planned behaviour have been widely 
used, mainly to predict and understand exercise, dietary, addiction and HIV 
prevention behaviours.65  However, the tKHRULHV¶KLJKOHYHORIJHQHUDOLVability 
means that it is possible to relate them to medicine taking behaviour.75  Poor 
adherence could result from a negative attitude towards medicine taking, a 
belief that influential people disapprove of them taking medicines, and a 
desire to comply with their views, and/or a belief that the individual does not 
have the power to control their medicine taking behaviour.  Conversely, an 
individual may be adherent to their medicine if they have a positive attitude 
towards taking the medicine, believe that the people around them encourage 
them to be adherent and have a desire to comply, and/or believe that they 
have to power to become more adherent. 
A criticism of the theory of reasoned action is that it is individualistic; relying 
RQ DQ LQGLYLGXDO¶V LQWHUSUHtation of factors and does not take external 
YDULDEOHVRXWVLGHRIWKHLQGLYLGXDO¶VFRQWUROLQWRDFFRXQW77  The addition of the 
perceived behavioural control component in the theory of planned behaviour 
goes some way to addressing this problem.  It is possible that these factors 
are already addressed within the structure of the NMS as during the 
consultations pharmacists should ask patients about all barriers to taking their 
PHGLFLQHVZKHWKHUZLWKLQWKHSDWLHQW¶VFRQWUROVXFKDVUHPHPEHULQJWRWDNH
the medicine) or outside of their control (struggling to take the medicine in 
tablet form), in order to resolve problems where possible. 
The theories of reasoned action and planned behaviour have primarily been 
used to understand behaviour retrospectively rather than used to develop 
interventions to change behaviour.67,78  This may be because the theories 
allow prediction and understanding of behaviours rather than explain ways to 
encourage behaviour change.  This means that the theories of reasoned 
action and planned behaviour may be less useful to pharmacists conducting 
the NMS than the transtheoretical model because they do not suggest 
mechanisms for making patients more likely to change their medicine taking 
behaviour.   
Whilst the theories of planned behaviour and reasoned action have greater 
predictive power than the health belief model, I would suggest that the health 
belief model is more helpful in relation to improving adherence as it provides 
ways for pharmacists tRLQIOXHQFHSDWLHQWV¶EHOLHIVDQG make them more likely 
to take their medicines.  However, its weak predictive power and lack of 
clarity means that the success or failure of the health belief model based NMS 
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is very unlikely to be due to the model¶V LQIOXHQFH  , ZRXOG VXJJHVW D
pragmatic approach, incorporating some aspects of the transtheorectical 
model into the current structure of the NMS.  By understanding that some 
patients may be more prepared to take their medicines than others, and using 
some of the processes of change derived from the transtheoretical model, it is 
SRVVLEOHWKDWSKDUPDFLVWVFRXOGLPSURYHWKHOLNHOLKRRGRI LPSURYLQJSDWLHQWV¶
adherence to medicines. 
 
1.4    The New Medicine Service 
In 2008 the Government released a white paper HQWLWOHG µ3KDUPDF\ LQ
England; Building on strengths ± GHOLYHULQJ WKH IXWXUH¶  7KLV GRFXPHQW
GHWDLOHG WKH*RYHUQPHQW¶VYLVLRQ IRUSKDUPDF\ LQFOXGLQJ LQWURGXFLQJD µQHZ
service for those who are starting to take regular medicines to treat their 
>ORQJWHUP@FRQGLWLRQIRUWKHILUVWWLPH¶79.  In March 2011 the Pharmaceutical 
Services Negotiating Committee (PSNC) and the NHS Employers announced 
that funding had been agreed for this new advanced service, called the New 
Medicines Service (NMS) with the aims of increasing adherence and reducing 
wastage of newly initiated medicines in patients with long term conditions. 
 
1.4.1 Introduction of a New Advanced Service 
The NMS has been developed by the PSNC and NHS employers.  When 
planning this service, they focused on five articles about three studies from 
one research group.41,80-83  These articles describe: a telephone-based 
pharmacy intervention service that aimed to improve adherence to newly 
prescribed medicines; literature around education, policy and research about 
adherence and community pharmacy in England; and beliefs held by patients 
about their medicines.  The findings of the five influential papers are 
summarised in Table 1.1. 
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Table 1.1:  Summary of the five articles that influenced the PSNC and the NHS employers when developing the NMS (page 1 of 2).  
Article Title Authors Year Study Population Methods Main Findings 
Patients' problems with 
new medication for 
chronic conditions 
N. Barber, 
J. Parsons, 
S. Clifford, 
R. 
Darracott, 
R. Horne. 
Participants 
recruited 
March 1999 
to February 
2000. Article 
published 
2004. 
258 participants prescribed a 
new medicine and aged 75 
years or over or with at least 
one of the following 
conditions: stroke, coronary 
heart disease, asthma, 
diabetes.  Recruited from 23 
pharmacies. 
Longitudinal survey using semi-
structured telephone interviews at 
10 days and 4 weeks, and a 
questionnaire at 4 weeks.  
Measuring self-reported 
adherence, causes of non-
adherence, problems with 
medicines and information needs 
30% of participants still taking 
medicines at 10 days were non-
adherent.  This dropped to 25% at 4 
weeks.  66% of patients taking their 
medicines at 10 days experienced 
problems.  Over half of participants 
wanted more information at both time 
points. 
Understanding different 
beliefs held by adherers, 
unintentional non-
adherers, and intentional 
non-adherers: Application 
of the Necessity-Concerns 
Framework 
S. Clifford, 
N. Barber, 
R. Horne. 
Participants 
recruited Mar 
1999 - Feb 
2000. Article 
published 
2008. 
As above Using 10 day telephone interview 
data from above study to measure 
necessity-concern differential 
(BMQ) and self-reported 
adherence. 
Of the non-adherent participants, 30/67 
were intentionally non-adherent and 
37/67 were unintentionally non-
adherent.  There was a significant 
difference in necessity-concern 
differential between adherent and non-
adherent participants. 
Medication adherence and 
community pharmacy: a 
review of education, 
policy and research in 
England 
S. Clifford, 
S. Garfield, 
L. Eliasson, 
N. Barber. 
Article 
published 
2010 
13 of 21 pharmacy schools in 
England.   
Literature review to understand 
current policy, education and 
research related to community 
pharmacy and adherence in 
England. 
All pharmacy schools that responded 
included adherence in the 
undergraduate teaching.  Improving 
adherence is a priority for policy.  
Research centred on compliance aids, 
patient education, community 
pharmacy involvement in discharge 
planning and patient centred 
interventions.  
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Article Title Authors Year Study Population Methods Main Findings 
Patient-centred advice is 
effective in improving 
adherence to medicines 
S. Clifford, 
N. Barber, 
R. Elliott, E. 
Hartley, R. 
Horne. 
Article 
published 
2006 
500 participants prescribed a 
new medicine and aged 75 
years or over or with at least 
one of the following 
conditions: stroke, coronary 
heart disease, asthma, 
recruited from 40 
pharmacies.  237 control and 
255 intervention participants.  
Randomised control trial with 
telephone interviews at 2 and 4 
weeks and  questionnaire at 4 
weeks.  Measured self-reported 
adherence, problems with 
medicines, and beliefs about 
medicines. 
At 4 weeks  non-adherence in the 
intervention group was lower (9% vs 
16%), fewer problems were 
experienced by the intervention group 
(23% vs 34%) and the necessity-
concerns differential was higher in the 
intervention group. 
The cost effectiveness of 
a telephone-based 
pharmacy advisory 
service to improve 
adherence to newly 
prescribed medicines 
R. Elliott, N. 
Barber, S. 
Clifford, R. 
Horne, E. 
Hartley 
Article 
published 
2007. 
As above Questionnaire at 2 months after 
starting medicine.  Measured cost 
to UK NHS using incremental cost 
effectiveness ratios.  
The mean cost for the intervention 
group was £187.70 per patient 
compared to £282.80 per patient in the 
control group. 
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The first two papers listed in Table 1.1 describe a longitudinal study looking at 
patients who were 75 years old or over, or had one or more of the following 
conditions: stroke, coronary heart disease, asthma, diabetes and rheumatoid 
arthritis, and had been prescribed a new medicine.  The study measured: self-
reported adherence, as well as recording the causes of non-adherence; 
problems participants experienced with the new medicines; and the 
paUWLFLSDQWV¶ LQIRUPDWLRQ QHHGV DW  GD\V DQG  ZHHNV DIWHU UHFHLYLQJ WKH
new medicine.  The study also used the Beliefs about Medicines Questionnaire 
in order to determine the necessity-concerns differential for participants at 10 
days.  The results of the study showed that at 10 days 30% of participants 
still taking the medicines were non-adherent.  This figure dropped to 25% at 
4 weeks.  The study also found that two-thirds of participants still taking their 
new medicines at 10 days were experiencing problems and at both time 
points over half of the participants wanted more information.  A significant 
difference in beliefs about medicines was found between adherent and non-
adherent participants, with adherent patients having greater necessity scores 
and lower concern scores than non-adherent patients. Of the non-adherent 
patients, 45% were intentionally non-adherent and 55% were unintentionally 
non-adherent.80,81   
The implications of this study are that there is a problem with non-adherence 
to new medicines in that population combined with a majority of patients 
experiencing problems.  The study also shows that there is a significant desire 
for more information about new medicines.    This suggests that adherence to 
medicines in the elderly or patients with long term conditions may be 
improved by intervening when a medicine is newly prescribed, to provide 
information about the new medicine and to address any problems patients 
may be experiencing. The results of the Beliefs about Medicines Questionnaire 
show that there is the potential to encourage non-adherent patients to 
become more adherent by addressing their beliefs about the necessity of 
taking the medicine and their concern regarding the treatment. 
The third paper in Table 1.1 by Clifford et al. details the results of a study 
conducted in order to understand the policy, the education provided to 
pharmacists, and research conducted in relation to adherence and community 
pharmacy in England.  The review found that tackling problems with non-
adherence was seen as important and guidelines had been issued suggesting 
that adherence could be promoted by involving patients in decision making, 
by supporting patients in their medicine taking, and by regularly reviewing 
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SDWLHQWV¶ PHGLFLQHV ,Q WHUPV RI HGXFDWLRQ WKe study found that all of the 
schools of pharmacy that responded included teaching regarding adherence in 
the undergraduate curriculum as well as in postgraduate training, suggesting 
that pharmacists have knowledge about adherence and may be under-utilised 
in addressing the problem of non-adherence.  The study found that research 
regarding community pharmacy and adherence mainly focused on compliance 
aids, patient education, hospital discharge and some patient tailored 
interventions.  The authors concluded that more research was needed in order 
to be able to identify a successful as well as cost-effective way of improving 
adherence.  The study demonstrated that there is scope for community 
pharmacists to be involved in supporting patients in their medicine taking in 
order to improve adherence.82 
The last two articles included in Table 1.1 describe an intervention conducted 
by community pharmacists aiming to improve patient adherence.  The 
randomised control trial involved patients who were 75 years old or over, or 
had one or more of the following conditions: stroke, coronary heart disease, 
asthma, diabetes and rheumatoid arthritis, and had been prescribed a new 
medicine.  Of 500 participants recruited, 255 received the intervention and 
237 received usual care (8 participants withdrew from the study).  The 
intervention consisted of a telephone call conducted by one of two specially 
trained community pharmacists two weeks after the patient had received the 
new medicine using an interview schedule developed in the first study.  All 
participants then received a telephone call at four weeks in order to assess 
adherence as well as problems experienced by participants and their beliefs 
about medicines.  Participants also completed a questionnaire after two 
months that was used to calculate incremental cost effectiveness ratios in 
order to assess the cost to the NHS.41,83   
The study found that the intervention group had a lower level of non-
adherence (9% compared to 16%), fewer problems experienced (23% 
compared to 34%) and a higher necessity-concern differential than the 
control group.  The economic evaluation found that the intervention had a 
lower cost to the NHS than usual care (£187.70 per patient compared to 
£282.80 per patient.41,83  The results from this study suggest that pharmacists 
can improve adherence in elderly patients and patients with long term 
conditions in a cost effective way by providing advice soon after they are first 
prescribed a medicine. 
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The articles suggest that there is a need for a patient centred approach to 
improving adherence, that non-adherence is more of a problem in patients 
with long term conditions than patients with acute illnesses80, and that the 
first few days of taking a medicine are critical for developing adherence41.  
The studies show that a patient-centred intervention conducted by 
pharmacists soon after the prescribing of a new medicine can improve 
adherence in a cost effective manner and on this basis the NMS was 
developed.  
1.4.2  Description of the New Medicine Service  
In documents published by the PSNC in May 2011 and August 2013, the PSNC 
and NHS employers set out the aims and outcomes of the NMS.  They stated 
WKDWµthe service should; 
x Help patients and carers manage newly prescribed medicines for a long 
term condition and make shared decisions about their condition 
x Recognise the important and expanding role of pharmacists in 
optimising the use of medicines 
x Increase patient adherence to treatment and consequently reduce 
medicines wastage and contribute to Quality, Innovation, Productivity 
and Prevention agenda 
x Supplement and reinforce information provided by the GP and practice 
staff to help patients make informed choices about their care 
x Promote multidisciplinary working with the patieQW¶V*3SUDFWLFH 
x Link the use of newly prescribed medicines to lifestyle changes or 
other non-drug interventions to promote well-being and promote 
health in people with long term conditions 
x Promote and support self-management of long term conditions, and 
increase access to advice to improve medicines adherence and 
knowledge of potential side-effects 
x Support integration with long term condition services from other 
providers and provide appropriate signposting and referral to the 
services 
x Improve pharmacovigilance 
x Through increased adherence to treatment, reduce medicines related 
hospital admissions and improve quality of life for patients.84,85 
 
The New Medicine Service (NMS) is specifically for four long term condition 
groups.  It targets asthma and COPD, type 2 diabetes, 
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antiplatelet/anticoagulation therapy, and hypertension.  The majority of these 
conditions are widely accepted as having low adherence rates.  COPD, type 2 
diabetes and antiplatelet/anticoagulant therapy mainly affect adults with few 
children being affected.86-88   
Figure 1.4 shows the structure of the NMS as proposed by the PSNC.84  The 
NMS consists of three parts; patient engagement, intervention and follow-up. 
The first part, patient engagement, involves the existing practice of providing 
appropriate advice regarding how to take the medicine and possible side 
effects the patient should be aware of, followed by identifying the patient as 
eligible for the service and gaining written consent from the patient to enter 
the service. The intervention stage occurs seven to fourteen days later and 
consists of a consultation with a pharmacist which can be conducted either by 
telephone or face-to-face in the pharmacy consultation room.  The pharmacist 
uses a semi-structured questionnaire to identify any problems affecting 
adherence that the patient may be experiencing. Two to three weeks after the 
intervention, the follow-up stage of the service occurs again either by 
telephone or face-to-face in the pharmacy consultation room. The follow-up 
consultation with the pharmacist also uses a similar semi-structured 
questionnaire to assess adherence, whether recommendations made at the 
intervention stage have been successful, and whether the patient is 
experiencing any new or further problems with their new medicine. If the 
pharmacist judges that the patient is experiencing significant problems at the 
intervention and follow-up stages, the patient can be referred back to their 
prescriber. At each stage of the service the pharmacist can make public health 
and lifestyle interventions.  Patients can be recruited into the service in 
several ways: the patient may request the service, a pharmacist may offer a 
patient the service, or the patient may be referred into the service by a health 
care professional in primary or secondary care. There is no compulsory 
training required to provide the NMS, however a pharmacist must be 
accredited to provide MURs and must declare themselves competent to 
provide the new service.89 
39 
 
 
 
Remuneration for providing the NMS is allocated from the global pharmacy 
sum.  Initially the service had funding until 1st April 2013 but funding has 
been extended pending the results of an evaluation of the NMS.  The payment 
structure introduced for the NMS in October 2011 linked the number of 
services that could be claimed for with D SKDUPDF\¶V GLVSHQVLQJ YROXPH a 
novel concept for pharmacy.  The expectation was that 0.5% of all 
prescription items dispensed would be eligible for the service and the 
Figure 1.4: The structure of the NMS 
Patient is prescribed a new 
medicine for one of the following 
conditions and is identified by the 
pharmacy or referred by a 
prescriber: 
 Hypertension 
 Asthma/COPD 
 Type 2 diabetes 
 Anti-platelet/Anti-
coagulant First stage: Patient engagement 
 Initial advice given 
 Agreement on time 
and method of follow-
up 
Second stage: Intervention 
 Semi-structured 
interview 
 Face-to-face or 
telephone consultation 
7-14 days 
later 
Third stage: Follow-up 
 Semi-structured 
interview 
 Face-to-face or 
telephone 
consultation 
14-21 days 
later 
Problem identified 
Adhering to 
regimen 
Referred to prescriber 
and exit service 
Pharmacist and 
patient agree 
solution and time 
and method of 
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Problem identified: 
 Referred to 
prescriber 
 Exit service 
Adhering to regimen: 
 Exit service 
The Structure of the NMS 
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structure allowed payment to be triggered by reaching 20%, 40%, 60% and 
80% of expected opportunities within tiers of dispensing volume.  These 
thresholds meant that a maximum of £25 would be paid per NMS.  The 
complex nature of the payment structure meant that it was difficult to predict 
how much a pharmacy would be paid for providing the service in a given 
month.  This payment structure was amended in May 2012 and, whilst the 
structure retains the percentage targets, it now means that a pharmacy will 
be remunerated for each completed NMS.90 
The recording requirements for the NMS allowed pharmacies to record the 
services completed in a variety of ways.  One tool available to pharmacists via 
the PSNC was PharmaBase (now PharmOutcomes) which is a national web-
based program which has the facility to record NMS as well as other services.  
The PharmaBase NMS module was made available for NMS recording at the 
same time as the launch of the service. 
Earlier the characteristics of interventions associated with improved 
adherence were discussed.  The NMS has four of the characteristic associated 
with successful interventions: providing more information (including 
information about possible side effects), counselling by a health care 
professional, telephone follow up by pharmacists, and supportive care.  These 
characteristics may improve the likelihood of the NMS improving adherence. 
1.4.3 Existing NMS Research  
In an editorial De Simoni et al set out the potential, evidence and challenges 
facing the NMS.91  They suggested that the new service had the potential to 
improve long term health as well as save the NHS money, but this potential 
would only be realised if the NMS was implemented successfully.  The article 
UHSRUWHG WKH HYLGHQFH EDVH IRU WKH VHUYLFH DV µsparce¶ DQG QRWHG WKDW
systematic reviews of community pharmacy interventions had mixed findings.  
The article set out several challenges that the NMS faced, including the time 
pressures experienced by pharmacists and the need to organise appointments 
for NMS consultations.  They also questioned whether GPs were likely to refer 
patients into the service. 
An analysis of the national PharmaBase database (now PharmOutcomes) was 
published in the form of a report by the PSNC in November 2012 for the first 
year of the NMS.92  It reported that of the 418,744 completed NMS claimed 
for from the NHS Precription Authority between October 1st 2011 to July 31st 
2012, 43.1% had been recorded on PharmaBase.  They reported that the 
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proportion of male and female patients were similar and that 99.6% of NMS 
were recruited by the pharmacy, with just 0.4% being referred by GPs or 
practice nurses.  The most common condition was hypertension (54.4%), 
followed by asthma/COPD (26.4%), type 2 diabetes (11.3%), and anti-
platelet/anti-coagulants (7.9%).  The also reported that where the 
consultation method was reported, over two-thirds of intervention and follow-
up consultations were conducted by telephone.  The results showed that 
pharmacists provided healthy living advice (HLA) at each stage of the service 
with advice regarding diet and nutrition being the most common HLA offered 
and sexual health advice the least common.   
The analysis of the PharmaBase records suggested that nearly a third of 
patients reported as non-adherent at the intervention stage became adherent 
at the follow-up stage, and this rate of adherence change improved rapidly 
over the first few months of the service.  However the questions used in NMS 
consultations do not include a validated adherence measure, therefore the 
data captured using PharmaBase cannot reliably be used to calculate 
adherence or non-adherence.  Instead it gives only an indication of 
adherence, so one must be careful when drawing conclusions from this data.  
In addition, the report does not detail the methods used during the analysis of 
the data and has not been peer-reviewed, so it is not possible to conclude 
whether the methods used are valid or reliable. 
Due to the fact that the NMS was introduced so recently (October 2011) there 
is little published data about the service.  One effect of the service that has 
been reported in the press is that the service has lead to an increase in 
reporting of adverse drug reactions through the Yellow Card scheme which 
has been hailed as proof that the service is meeting its objective of improving 
pharmacovigilance.93 
One small survey of community pharmacists in Cornwall, conducted after the 
implementation of the NMS, found that respondents held broadly positive 
views of the service.  They reported that the majority of services conducted 
were opportunistically initiated by pharmacy staff and more than half of 
respondents said that the majority of interventions and follow-ups were 
conducted by telephone.  Twenty-two respondents suggested that more 
training on the conditions eligible for the NMS would be beneficial whilst only 
two of the pharmacists surveyed reported that they would find further training 
regarding communication skills helpful.94  This survey was very small with 
only 39 pharmacists responding from one area of England and the results 
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were published without peer review, therefore it is unclear how robust the 
survey was and the degree to which the results are generalisable is 
questionable. 
The Department of Health funded a national evaluation of the NMS conducted 
through a collaboration between the University of Nottingham and University 
College London.  The evaluation comprised of a health technology assessment 
in the form of a RCT, an economic evaluation and a qualitative stream.  The 
RCT aimed to find out if the NMS affects adherence and involved patients 
being randomised into either receiving the NMS, or usual care and were 
followed up for 6 months.  The economic evaluation aimed to determine the 
FRVWRIWKH106WRWKH1+6UHODWLYHWRWKHFRVWRIµXVXDOFDUH¶7KHTXDOLWDWLYH
stream explored the patient experience as well as profiling pharmacies and 
eliciting stakeholder perspectives regarding the service.  The protocol for the 
RCT has been published but the results of the study have yet to be published 
however.95 
 
1.5  Community Pharmacy Research Identifying Barriers and 
Facilitators to Service Implementation and Provision 
Understanding factors that affect implementation and provision of new 
services has become more important as the role of community pharmacists 
has expanded to include more clinical services.  Numerous literature searches 
were conducted throughout the four years of this PhD using the PubMed and 
Scopus databases, looking at factors affecting the uptake and implementation 
RI SKDUPDF\ VHUYLFHV  6HDUFK WHUPV XVHG LQFOXGHG µSKDUPDF\ VHUYLFHV¶
µ0HGLFLQH 8VH 5HYLHZV¶ DQG µSKDUPDF\ LPSOHPHQWDWLRQ¶  :KLOVW SDSHUV
published before 2005 were reviewed, the majority of papers deemed 
relevant to the implementation of pharmacy services in the UK, and therefore 
included in this review, were published after the introduction of the revised 
NHS pharmacy contract in 2005. The reference lists of papers included in this 
review were examined for further papers that may have been relevant.  
Since 2005 much research has been conducted investigating the uptake and 
introduction of MURs as well as examining the MUR service itself.  The results 
of such research may be used in to give an indication of factors that may 
affect NMS provision. 
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MUR activity was initially slow after its introduction in April 2005 with just 
18% of MURs for which funding was available being conducted in its first 
year.8   A study by Bradley et al found that uptake of MURs was greater in 
multiple pharmacies (chains with 6 or more pharmacies) compared with 
independent pharmacies.6  This trend has been confirmed by other studies8 
and several reasons for this have been suggested.  The MUR service was 
introduced at the same time as major contractual changes for community 
pharmacy and this may have disproportionally affected independent 
pharmacies because they do not have corporate support for implementing 
changes.8  In addition it has been suggested that company pressure facilitated 
provision of MURs in volume6,8, although this has been linked to MURs of 
questionable quality.96  The findings from these studies suggest that the 
uptake of the NMS may be greater in multiple pharmacies as the NMS was 
introduced at the same time as other contractual changes and the pressure 
from companies to provide advanced services is likely to remain the same.  It 
is less likely that the NMS will experience the same problems with quality as 
MURs as the eligibility criteria are much narrower. 
A commonly identified barrier to MUR uptake was the requirement that 
pharmacies providing MURs must have an approved consultation room.6-8  
This is unlikely to affect NMS implementation because pharmacies wishing to 
offer the new service are likely to already be providing MURs and will already 
have an approved consultation room.  Another barrier associated with 
consultation rooms is the lack of access to patient medical records (PMRs) in 
consultation rooms without IT access.8  This barrier may affect the provision 
of the NMS as some consultation rooms still lack access to PMRs.  As the 
number of services requiring consultation rooms increases, the need for PMR 
access in the consultation room grows.  Therefore providing PMR access in 
these rooms may facilitate not only the NMS service, but other services as 
well. Whist there appears to be very little literature about how PMR systems 
can affect the provision of pharmacy services, an international study found 
that IT solutions are important to the provision of professional services and 
WKDWD ODFNRI ,7VROXWLRQVFRXOG WKUHDWHQSKDUPDF\¶V UROH LQSDWLHQWFHQWUHG
care.97   
Studies in Australia and Sweden have found low GP awareness and a lack of 
interest and participation in pharmacy services.98-101  However, where GPs can 
see the potential benefits of a pharmacy service to patients, they are more 
likely to engage with it and collaborate with pharmacists.102  In the UK a 
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widely reported barrier to MUR implementation and provision was a lack of GP 
support for the service.6-8,94  It has been suggested that poor communication 
between pharmacists and GPs regarding the service had led to GPs being 
unclear about the purpose of MURs and therefore not seeing value in the 
service.6.8  That, in combination with the volume of paperwork associated with 
MURs during early implementation, had aggravated GPs6 and may have led to 
very few patients being referred into the service by GPs8.  This was supported 
by reports of better GP support for the service where good relationships 
between pharmacies and practices already existed.8  This suggests that if 
pharmacy is to avoid this pitfall when implementing the NMS, pharmacists 
and GPs must communicate to ensure that GPs understand the purpose of the 
new service.  Pharmacists should also avoid sending unnecessary paperwork 
to GPs if they are to avoid aggravating them.  It also emphasises the 
importance of good relationships between pharmacies and GP practices and 
suggests that pharmacists should endeavour to foster good relationships if 
they want GP support for the services they provide.  It has also been 
proposed that one way to build trust between GPs and pharmacists would be 
to introduce a service for one condition and establish that it is beneficial for 
that condition before including other conditions.9  This suggests that the 
introduction of the NMS may help to build trust between GPs and pharmacists 
if it is found to be helpful in the four disease areas eligible for the service.  
A facilitator to the provision of MURs identified by the national evaluation of 
the new community pharmacy contract was the location of community 
pharmacies.  It was found that pharmacies located close to GP practices 
conducted more MURs.8  It is possible that proximity of GP practices may 
affect NMS provision more greatly than MUR provision as the eligibility criteria 
for MUR states that the patient must have been receiving prescriptions from 
the pharmacy for three months whereas a NMS may be provided to any 
patient receiving an eligible medicine; they do not need to be a regular 
patient.  I would suggest that some patients receiving a prescription for a new 
medicine are likely to get that first prescription dispensed at the nearest 
pharmacy rather than their regular pharmacy which may be located further 
away from the GP practice.  This would mean that pharmacies co-located with 
GP practices may have more opportunities to provide the NMS than 
pharmacies further away. 
An increase in pharmacist workload is often cited as a barrier to service 
provision and a commonly reported obstacle to MUR provision along with a 
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lack of support staff.6-8,96,103  However in situations where there was sufficient 
support staff effectively used to free the pharmacist to conduct MURs, this 
was found to facilitate MUR provision.8,96  Concerns have been raised that the 
increasing workload on pharmacist could affect patient safety.104-108  Since 
 DQG WKH LQWURGXFWLRQ RI 085V D SKDUPDFLVW¶V potential workload has 
increased with the expansion of services they can provide, therefore the 
effective and efficient use of support staff had become increasingly important 
DQG LW LV OLNHO\ WKDW SKDUPDFLVWV¶ZRUNORDGPD\EH SURSRVHG DV D EDUULHU WR
NMS implementation. 
3UHYLRXVVWXGLHVKDYHVKRZQWKDWDKHDOWKFDUHSURIHVVLRQDO¶VNQRZOHGJHRID
service and their attitude and confidence towards providing it can affect 
service implementation.96,109-111  In addition, several studies have found that 
positive pharmacist attitudes facilitated MUR implementation and provision.6,8  
It has been suggested that this positive attitude towards MURs stems from 
pharmacists seeing the service as an opportunity to use their professional 
skills.7  A study in New Zealand suggested that pharmacists see service 
provision as crucial to the future of pharmacy as a profession which may also 
FRQWULEXWH WR SKDUPDFLVWV¶ PRWLYDWLRQ WR SURYLGH VHUYLFHV112  This suggests 
WKDW SKDUPDFLVWV¶ DWWLWXGHV WRZDUGV WKH 106 could facilitate or hinder the 
implementation of the new service.  The NMS service is an opportunity to 
IXUWKHUXVHSKDUPDFLVWV¶SURIHVVLRQDOVNLOOVVR LW LVSRVVLEOH WKDWSKDUPDFLVWV
may welcome the new service. 
In order to provide MURs, pharmacists must undergo training in order to 
become accredited to provide the service.  This need for accreditation has 
been identified as a barrier, and good consultation skills and the provision of 
training opportunities as facilitating MUR implementation and provision.6,103  
Whilst good consultations skills facilitated MUR implementation, it has been 
found that pharmacists do not always demonstrate these skills in MUR 
consultations and that specific training in conducting patient-centred 
consultations may be beneficial.113   A potential way to facilitate NMS 
provision would be to ensure that there are opportunities for pharmacists to 
undergo training in patient centred consultations. However, an Australian 
study found that pharmacists perceived training in communications skills as 
less necessary than training in other areas for the provision of extended 
pharmacist roles, supporting the idea that pharmacist see themselves as 
already possessing good communication skills.111 
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There seems to have been a further barrier to pharmacists conducting MURs 
as several studies identified that a proportion of accredited pharmacists were 
not providing the MURs in the first and second year of the service.8,103  
Bradley et al IRXQG WKDW SKDUPDFLVWV¶ ODFN RI FRQILGHQFH LQ SURYLGLQJ 085V
acted as a barrier to MUR implementation.6  This may explain why some 
pharmacists do not go on to provide MURs after becoming accredited.  In the 
case of NMS implementation, accreditation is very unlikely to act as a barrier 
because the process is very different, with pharmacists having to complete a 
declaration of competence.  Good consultation skills and the provision of 
training opportunities are still relevant to the NMS therefore it is likely that 
they could facilitate the implementation of the new service.  However, the 
findings from MUR research suggest that pharmacists need to be confident in 
providing the new service if they are to move from being accredited to 
actually providing the NMS to patients. 
A study by Latif et al found that pharmacists reported that personal financial 
incentives would facilitate MUR provision.7  In addition research into other UK 
services and a Finnish pharmacy service found that inadequate remuneration 
is viewed as a barrier to service implementation.115-117  This suggests that the 
payment structure of the NMS has the potential to facilitate or hinder the 
implementation of the new service and therefore needs careful consideration. 
Several studies examining medicine review services found that patients see 
pharmacists as a source of reassurance for their medicine taking 
behaviour.118,119  The NMS is specifically designed to offer patients 
reassurance and support for medicine taking provided by pharmacists, and 
therefore does not represent a change in role of the pharmacist as viewed by 
patients.  This could potentially facilitate the provision of NMS as patients may 
be more willing to consent to the service. 
In order to identify barriers and facilitators to NMS implementation and 
provision, the service needs to be evaluated.  The next section discusses how 
the NMS could be evaluated.  
 
1.6  Service Evaluation 
When evaluating a service, the investigations can be formative (aiming to use 
the results to develop or improve the service) or summative (aiming to 
produce results to inform a decision as to whether the service should be 
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continued).120  Traditionally health services have been evaluated using 
'RQDEHGLDQ¶V Structure, Process and Outcome model.  µStructure¶ refers to 
µWKH FRQGLWLRQV XQGHU ZKLFK FDUH LV SURYLGHG¶118 which include material 
resources, human resources and organisational characteristics.  µProcess¶ 
refers to tKHDFWLYLW\RIKHDOWKFDUHDQGµ2utcome¶ covers all changes that can 
be attributed to the health care.  These outcomes can be clinical, physical, 
social or psychological as well as patient opinions of the service.121  
When assessing the quality of the structure in place for the provision of the 
NMS one could look at the availability of a consultation room, whether the 
pharmacist is able to conduct telephone calls in the consultation room, and 
the mechanism in place for recording the consultations.  Human resources 
could also be examined; whether or not the pharmacist conducting the NMS is 
the sole pharmacist and what support is provided by other pharmacy staff.  
The remuneration paid to pharmacies for the provision of the NMS, and the 
suitability of the payment structure could be investigated as part of an 
assessment of the quality of the structure. 
The process of a service should be assessed µLQUHODWLRQWR deviation from pre-
defined standards¶120.  Therefore what happens in each of the three stages of 
the service should be examined when assessing the process of the NMS.  This 
could include investigating whether pharmacists use the consultation 
schedules provided and how pharmacists complete records of the 
consultations, for example, do pharmacists fully complete the consultation 
records? 
An assessment of the outcomes of a service should look at the effectiveness 
of the service in achieving its goal.121  In the case of the NMS, the goal of the 
service is to improve adherence to medicines and therefore reduce medicines 
waste.  Therefore to assess the outcomes of the NMS one would need to find 
out whether the NMS improves adherence. 
This doctoral project evaluates the implementation of the NMS, therefore 
some aspects of the structure-process-outcome model are not appropriate.  
Whilst it remains helpful to consider the structure and processes in place for 
the provision of NMS, outcomes are less relevant when considering the 
implementation of the service and I would suggest that investigating barriers 
and facilitators to NMS implementation would be more informative at this 
stage. 
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Chapter 2: Methods Overview 
2.1  Aims and Objectives 
The overall aim of this project was to evaluate the implementation of the NMS 
in community pharmacies in England. 
The objectives were to: 
x Investigate how the NMS was developed and introduced into 
community pharmacies 
x Identify potential barriers and facilitators to NMS implementation prior 
to the services introduction 
x Identify actual barriers and facilitators affecting NMS implementation 
x Investigate the proportion of prescription items that are eligible for the 
NMS 
x Investigate the uptake of the service 
x Understand the types interventions pharmacists make when providing 
the NMS 
2.2  Available Methods  
When assessing the implementation of the NMS it would have been possible 
WRXVHTXDQWLWDWLYHPHWKRGVµthe measurement and analysis of observations 
in a numerical way¶TXDOLWDWLYHPHWKRGVµsocial research which is carried out 
in the field and analysed largely in non-statistical ways¶RUDFRPELQDWLRQRI
the two.120 
Quantitative methods can be used to test hypotheses and include randomised 
controlled trials, surveys and numerical analysis of collected data.  Qualitative 
methods include gathering data through conducting interviews and focus 
groups, or through observations.  As these methods are used to explore and 
understand phenomena they do not require hypotheses, therefore are suited 
to exploratory research.120 
2.2.1 Qualitative Methods 
Although often associated with quantitative research, one method available 
for qualitative research is the use of questionnaires.  This is generally a list of 
open-ended or closed questions for participants to answer.  The advantage to 
using a questionnaire method would be that it would be possible to gain 
information from a large sample of participants relatively easily with minimum 
cost.  It would be convenient for participants, requiring them to give up less 
of their time and allowing them to answer the questions at a time of their 
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choosing.  However questionnaires often have low response rates and require 
focussed questions, whether open or closed, so are less suited to exploratory 
studies.120 
Focus groups are commonly used to explore views of participants through the 
discussion of topics so are an excellent way of generating information 
regarding exploratory areas.  The format of focus groups allows researchers 
to tailor the discussion topics to the participants, taking in to account varying 
levels of understanding.  The disadvantages to this method are that it is 
relatively labour intensive and so not practical if information from a large 
sample of participants is desired, and that it requires participants to attend a 
session at a fixed time and date.  In addition, whilst the discussion generated 
by focus groups can be useful for exploratory subjects, a group setting may 
prevent some participants from expressing their true thoughts or experiences, 
either through a fear of judgement, or an awareness of commercial 
sensitivities.120 
Interviews are a flexible method for qualitative research, allowing researchers 
to make them as structured or unstructured as the topic requires.  They have 
many of the same advantages as focus groups in that they can be tailored to 
individual participant needs and can be employed to investigate exploratory 
topics.  Similarly, they share some of the disadvantages of focus groups; they 
are labour intensive and require participants to give up more of their time 
than for a questionnaire.  However, conducting individual participant 
interviews is more flexible than focus groups, allowing the interviews to be 
FRQGXFWHGDWDWLPHDQGSODFHRIWKHSDUWLFLSDQW¶VFKRRVLQJ,QWHUYLHZVDOVR
provide a greater level of participant anonymity and allow conflicting 
viewpoints to be expressed more easily than in focus group settings.120  
Therefore interviews are a useful tool for eliciting information from 
participants for whom focus groups are not practical. 
Another qualitative method that can be used is observations.  This method 
involves systematically observing a phenomena and making detailed field 
notes.  Like interviews, observations can be conducted with varying levels of 
structure.  Highly structured observations are generally used to gain 
quantitative data whereas more unstructured observations are used to 
generate qualitative information.  The advantage of observation studies are 
that results closely reflect reality, however the presence of a researcher in an 
environment may affect the results gained.  Observational studies are very 
time consuming and therefore expensive, so only a small number of 
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environments can be sampled meaning that the results would be less 
generalisable than a study sampling more environments.120 
2.2.2 Qualitative Analysis 
Once data has been produced using a qualitative method, it needs to be 
analysed to produce results.  Thematic analysis is a way of breaking down 
qualitative information into themes using codes.  The code may be a list of 
themes or a more complex model of themes relating to each other.  The code 
can be created inductively from the raw data or deductively using theory or 
prior research.  Inductive thematic analysis is particularly useful in 
exploratory research where there is no prior research to base the analysis on.  
There are 3 stages when using thematic analysis: stage 1, sampling and 
design issues; stage 2, developing themes and a code; stage 3 validating and 
using the code.123 
Stage 1: Sampling and Design Issues 
This stage occurs during the design of a study requiring the method of 
sampling as well as the unit of analysis and unit of coding to be decided on.  
The unit of analysis is µWKHHQWLW\RQZKLFKWKHLQWHUSUHWDWLRQRIWKHVWXG\ZLOO
IRFXV¶124.  For example if a study wanted to investigate the relationship 
between the size of a pharmacy chain and uptake of the NMS by interviewing 
individuals from different pharmacy chains, the unit of analysis would be the 
pharmacy chain.  The unit of coding is µWKHPRVWEDVLF VHJPHQW RI WKH UDZ
GDWD¶.  In the example above, the unit of coding would be the individual 
participants.124 
Stage 2: Developing Themes and a Code 
It is at this stage that the themes and code are established.  In a deductive 
approach to thematic analysis the code is derived from theory or from 
previous research.  This code will need to be reviewed and amended to make 
it applicable to the raw data.  In an inductive approach, a code is developed 
from the raw data.  First it is necessary to become familiar with the data by 
reading the transcripts or listening to the audio recordings repeatedly for each 
unit of analysis (subsamples).  The information should then be summarised 
and themes within subsamples identified.  The themes can then be compared 
across subsamples and the differences between the subsamples¶ themes 
should be used to create statements that differentiate the two subsamples.  
These statements, or themes, become a code.  Each theme should have a 
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label, a description, indicators, examples and exclusions.123  The last step in 
developing themes and a code is to ensure reliability.  The code should be 
applied independently to another subsample of data by the researcher who 
developed the code, and by a second researcher, to determine the 
consistency of the themes being applied. 
Stage 3: Validating the Code 
At this point the code developed in stage 2 should be applied to the rest of 
the sample of data.  Then the code can be validated statistically or 
qualitatively in order to determine the differentiation of the subsample for 
each theme.  The themes that show differentiation become the validated 
code. 
The Hybrid Inductive Approach to Thematic Analysis 
In some studies there is only one unit of analysis, therefore a true inductive 
approach is not possible as there are no subsamples. In these cases a hybrid 
inductive approach can be used.  For example, if a study aims to find out if 
there is a difference in the views of employee pharmacists and locum 
pharmacists regarding the NMS, there are two subsamples (employee 
pharmacists and locum pharmacists) therefore a true inductive approach can 
be used.  However, if a study just aims to understand the views of 
pharmacists regarding the NMS there are no subsamples to compare and a 
hybrid inductive method must be used.  In this method of analysis themes are 
developed in the same way as the pure inductive method described above, 
but the step in stage 2, where the themes from subsamples are compared is 
omitted.  The code is derived from the themes identified and applied to the 
rest of the raw data and reliability determined in the same way as for the 
pure inductive method.  The validation of the code described in stage 3 of the 
inductive method cannot be conducted if there is only one unit of analysis.123 
2.2.3 Quantitative Methods 
Quantitative methods are used when the desired data is in numerical form.  
Quantitative methods can be used to answer several types of research 
questions, including questions that demand a numerical answer (for example, 
the number of pharmacies providing the NMS), questions about numerical 
change (for example, did more pharmacies provide the NMS in October 2011 
or December 2011?), questions about phenomena (for example, did the 
introduction of the NMS affect MUR provision in October 2011?), and 
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questions testing hypotheses (for example, hypothesis: pharmacies co-
located with GP practices have more opportunities to provide the NMS than 
pharmacies located further away, question: is this true?).  These questions 
can be answered using several different methods. 
A common method used in quantitative research is the survey. They can be 
designed to ask specific questions in order to gain numerical data that can be 
used to answer research questions.  Surveys allow large populations to be 
sampled relatively cheaply.  Surveys can be administered through 
questionnaires and interviews but have more structured questions, often with 
a predetermined choice of answers, than qualitative questionnaires or 
interviews.120  There are many validated questionnaires available in published 
literature, such as the Morisky scale35 which is used to determine adherence. 
Randomised controlled trials (RCTs) are most commonly used to compare 
effectiveness, whether that is of interventions or drugs, and are the gold 
standard for clinical trials.  An important feature of RCTs is that participants 
are randomly allocated to a group and they should ideally be unaware of 
ZKLFK JURXS WKH\ DUH LQ DOWKRXJK WKLV LVQ¶W DOZD\V SRVVLEOH  7KH VHFRQG
important characteristic of RCTs is that the variables that could potentially 
affect the outcome are controlled meaning that the different groups within the 
trial should be treated identically except for the variable being tested.  Whilst 
RCTs are seen as the gold standard for determining effectiveness of 
interventions, a criticism of the method is that it is an artificial environment 
due to all bar one variable being controlled.  They also require very clear and 
specific research questions and therefore are inappropriate for most 
exploratory research.  A third drawback to RCTs is that they are relatively 
expensive to run.120 
Another way of answering research questions quantitatively is through audit.  
Audit can be defined as µA procedure whereby an independent third party 
systematically examines the evidence of adherence of some practice to a set 
RIQRUPVRUVWDQGDUGV IRUWKDWSUDFWLFHDQG LVVXHVDSURIHVVLRQDORSLQLRQ¶124  
)RUH[DPSOHLIWKHUHVHDUFKTXHVWLRQZDVµGRSKDUPDFLVWVXVHWKHTXHVWLRQV
SURYLGHGIRU106FRQVXOWDWLRQVDVWKH\DUHZULWWHQ"¶DQDXGLWFRXOGEHFDUULHG
out where a researcher observed NMS consultations and recorded whether 
each question in the services specification had been asked.   
Quantitative data is analysed mathematically with statistical tests used to 
determine the significance of the results.  There are rules governing what 
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each statistical test can be used for and when they are not appropriate.  
When designing a quantitative study it is important to calculate the sample 
size needed to allow the statistical analysis to detect a change in the variable.   
2.3 Study Designs 
2.3.1 Understanding the development and introduction of the service  
After examining the different ways the implementation of the NMS could be 
investigated, I decided that it would be important to understand how the 
service was developed and introduced into pharmacies because there is so 
little literature on the subject.  One way to find this out would be to explore 
the experiences of individuals involved in the process of developing and 
implementing the service.  Individual interviews were chosen as the most 
appropriate method to use as the number of people involved in the 
development and introduction of the NMS was small.  In addition, interviews 
FDQ EH WDLORUHG WR PHHW WKH SDUWLFLSDQWV¶ RU VWXG\¶V QHHGV PDNLQJ WKHP
particularly suited to exploratory studies with heterogeneous populations like 
this one. 
2.3.2 Identifying Potential and Actual Barriers and Facilitators to 
NMS Implementation 
An examination of the literature revealed many barriers and facilitators that 
had affected the implementation and provision of other services.  Therefore I 
decided to explore what barriers and facilitators affected NMS 
implementation, what barriers and facilitators were anticipated prior to the 
introduction of the NMS and whether they were actually experienced in 
practice.  As the barriers and facilitators to the implementation of other 
services could all be found in pharmacies it would make sense if an 
investigation of NMS barriers and facilitators was conducted in pharmacies, or 
using pharmacists as participants. 
A possible way of investigating the barriers and facilitators to NMS 
implementation would be to ask pharmacy staff and others involved with 
implementing new services in community pharmacies. As the literature 
identified community pharmacist attitudes to a service as facilitating the 
implementation of the service5,8,109,110, it would be sensible to use pharmacists 
as representatives of pharmacy staff.  Superintendent pharmacists could be 
included in the study as they play a strategic and an administrative role, 
taking ultimate responsibility for pharmacists employed by their organisations, 
and the services they provide.121 The implementation of a new service will 
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therefore be heavily influenced by them and their views will impact on the 
attitudes and opinions of the pharmacists they employ.   
In this study the views of community pharmacists and superintendent 
pharmacists were elicited through focus groups and interviews respectively.  
Using a combination of methods allows the advantages of each method to be 
utilised.  Focus groups can be used to generate discussion which is 
particularly useful for exploratory research and interviews can be tailored to 
DQLQGLYLGXDO¶VQHHGVDQGFRXOGWDNHSODFHDWDWLPHDQd place convenient to 
the participant.   
2.3.3 Investigating the proportion of prescription items that are 
eligible for the NMS  
The literature from other pharmacy services suggested that adequate 
remuneration is an important factor in the success or failure of a service.115-117  
The payment structure is unusual for pharmacy services as it links service 
provision to dispensing volume.  As the payment structure is based on the 
assumption that 0.5% of all prescription items dispensed are eligible for the 
service, it was deemed important to find out whether the assumption is 
accurate.  Therefore this evaluation will investigate the proportion of 
prescription items dispensed in pharmacies that are eligible for the NMS.   
The method chosen for this study is an audit in a sample of community 
pharmacies, looking at the opportunities for providing the NMS as well as the 
numbers of prescription items dispensed.  This method could collect more 
LQIRUPDWLRQ ZLWK OHVV LPSDFW RQ D SKDUPDF\¶V ZRUNORDG DQG ZRXOG QRW EH
affected by pharmacy staff not identifying every NMS opportunity.  However, 
this method would be time consuming and therefore the number of 
pharmacies that could be sampled would be less than a questionnaire could 
sample. 
2.3.4 Investigating the uptake of the NMS and the interventions 
pharmacists make when providing the NMS 
The uptake of MURs was gradual, linked to identified barriers to MUR 
implementation.8  Therefore as well as investigating barriers and facilitators to 
NMS implementation, it would be important to understand the uptake of the 
service.  In addition the structure-process-outcome model would suggest that 
an evaluation of a service should include an investigation into how the service 
is conducted.   
55 
 
NMS service records will be analysed in order to understand the uptake and 
provision of the NMS service.  Service records contain information specified by 
the data recording requirements set out in the service specification, therefore 
they could be used to understand the numbers of NMS being conducted as 
well as the number and types of interventions pharmacists make during the 
FRQVXOWDWLRQV 6HUYLFH UHFRUGVFDQEHDFFHVVHGWKURXJKDSKDUPDF\FKDLQ¶V
head office, allowing all pharmacies within a chain to be sampled.  However, 
using data from one chain may lead to the results being less likely to be 
generalizable as factors related to the chain will have influenced the uptake.  
A disadvantage to using service records is that it relies on pharmacists 
completing records of the NMS consultations so the quality of the data may be 
variable. 
After careful consideration of the different methods available I decided that in 
order to meet the objectives, the following studies would be carried out: 
x Stakeholder interviews regarding the development and implementation 
of the New Medicine Service 
x Pre-implementation focus groups and interviews exploring the views 
and opinions of community pharmacists and superintendent 
pharmacists regarding the New Medicine Service 
x Post-implementation focus groups and interviews exploring the views 
and experiences of community pharmacists and superintendent 
pharmacists regarding the New Medicine Service 
x Quantitative study investigating the proportion of prescriptions 
dispensed that are eligible for the New Medicine Service 
x Statistical analysis of service records from a large pharmacy chain 
 
2. Ethical Approval  
The research team were advised by National Research Ethics Service and the 
local PCT Research and Development department that the stakeholder 
interview, pharmacist focus group and superintendent pharmacist interview 
studies fell into the category of service evaluation, therefore ethical approval 
was not required. The studies¶ protocols were reviewed by a senior academic 
in the School of Pharmacy at the University of Nottingham. 
The research team were also advised by University Research Governance and 
the local Primary Care Trust Research and Development leads that ethical 
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approval was not required for the study investigating the proportion of NMS 
eligible patients as it was classified as an audit - the researcher conducting 
the study was a part time employee of the pharmacy chain from which the 
data was collected and there was no intervention.  The study protocol was 
reviewed by a senior academic at the University of Nottingham and approval 
gained from the pharmacy chain head office and relevant area managers. 
The study exploring the PharmaBase service data was also determined as not 
requiring external ethical approval because the data were anonymised, the 
researcher was an employee of the chain providing the data, and the study 
was classified as service evaluation.  The protocol was reviewed and approved 
by senior managers of the pharmacy chain and acedemic supervisors at the 
University of Nottingham. 
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Chapter 3: Stakeholder Interviews Regarding the Development and 
Implementation of the New Medicine Service 
3.1  Introduction 
The purpose of this study was to develop and understanding of how the NMS 
was developed and implemented.  As there is no published literature on the 
subject, key stakeholders involved in the development and implementation 
were interviewed. 
3.2  Methods 
In this study participant views and experiences of the development and 
implementation of the NMS were sought in individual semi-structured 
interviews.  This method of data collection was chosen for two reasons.  
Firstly the stakeholders we wished to sample were spread out nationally so 
focus groups would have been difficult to arrange and could have prevented 
some individuals participating.  Secondly it was felt that these participants 
would be more open in individual interviews compared with in a focus group 
setting, as they may have had concerns regarding inter-participant 
confidentiality due to their roles within the organisations. 
Data Gathering 
Stakeholders involved in the development and implementation of the NMS 
were identified through informal conversations with individuals already known 
to have been influential in the development of the service.  Participants were 
recruited through email invitations and personal contacts and an effort was 
made to include participants from each organisation known to be involved in 
the development and implementation of the NMS.  The number of participants 
in this study is low due to the limited number of organisations and individuals 
involved in the service development process. 
Six interviews were conducted with a total of seven participants.  Two of the 
interviews were conducted face-to-face and the remaining four interviews 
were conducted by telephone according to participant preference.  All 
interviews were conducted by KW and averaged 52 minutes in length. 
The interview schedule used in this study has been included in Appendix 1.    
The schedule included questions regarding the involvement of the participant 
and their organisation in the development of and preparation for the NMS, the 
implementation of the service, the payment structure and the effect of the 
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introduction of the NMS on the participant and their organisation as well as on 
the pharmacy profession. 
Analysis 
All interviews were audio-recorded and transcribed verbatim and the 
transcripts read repeatedly before analysis began.  The transcripts were 
analysed to produce a chronological narrative of the process of developing 
and implementing the new service.  It was felt that this would be more helpful 
to understanding the process than using thematic analysis.  In order to 
produce the chronological narrative of the development and implementation 
of the NMS, the analysis involved each of the transcripts being read and 
summarised focussing on the activity at time points throughout the 
development and implementation process.  These summaries were then 
consolidated to produce a coding framework of events and activities over 
time.  This coding framework was applied to the transcripts to ensure that no 
important activities were missed. 
 
3.3  Results 
The six interviews were conducted between February and May 2012, several 
months after the introduction of the NMS, so that participants could be 
questioned about the implementation of the service.  The seven participants 
in this study represented a number of different organisations who were 
involved in the development and implementation of the NMS including the 
PSNC, NHS Employers &RPSDQ\ &KHPLVWV¶ $VVRFLDWLRQ 1DWLRQDO 3KDUPDF\
Association, Numark as well as pharmacy contractors.  Some individuals 
represented more than one organisation.  Demographics of the participants 
have not been reported in order to protect their anonymity.  Due to the 
restricted number of potential participants, the individuals in this study were 
not promised complete confidentiality, however an effort has been made to 
reduce the likelihood of being identified wherever possible.  In particular, no 
demographic or interviewee status information has been reported with 
quotes. 
The study aimed to question participants about their involvement with the 
development and implementation of the NMS.  Data saturation (the point at 
which no new themes emerge)120 was unlikely to be reached due to the 
limited number of potential participants and their different roles in the 
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development and introduction of the service. However data saturation was not 
required as this study did not use grounded theory, there was however 
consensus regarding some details.  
The analysis of the interviews found 4 key phases in the development and 
implementation: pre-negotiation, negotiations, the launch and the post-
implementation phases. 
 
3.3.1  Pre-negotiation phase 
The NMS is based on research conducted by a team at the London School of 
Pharmacy, led by Professor Nicholas Barber.  The original study was 
conducted in the late 1990s and early 2000s and the results published later.  
One participant reported that the PSNC were aware of the results of the study 
by 2005 at the latest. 
Early in 2008 it was widely discussed that a new white paper was being 
drafted that would look at the contribution of pharmacy to the NHS.  As a 
result of this, a meeting was held in February 2008 between pharmacy 
stakeholders (including members of the CCA and Prof Barber), and the 
Department of Health (including the Director General of Commissioning, Mark 
Britnell, and the Chief Pharmaceutical Officer, Keith Ridge).  During the 
meeting the pharmacy stakeholders presented their ideas of how pharmacy 
services could be developed which included the original research conducted by 
the London School of Pharmacy. 
µ6RZHSUHVHQWHGRXULGHDVRIZKDW«ZHWKRXJKWFRPPXQLW\
pharmacy could do to improve the health of the public and because 
Nick [Barber] ZDVWKHUHZHWDONHGDERXWWKLVVHUYLFHWKDWZH¶G
ZRUNHGRQ«DQGZHSUHVHQWHGVRPHRIWKHHYLGHQFH¶SH1 
Participants reported that the Department of Health were interested in the 
original research and saw published research evidence for the service as 
desirable.  As a result of this the 2008 white paper included what participants 
saw as a reference to a service based on the study conducted by Prof %DUEHU¶V
team.   
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3.3.2  Negotiation Phase 
After the publication of the 2008 white paper NHS Employers entered 
discussions with the Department of Health about potential new services that 
would result in µDQ LQFUHDVHG SDWLHQW IDFLQJ role for community pharmacists 
XVLQJPRUHRI WKHLU VNLOOV¶ (SH6).  At this time some representatives of NHS 
Employers attended a meeting where Prof Barber spoke about the original 
research his team had conducted.  Whilst the NHS Employers were interested 
in the potential of a service based on the published study, it was the economic 
evaluation that particularly caught their attention as it was important that any 
new service had a µEXVLQHVV FDVH LQ RUGHU WR JHW DQ\ PRQH\ WKURXJK WKH 
finance department and the treasury, and Nick made a very convincing case 
IRULQYHVWPHQWLQWKLVVHUYLFH¶ (SH6). 
At this stage NHS Employers were given a mandate from the Department of 
Health to negotiate changes to the pharmacy contract with the PSNC.  The 
negotiations were conducted by NHS Employers and the PSNC in a series of 
closed meetings.  As well as the service that would become the NMS, changes 
to clinical governance and MURs were also discussed.  On entering 
negotiations NHS Employers had three requirements for the new service; it 
must be based on evidence, it must be evaluated and that it should be within 
a funding envelope without risk of overspend. 
There were three main areas for negotiations; the service specification, the 
disease groups that would be included, and the funding for the service.  
Initially discussions focused on the structure of the service with both parties 
keen to make the new service as similar to the original research as possible, 
as that is where the evidence for benefit lies;  
µ:HGHFLGHGWRNHHSTXLWHFORVHO\WRWKHSURRIRIFRQFHSWUHVHDUFK
the rationale for that being that you need an evidence base to get 
the money out of the Treasury, and there was a risk that if we 
changed the service too much from that point they couOGVD\µ\RX
FDQ¶WDSSO\WKDWSURRIRIFRQFHSWUHVHDUFKEHFDXVHLW¶VFRPSOHWHO\
GLIIHUHQW¶ SH5 
A key detail discussed was whether the service should be conducted by 
telephone or in face to face consultations.  The interventions and follow-up 
consultations in the original research had been conducted by telephone using 
two pharmacists located at a SKDUPDF\FKDLQ¶VKHDGRIILFH:KHQFRQVLGHULQJ
the method of conducting consultations the PSNC and NHS Employers had a 
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concern that allowing the consultations to be conducted by telephone only 
may OHDG WR WKH VHWWLQJ XS RI 106 µFDOO FHQWUHV¶ 6+.  They spoke to 
members from the team that conducted the original research who reported 
that the study had used centralised pharmacists conducting telephone 
interviews for practical reasons and that it was their view that face-to-face 
consultations would be even more beneficial to patients.  Therefore whilst 
making provision for consultations to be conducted by telephone, the PSNC 
and NHS Employers stressed that face to face consultations should be the 
norm.   It is worth noting that some participants had the perception that the 
PSNC and NHS Employers did not ask for any guidance from stakeholders 
until after the service had been approved by the Minister for Health, but the 
information gained from the PSNC and NHS Employers contradicts this.  It is 
an example of a misconception due to rumour.  
One aspect of the service specification that received complete consensus was 
that the service should be recorded electronically.  The reason given for this 
was that in the case of MURs, there is little evidence of what happens in the 
consultations as many are recorded on paper, or are recorded on patient 
medical records (PMRs) that are not accessible outside the pharmacy chain.  
Therefore the PSNC and NHS Employers were keen that NMS consultations 
should be recorded electronically on a national database.  PharmaBase (now 
called PharmOutcomes) was the preferred electronic database. 
The second distinct area of negotiation was the disease groups that would be 
eligible for the service.  Once again the negotiators were keen to stick closely 
to the original research: 
µ7KHUHZHUHVLPLODULWLHVEHWZHHQWKHFRQGLWLRQVLQUHVHDUFKDQG
ZKDWWKHFRQGLWLRQVIRUWKHVHUYLFHDUHQRZ¶6+ 
As well as considering the disease groups included in the original research 
(patients aged 75 years old or over, or had one or more of the following 
conditions: stroke, coronary heart disease, asthma, diabetes and rheumatoid 
arthritis), negotiators were keen for the included disease groups to be ones 
that pharmacists were confident they could make a difference to and that 
were relatively common.  There was always an intention that the service 
would be extended to include more disease groups but that the µILUVWWUDQFKH¶ 
(SH6) of disease groups were chosen to provide the best opportunity for 
evaluation of the service.  Some disease groups were excluded from the 
service not because there was a belief that they would not benefit, but that 
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the conditions were so complex that it would be difficult to evaluate the effect 
of the service.  Individual drugs eligible for the NMS were chosen later, after 
some analysis of RQH SKDUPDF\ FKDLQ¶V patient medical records to identify 
commonly initiated drugs for the included disease groups. 
The last area of negotiation was the funding of the service and how pharmacy 
contractors would be remunerated for providing the NMS.  It was clear that 
the NHS Employers were not prepared to negotiate a pay per item of service 
structure and that the remuneration for the NMS should not be greater than 
for providing MURs.  Participants explained this as part of a move towards 
target payments for bundles of care: 
µ,ILWZHUHSRVVLEOHWRKDYHDV\VWHPZKHUHLW¶VQRWVWUDLJKWLWHPRI
service linked, which was a strong desire from the NHS, because 
XOWLPDWHO\WKHGLUHFWLRQRIWUDYHO«ZLWKFRQWUDFWXDOIXQGLQJLVPRUH
around fees per packaJHRIFDUH¶ SH5 
The negotiators had a desire to incentivise pharmacists to capture as many 
eligible patients as possible and it was important to them to minimise any risk 
to the NHS of overspend.  With these principles in mind a payment structure 
was developed that linked remuneration to the volume of prescriptions 
dispensed.  The targets for pharmacies required an opportunity rate to be 
FDOFXODWHG  7KLV ZDV FRQGXFWHG XVLQJ D QDWLRQDO FKDLQ RI SKDUPDFLHV¶ 305
database and a preliminary list of eligible medicines to examine the number of 
new prescriptions versus dispensing volume.  The analysis found that the 
average opportunity rate was 0.5% of dispensing volume, but this rate 
decreased in pharmacies with very low or very high dispensing volumes.  The 
results also showed some monthly variation in the opportunity rate and 
dispensing volume, therefore the PSNC proposed a quarterly payment scheme 
that would mean that the effect of variation would be reduced.  This was not 
included in the final payment structure.  At this point some concerns were 
raised about factors that may potentially affect the opportunity rate, including 
WKHOHYHORI µSDWLHQWFKXUQ¶SDWLHQWVZKRGRQRWXVHDUHJXODUSKDUPDF\EXW
who present prescriptions at many different pharmacies).  However it was 
decided that these factors would have minimal impact on the opportunity 
rate. 
As well as incentivising pharmacists to provide the NMS at every opportunity, 
the negotiators were also keen to encourage quick uptake of the service.  
Therefore they introduced an implementation payment into the funding 
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structure that pharmacy contractors would be able to claim after completing 
six NMS.  It was reported that the funding allocated for the NMS had been 
taken from the dispensing margin and was not additional money for 
pharmacy: 
µ,WZDVPDUJLQWKDWZDVEHLQJWDNHQDZD\>IURPGLVSHQVLQJ@DQG
they would re-invest [it in the NMS]¶6+ 
During the development and negotiations for the service there was a change 
in government and therefore the Minister for Health also changed.  
Participants reported that this caused a delay in approval for the NMS.  The 
service was approved by the Minister in February or March 2011 and a smaller 
team made up of representatives for the PSNC, NHS Employers and the 
Department of Health addressed the fine detail for the NMS service 
specification.  This marked a move from the negotiation phase to the launch 
phase of the service. 
 
3.3.3  Launch Phase 
The launch of the NMS was coordinated by an oversight group made up of the 
PSNC, NHS Employers and the Department of Health.  They created working 
groups, collaborating with pharmacy stakeholders, to address certain areas of 
the service.  Examples given included a group set up to look at competency 
and training and a group that decided on the final list of medicines eligible for 
the service.  Stakeholders from across the pharmacy sector were involved.  
They included representatives from training bodies, academia, the 
pharmaceutical industry, as well as representatives from community 
pharmacy. 
All participants reported that stakeholder engagement with the service had 
been good and that there had been more stakeholder involvement in the 
launch of NMS than the implementation of MURs. 
µ6RPHRIWKHZRUNEHWZHHQWKHSKDUPDF\VWDNHKROGHUVZDV
partiFXODUO\LPSUHVVLYH¶SH7 
µ7KLVWLPHURXQGWKHUHZDVOHDUQLQJIURP085V,WKLQN
VWDNHKROGHUVZHUHPRUHLQYROYHG>ZLWKWKH106@¶ SH2 
One key factor suggested as facilitating stakeholder engagement was the 
communication of the importance and purpose of the NMS by the members of 
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the oversight group. Participants reported that this had been done well.  An 
example given of good communication and collaboration with stakeholders 
were the roadshows carried out in August and September 2011.  These 
events provided information describing the structure of the new service as 
well as the purpose of the NMS and where it came from.  The roadshow 
events were a collaborative effort between the PSNC, NHS Employers, Local 
Pharmaceutical Committees and a member of the team that conducted the 
original research.  In addition, the pharmaceutical industry was involved by 
providing financial support for the events. 
Whilst many stakeholders were aware that a new service was likely to be 
introduced, one participant stated that their body had first heard of the 
service when it was announced by the PSNC and NHS Employers in May 2011.  
This meant that when workload and budget had been planned for the 
2011/2012 financial year, allowances had not been made for the introduction 
of a new service.  However, in common with other stakeholders, there was a 
feeling that it was very important to engage with the service and support its 
introduction. 
Whilst the participants were impressed with the level of stakeholder 
engagement with the service, it was also suggested that the launch of the 
NMS could have been further facilitated by a greater degree of stakeholder 
involvement at an earlier stage.  It was suggested that involving stakeholders 
E\ JLYLQJ WKHP D VSHFLILF UROH LQ LQWURGXFLQJ WKH 106 µbinds all the 
stakeholders to the success of the project¶6+DQGWKLVGLGQRWKDSSHQ 
µ7KHVLJQDOIDLOXUHLQDOORIWKLVZDVWKDW>WKHRYHUVLJKWJURXS@GLGQ¶W
ask other organisations what they thought their role was in making 
>WKH106@DVXFFHVV¶ SH1 
The engagement of PMR suppliers was given as an example of stakeholders 
who could have facilitated the implementation of the NMS had they been 
involved in the launch sooner.  PMR suppliers were not engaged until July 
2011 which meant that they had very little time to develop modules for 
recording the service in the PMRs before the NMS was implemented. 
Another criticism reported by participants was that the length of the 
implementation period was too short.  This meant that all stakeholders 
involved in the launch of the NMS were under considerable pressure and 
PDGH WKH LPSOHPHQWDWLRQRI WKH VHUYLFH µFKDOOHQJLQJ¶ +RZHYHUSDUWLFLSDQWV
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were impressed with how quickly stakeholders engaged with the service and 
µgot the message out about the new service¶6+Whilst the short launch 
phase was mainly viewed as a challenge, one participant suggested that it 
facilitated the implementation of the NMS; 
µ,WGLGPHDQWKDWWKHUHZDVDFHUWDLQHQHUJ\WKDWZHFRXOGKDYH
ORVWLIWKHUHKDGEHHQDORQJHULPSOHPHQWDWLRQSHULRG¶ SH6 
 
3.3.4  Post Implementation 
3.3.4.1  Engagement and Uptake  
Participants reported that they saw their role in supporting uptake and 
engagement in community pharmacies as on-going.  Many suggested that it 
was important for them to continue to encourage their members to provide 
the NMS and had dedicated resources to this end.  Support was provided 
through the sharing of good practice and telephone support as well as by 
providing practical tools to facilitate the provision of the service. 
The implementation of WKH106ZDVGHVFULEHGDVµJRRG¶DQGDVEHLQJTXLFNHU
than the implementation of MURs with the provision of the NMS being fairly 
consistent.  Participants gave many reasons for the successful 
implementation.  It was felt that good communication of the purpose of the 
service and pharmacists seeing a clear potential benefit to their patients had 
been important.  
µ7KHRYHUDOOLPSOHPHQWDWLRQKDVEHHQJUHDW,WKLQNSKDUPDFLVWV
have understood what we were trying to achieve and have bought 
LQWRWKDWYLVLRQ¶ SH5 
It was also suggested that by following up patients after the intervention 
consultation, pharmacists were seeing the effect of their intervention and this 
was an important motivation for providing the NMS.  Participants reported 
that aspects of the service structure had facilitated implementation.  Clear 
eligibility criteria for the NMS and the provision of suggested consultation 
questions were suggested as making the service easier to provide and thereby 
facilitating its provision and uptake.  
A key factor that allowed quicker uptake of the NMS compared to MURs was 
the accreditation process.  The process for MUR accreditation took much 
longer as it required the provision of evidence of competencies to a higher 
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education institution, whereas in order to provide the NMS a pharmacist who 
had previously been accredited to provide MURs merely needed to complete a 
self-declaration of competence.  This meant that there was no delay whilst 
pharmacists became accredited between the introduction of the service and it 
being provided in community pharmacies, except where MURs were not 
already being provided.  The process of accreditation for the NMS was also 
described as recognising pharmacists as professionals and marking a move 
towards giving responsibility to pharmacists to ensure they are competent: 
µ5HO\RQXVDVUHJXODWHGKHDOWKSURIHVVLRQDOV:HKDYHDGXW\WR
QRWRSHUDWHRXWVLGHRIRXURZQVSKHUHRIFRPSHWHQFH:H¶YH
moved to that model and I hope it will help us move to that more 
JURZQXSPRGHO¶ SH5 
3.3.4.2  Challenges Encountered 
Another reason suggested by participants for the implementation of the NMS 
being more successful than the implementation of MURs was that fewer 
barriers were encountered in the introduction of the NMS.  The challenges 
cited by participants included the pressure faced by pharmacists, a lack of GP 
and hospital pharmacist engagement, the need for pharmacists to develop 
different skills, data capture, and the payment structure.  Consent was also 
mentioned as an initial barrier but was quickly overcome. 
Participants reported that community pharmacists are under increasing work 
load pressure with dispensing volumes growing year on year and the 
introduction of the Responsible Pharmacist Regulations (regulations setting 
out the level of supervision required for operational activities within a 
pharmacy)125.  The target culture in some pharmacy chains was also 
described as adding to the pressure pharmacists are under and there was 
some concern that there may be understaffing in some pharmacies meaning 
that there was not the support available to allow pharmacists to conduct 
clinical services.  It was suggested that the increasing work load pressure on 
SKDUPDFLVWVPHDQW WKDW µmost of them will be feeling they have got enough 
workload already¶ 6+ DQd this could have affected the uptake of the 
service. 
Another challenge experienced was the lack of GP and hospital pharmacist 
engagement resulting in fewer referrals into the service than hoped for.  Local 
relationships between GPs and pharmacists were cited as the factor 
determining GP engagement with the service whereas a lack of awareness 
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was suggested as the reason for the lack of hospital pharmacist engagement.  
It was also mentioned that the lack of consistency in hospital discharge 
procedures could be a problem and that the rate of hospital referrals into the 
NMS could be increased by pharmacies and hospitals finding solutions locally. 
µ:H¶YHDOZD\VVWUXJJOHGWRZRUNRXWKRZZHFDQKHOSLPSURYH
UHODWLRQVKLSVORFDOO\«XOWLPDWHO\LWFRPHVGRZQWRKRZSHople get 
RQORFDOO\¶ SH6 
Participants highlighted that whilst pharmacists have been conducting face to 
face consultations for several years, this is the first pharmacy service that can 
be conducted by telephone.  There was a view that different skills were 
needed for telephone consultations and this was a challenge pharmacists had 
to overcome during early implementation of the NMS. 
It was suggested that the introduction of the NMS has highlighted the need 
for consistent data capture at a national level as a condition for it receiving 
funding was that it would be evaluated.  This was described as a huge 
challenge as pharmacies use a variety of different PMR systems rather than 
using a universal system to record services.  PharmaBase was introduced as a 
solution to this problem, the idea being that any pharmacy would be able to 
record their NMS consultations on this database that would provide national 
data allowing evaluation of the service.  However participants suggested that 
the uptake of PharmaBase was much lower than the uptake of the service and 
that many pharmacies were not recording the consultations on the database.  
Several reasons for this were proposed.  It was suggested that 
communication from the PSNC about the purpose of the database could have 
been better and had led to PharmaBase being viewed as competing with PMR 
systems.  A second reason for the slow uptake in using the database was that 
recording the service on PharmaBase often resulted in double entry of data as 
it is not integrated with PMR systems.  It was also reported that there had 
been some functional problems with the database but that this had been 
addressed soon after implementation. 
The largest reported obstacle to the successful implementation of the NMS 
was the payment structure. The move away from a pay per item 
remuneration structure to a target based payment was described as 
necessitating a mind-set change for pharmacists and was described as the 
way future services are likely to be funded.   
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µ:KHUHZHDUHJoing with contractual funding is more around fees 
SHUSDFNDJHVRIFDUH¶SH5 
However it was recognised that there were problems with the payment 
structure (detailed in Chapter 1) with pharmacies struggling to meet the 20% 
target.  Rather than encouraging uptake of the NMS, the payment structure 
was described as dis-incentivising and impacting on enthusiasm. 
Participants reported multiple reasons for the failure of the payment structure 
which focused on the assumption that 0.5% of prescription items dispensed 
would be eligible for the NMS.  It was reported that the calculation of the 
opportunity rate was carried out using a preliminary list of medicines which 
could have affected the result; however one participant said that the rate had 
been re-calculated with the final list of medicines and was not significantly 
different.  Another potential limitation of the calculation was that it could not 
DOORZIRU µSDWLHQWFKXUQ¶SDWLHQWVZKR do not have a regular pharmacy they 
use but have their prescriptions dispensed at a variety of pharmacies and so 
would appear to be presenting prescriptions for new medicines at each 
pharmacy they visit).  Without knowing what the rate of patient churn is, it is 
possible that the opportunity rate of 0.5% could be artificially high.  
Stakeholders also reported that the rate varies between different types of 
pharmacies with pharmacies co-located with GP practices seeing more eligible 
items.  Therefore the mean opportunity rate nationally may be 0.5% but 
pharmacies located further away from prescribing practices may see a lower 
rate of opportunity.  Other factors affecting the accuracy of the calculated 
opportunity rate include changing prescribing patterns, and the inclusion of 
titration doses and paediatric prescriptions. 
Another concern was that fluctuating monthly dispensing volume means that 
the opportunity rate in pharmacies could vary each month.  This could cause 
a problem because the targets in the payment structure make no allowance 
for fluctuations and could lead to pharmacies losing out financially.  The PSNC 
had proposed the inclusion of a quarterly averaging system during the 
negotiations to address this problem however it was not included in the final 
payment structure. 
3.3.4.3  The Effect of the NMS 
Participants reported that the number of MURs dipped temporarily after the 
introduction of the NMS as pharmacists focused on the new service.  However 
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the dip in MURs quickly resolved itself and the NMS does not seem to have 
adversely affected the provision of other services in the long term. 
It was also suggested that the process of implementing the NMS had built 
relationships, not only between pharmacists and patients, and pharmacists 
and GPs, but also between stakeholders.  Participants suggested that this 
would facilitate the introduction of pharmacy services in the future.  It was 
also reported that outside the pharmacy profession the NMS has helped to 
increase awareness of pharmacy as a service provider.  This combined with 
the evidence that pharmacy is keen to provide services and engaged with the 
NMS quickly could give pharmacy a good sales platform when negotiating 
future services.   
3.4  Discussion 
This study aimed to understand how the NMS was developed and 
implemented by interviewing key stakeholders involved in the process.  The 
information gained regarding the development and implementation of the 
NMS can be broken down into four stages; the pre-negotiation phase, 
negotiations, the launch phase and the post-implementation phase. 
When asked about the pre-negotiation phase participants talked about the 
inclusion in the 2008 white paper of a proposed new service based on the 
original research carried out by the London School of Pharmacy.  Whilst the 
white paper does not mention the original research it does state that the 
GRYHUQPHQW¶V YLVLRQ IRU SKDUPDF\ LQFOXGHV D QHZ VHUYLFH WKDW SURYLGHV
support for patients prescribed new medicines for their long term conditions 
which could be seen as a reference to the NMS service.55  It was also noted 
that some participants had misconceptions regarding how the negotiations 
were conducted and who was consulted.  This could be due to the closed 
nature of negotiations meaning that information was not made public, 
allowing rumour to flourish. 
The participants described the uptake of the NMS as good, and better than 
the uptake of MURs had been in 2005.  It was suggested that learning had 
been gained from the MUR experience so there were fewer barriers to NMS 
implementation.  An example of this was the introduction of self-accreditation 
which all participants saw as facilitating the implementation of the NMS.  
Participants also agreed that pharmacists were motivated to provide the NMS 
by seeing the difference the intervention makes to patients at the follow-up 
stage of the service, and this positive attitude towards the service reportedly 
70 
 
facilitated its implementation.  This is supported by the results of the study 
conducted with community pharmacists that found that pharmacists 
recognising the potential benefit to patients contributed to a positive view of 
the NMS.  There is also evidence that a positive view of a service facilitates its 
implementation.110-112 
When discussing the post-implementation phase the participants identified 
several barriers affecting the NMS.  It was suggested that telephone 
consultations use different skills to consultations conducted face to face and 
that therefore pharmacists needed different communications skills to provide 
the NMS compared to conducting MUR consultations. Community pharmacists 
seem to disagree with this view as a study conducted prior to NMS 
implementation found that pharmacists were confident that they had the 
necessary communication skills for conducting consultations both face-to-face 
and by telephone from conducting MURs (Chapter 4).  However there is 
evidence to suggest that pharmacists do not always display good 
communications skills in MUR consultations and that training in conducting 
patient centred consultations may be beneficial.7,113 
Another identified barrier to NMS implementation was a lack of GP 
involvement.  This is supported by the findings of the study with community 
pharmacists that found that good local pharmacist-GP relationships would 
facilitate NMS provision but that where GPs had not engaged with the service 
it was acting as a barrier to NMS implementation (Chapter 4).  In addition, 
MUR research found that the greatest barrier to MUR implementation was a 
lack of GP participation.6  The problem of poor GP engagement with pharmacy 
services is not unique to England with a lack of GP interest and participation 
in pharmacy services being reported by studies in Australia and Sweden.98,99  
All participants identified the payment structure as a key barrier to NMS 
implementation with particular concern that the actual figure of prescription 
items eligible for the service was lower that the estimated 0.5%.  The 
payment structure was revised with effect from 1st May 2012.  The modified 
payment structure still includes the 0.5% assumption; however its importance 
has been decreased by ensuring that pharmacies will be remunerated for each 
NMS conducted.12   
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Chapter 4: Pre-Implementation Views and Experiences of Community 
Pharmacists and Superintendent Pharmacists Regarding the New 
Medicine Service 
 
4.1  Introduction 
This chapter presents the results of a study exploring the views of community 
pharmacists and superintendent pharmacists regarding the introduction of the 
NMS, through focus groups and interviews, prior to the implementation of the 
service. 
4.2  Methods 
As this study was exploratory in nature and it was unclear how familiar 
participants would be with the new service, the views and experiences of 
pharmacists were explored in focus group settings in order to facilitate 
discussion.  Focus groups are a method of collecting qualitative data from 
several participants at once.  They involve multiple participants being asked 
questions by a facilitator (usually a member of the research team) and their 
answers being recorded.  Focus groups can generate discussion between 
participants which is beneficial when conducting exploratory research. 
It was decided that it would be inappropriate to include superintendent 
pharmacists in the pharmacist focus groups as there was a concern that their 
presence could affect the willingness of employee pharmacists to participate 
in the discussion. Therefore superintendent pharmacist opinions regarding the 
service were sought separately in semi-structured interviews.  Interviews are 
a method where qualitative data is collected usually from individual 
participants in conversation with a researcher.    It was decided that 
interviews were preferable to a focus group setting for superintendent 
pharmacists for two reasons.  Firstly, the superintendent pharmacists were 
recruited nationally so arranging a mutually convenient time and location for a 
focus group would have been difficult.  Secondly, it was felt that discussion 
was unlikely to be generated between superintendent pharmacists from 
competing companies and conducting individual interviews would prevent 
concerns around commercial sensitivities reducing the quality of the data 
gained.  Interviews can be unstructured, structured or semi-structured. Semi-
structured interviews were chosen as they allow a degree of flexibility in the 
interviews whilst still providing enough structure to ensure the topics I wanted 
to cover were discussed. 
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Data Gathering 
Using the NHS choices website I identified that there were 98 pharmacies in 
Nottingham.  Before contacting pharmacies, approval for us to contact them 
was gained from the head offices of the pharmacies belonging to pharmacy 
chains.  Permission was not given to contact 18 pharmacies as some head 
offices did not respond to the request and one chain asked that their 
pharmacists not be contacted as the head office felt their pharmacists should 
concentrate on the imminent contractual changes. Pharmacists were initially 
recruited for focus groups by sending invitation letters to the 80 community 
pharmacies in Nottingham that we had received permission for.  Due to poor 
recruitment rates, further participants were recruited by inviting pharmacists 
whilst at an NMS and MUR training event provided by their employers, and 
using personal contacts.  The superintendent pharmacists were recruited for 
interview nationally by sending email invitations to participate in the study.   
The number of participants recruited was limited by a low recruitment rate 
and the short period of time between the provisional service specification 
publication in May 2011 and the implementation date of the 1st October 2011.  
The questions used in the focus groups and interviews were developed with 
reference to literature including the provisional service specification and in 
discussion with the research team.  
A pilot focus group was conducted in August 2011 to test the validity of the 
questions being asked.  The focus group topic guide was then adjusted 
according to the feedback given.  The pharmacists attending the pilot focus 
group had very little understanding of the NMS, and therefore a pack of 
information about the service was put together for pharmacists to refer to 
during the main study. 
In addition to the pilot focus group, three focus groups were conducted during 
September 2011, making a total of 15 participants.  All pharmacist 
participants were UK registered pharmacists accredited to provide MURs (a 
pre-requisite for delivering the NMS) and represented locums, as well as 
employee pharmacists from across the sector.  The pilot and two focus groups 
were conducted at the University of Nottingham, and one focus group was 
conducted after a company training event which included some training on the 
NMS.  Each focus group was facilitated by one of my PhD supervisors whilst I 
observed and made notes.  The focus groups averaged 70 minutes in length.  
Semi-structured interviews were conducted with five superintendent 
pharmacists during September 2011 to explore their views and experiences of 
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the introduction of the NMS.  The superintendent pharmacist participants 
represented a range of pharmacies including independents, small chain 
pharmacies, larger chains and supermarket pharmacies.1 All interviews took 
place at the superintendent pharmacists place of work for their convenience.   
The interviews averaged 48 minutes in length.   
The topic guides and interview schedules have been included in Appendices 2 
and 3.  They were designed to cover the same topics but the focus group 
topic guide focused more on the practical implementation of the service in 
pharmacies whereas the superintendent interview schedule focused more on 
the implementation of the NMS across chains of pharmacies, to reflect the 
different roles played by the two groups of participants.  The focus group topic 
guide covered awareness and understanding of the service, training and the 
self-accreditation procedure, NMS eligible medical conditions, practically 
providing the service and how the service would be recorded. The interview 
schedule was similar to the focus group topic guide, covering awareness and 
understanding of the service, learning from the introduction of MURs, 
preparing for implementation, the payment structure, training and the self-
accreditation procedure and recording the service. 
Analysis 
All focus groups and interviews were audio-recorded with permission and 
transcribed verbatim.  Thematic analysis was chosen as a way of analysing 
the data collected.  Thematic analysis is a method of breaking the data down 
into themes in order to understand the information collected.  In this study an 
inductive approach was chosen as the study is exploratory in nature and there 
was no prior research on which to base the analysis.  A pure inductive method 
requires two groups separated by a criterion variable therefore a hybrid 
inductive method of thematic analysis was used as a criterion-referencing 
method was not appropriate for this study as there was no desirable criterion 
variable.  The transcripts were read repeatedly and the audio-recording of the 
focus groups and interviews were listened to several times in order to 
summarise the information given.  These summaries were then used to 
identify themes across the focus groups and interviews and the themes were 
used to create a coding framework.  The developed coding framework was 
then applied to the transcripts and revised as necessary to include any 
missing themes.123  The transcribed data was analysed by one researcher 
(KW) and the coding and analysis verified by an academic supervisor (HB) for 
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reliability and to ensure that no themes were excluded.  The analysis was 
facilitated by using NVivo 9, a data management software for qualitative data. 
 
4.3  Results 
The 15 community pharmacists who took part in the focus groups represented 
a range of ages and were almost evenly distributed across genders.  The 
majority of participants were employee pharmacists but locum pharmacists 
were also represented.  The participants worked in a range of pharmacies 
including independents, small chain pharmacies, large multiples and 
supermarket pharmacies.  The demographics of the community pharmacy 
participants are set out in Table 4.1.
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Table 4.1: Demographics of the community pharmacist participants (n=15) 
 Gender Age Employee/Locum 
Male Female 22-25 26-30 31-40 41-50 51+ Locum Employee 
Pilot focus group 2 1 - 2 - - 1 2 1 
Focus group 1 2 2 - 1 - 3 - 1 3 
Focus group 2 3 2 1 1 1 - 2 - 5 
Focus group 3 1 2 1 1 1 - - 1 2 
Total number of 
participants 
8  7  2  5  2  3  3  4  11   
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Five superintendent pharmacists took part in the study.  Two superintendent 
pharmacists represented independent (1-5 pharmacies) or small chain 
pharmacies (6 or more pharmacies not including the 10 largest pharmacy 
chains in England), and three represented larger chains (the 10 largest 
pharmacy chains in England).1  Demographics have not been reported to 
prevent identification of participants. 
The focus groups and interviews were carried out between five weeks and 
three days before the NMS was implemented.  As the NMS was introduced 
very quickly, with key pieces of information being released throughout 
September 2011, the understanding of the NMS and how to provide it varied 
across the focus groups.  The pilot focus group, carried out five weeks before 
implementation, displayed a lack of understanding and high levels of 
confusion around the NMS, whereas the focus group conducted three days 
before the launch of the service expressed greater understanding of the NMS 
and how to conduct the service.  One focus group was conducted after a 
company training event that included training on the NMS.  It could be 
reasonably expected that understanding would be greater in this group; 
however some confusion between the NMS and targeted MURs was still 
expressed. 
7KH IRFXV JURXSV DQG LQWHUYLHZV DLPHG WR H[SORUH SDUWLFLSDQW¶V YLHZV DERXW
the NMS before implementation, and to identify potential barriers or 
facilitators to its successful implementation.  As this study did not use 
grounded theory, data saturation was not required, however by the fourth 
focus group no new themes regarding the implementation of the NMS 
emerged. Four main themes arose from the four focus groups and five 
interviews;  participant awareness and understanding of the NMS, benefits of 
providing the NMS, potential facilitators to service provision and potential 
barriers to service provision.   
4.3.1 Participant Awareness and Understanding of the NMS 
Most pharmacist participants reported first hearing about the introduction of 
the NMS in July 2011, with a couple of participants having become aware of 
the service earlier through involvement with politics or pharmacy bodies.  
Pharmacists became aware of the service mostly through reading the 
Pharmaceutical Journal (the journal of the Royal Pharmaceutical Society), 
emails from the Centre for Pharmacy Postgraduate Education or through their 
employer.  Whilst all pharmacist participants had heard about the service and 
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most had undergone some training, there was some confusion between the 
NMS and the changes to MURs that were being introduced at the same time.   
The superintendent pharmacists interviewed had become aware of the service 
in different ways and at different times.  The majority of participants had 
heard of the NMS through positions in various pharmacy bodies 12 to 18 
months before implementation, however one superintendent pharmacist had 
only become aware of the service through the local Primary Care Trust four 
months before implementation. 
4.3.2 Benefits of Providing the NMS 
Participants described their views and experiences of providing existing 
pharmacy services.  The introduction of clinical pharmacy services such as 
MURs in 2005 had been welcomed and pharmacists expressed enthusiasm 
towards this latest role extension.  Both pharmacists and superintendent 
pharmacists expressed the opinion that providing pharmacy services 
improved job satisfaction.  One pharmacist described it as; 
µ:KHQ,ILUVWTXDOLILHGDQG,UHPHPEHUZRUNLQJLQWKHGispensary 
where we were doing nearly up to 3000 items a week and I felt 
OLNH,ZDVLQDSURGXFWLRQIDFWRU\MXVWFKHFNLQJVFULSWV«,ZDQWHG
to be challenged more. This is doing exactly that and I love my 
job now, I love doing all these services and I love the patient 
LQWHUDFWLRQ¶3)HPDOHODUJHPXOWLSOHDJH-50 yrs)  
Participants were generally very positive about the service and enthusiastic 
about the large potential benefit to be had from the service.  All participants 
thought that the most important benefit would be to the patient.  Potential 
patient benefits described by participants included improved clinical outcome 
and increased understanding of their condition and its treatment.  Participants 
anticipated a positive reception to the service from patients who were seen as 
appreciating additional care.  One participant described a patient being 
prescribed a new medicine as: 
µ$WLPHZKHQ,WKLQNSDWLHQWVFDQEHUHDOO\TXLWHFRQIXVHGDQG
VFDUHGDFWXDOO\6RWKHUH¶VDUHDOUROHIRUSKDUPDFLVWVKHUHWR
help take some of the mystique away, give them practical help 
on how to look after their condition and deal with their 
medicines, and ultimately to make sure that any ill health or 
78 
 
LQFRQYHQLHQFHWKDWWKH\¶UHVXIIHULQJDVDFRQVHTXHQFHRIWKDWLV
minimised¶63 
µ,WVRXQGVDVWKRXJKLW
VVRPHWKLQJWKDWSHRSOHZLOOSUREDEO\
DSSUHFLDWH¶30DOHODUJHPXOWLSOHDJH-50 yrs) 
Potential benefits for the pharmacy profession were also identified.  The NMS 
was seen as an opportunity for the profession to demonstrate its worth as a 
service provider and possibly increasing the level of respect for pharmacists.  
The NMS was also described as an opportunity for pharmacists to use their 
clinical knowledge to benefit patients.  Commercial benefits from the new 
service ZDV LGHQWLILHG KRZHYHU WKLV ZDV VHHQ DV µa bonus¶ 3
Superintendent pharmacists saw this benefit as more important than the 
pharmacists did.  Superintendent pharmacists saw income from clinical 
services as becoming increasingly important as remuneration for dispensing 
reduces: 
µThe additional income is significant for us when income around 
GLVSHQVLQJLVGURSSLQJ¶63 
4.3.3 Potential Facilitators to Service Provision 
The only other comparable service, MURs, were introduced to community 
pharmacy in 2005. Both pharmacists and superintendent pharmacists saw the 
introduction of MURs as a significant change in direction for pharmacy as a 
profession; 
µ,WIXQGDPHQWDOO\FKDQJHGWKHZD\SKDUPDFLVWVSHUFHLYHG
themselves, how they work in their own dispensary, how the 
VXSSRUWVWDIIDFWXDOO\VXSSRUW¶63 
This cultural change within the profession was cited as the main reason for 
the slow uptake of MURs with the attitudes of individual pharmacists 
determining the speed of service implementation.  Participants thought that 
the change in how pharmacists perceived their job role would enable quicker 
uptake of any new service introduced; 
µ7KLVLVEXLOGLQJRQWKH085
VVHUYLFHWKDWDOUHDG\H[LVWVVR«WKH
H[SHFWDWLRQZLOOEHWKDWWKLVLVWKHVRUWRIWKLQJ\RXGR¶3
(Female, large multiple, age 41-50yrs) 
When asked about how the NMS would affect the role of the pharmacist, 
SDUWLFLSDQWVUHVSRQGHGVD\LQJWKDWµit is something we are already doing¶3
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male, small chain, age 51+yrs) albeit in a less formalised and structured way.  
Therefore participants did not feel that it would significantly change the role of 
the pharmacist; 
µ,GRQ
WVHHLWEHLQJDQ\GLIIHUHQWEHFDXVHSDUWRIWKHUROHDWWKH
moment, it may not be in a formalised way, is to make sure 
people use their medicinHVFRUUHFWO\¶30DOHODUJHPXOWLSOH
age 41-50yrs) 
All participants bar one pharmacist expected to be offering the NMS from 1st 
October 2011.  The pharmacist who did not expect to be offering the service 
explained that the pharmacy they work in does not offer MURs so were 
unlikely to offer the NMS.  All superintendent pharmacist participants 
expected every pharmacy in their companies to offer the service from October 
1st.  This suggests that pharmacies are expecting to provide this service 
immediately after implementation and this could facilitate the quick uptake of 
the NMS. 
When asked about the selected conditions included in the NMS, participants 
acknowledged that the chosen medical conditions represented a large 
proportion of the patient population.  This was seen as being important to the 
success of the service: 
µ7KH\FRYHUHQRXJKRIRXUSDWLHQWVWREHZRUWKZKLOHGRLQJ,I
you're just going to do the odd person here and there then it's 
QRWZRUWK\RXUZKLOH¶3)HPDOHODUJHPXOWLSOHDJH\UV 
Participants suggested that patients with asthma/COPD, type 2 diabetes or 
patients taking warfarin already received more support than other conditions 
through nurse-led clinics, but still saw a role for pharmacists in providing 
advice when a patient is newly prescribed a medicine. 
Some participants felt that limiting the NMS to certain conditions was 
unhelpful.  One pharmacist said that including all long term medical conditions 
µZRXOG PDNH PRUH VHQVH¶ 3 )HPDOH ODUJH PXOWLSOH DJH -50 yrs).  A 
superintendent questioned limiting the eligibility for the NMS asking: 
µ:K\DUHZHEHLQJVHOHFWLYH":K\LVRQHSDWLHQW
VFRQGLWLRQ
more valuable? Why is that patient with that condition more 
important than helping this patient who is not on the list but the 
outcomHFRXOGEHPXFKPRUHEHQHILFLDO"¶63 
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Participants suggested medical conditions where patients would benefit 
including depression, rheumatoid arthritis, chronic pain and skin conditions 
such as psoriasis.  Participants felt that the NMS could especially benefit 
patients with asymptomatic conditions.  One participant did observe that the 
conditions chosen may have been chosen because they would allow the 
profession to prove the effectiveness of the NMS more easily than other 
conditions: 
µ,IZHZDQWHGWRSURYe that we are effective at what we're doing 
I suspect that something like antidepressants would not be a 
JRRGFKRLFHIRUXV¶30DOH, locum pharmacist, age 26-30 
yrs) 
The service specification allows the intervention and follow-up consultations to 
be carried out in the pharmacy consultation room or by telephone.  
Participants were concerned that patients would be unwilling to return to the 
pharmacy for the consultations: 
µ,FDQ¶WVHHZK\SDWLHQWVZRXOGZDQWWRFRPHEDFNVSHFLILFDOO\WR
have an intervieZZLWKWKHSKDUPDFLVW¶63 
Although most participants would prefer to conduct face-to-face consultations, 
they thought it was likely that most intervention and follow-up consultations 
would occur by telephone according to patient preference. Participants 
reported that ultimately the method of follow-up would be determined by 
patient choice. 
There were other factors identified by participants as affecting the choice of 
follow-up method.  It was suggested that where patients do not live close to 
the pharmacy, telephone consultations might be preferable.  Telephone 
consultations may also be more preferable in busier pharmacies, where 
telephone consultations could be carried out at less busy times.  The nature of 
WKHSDWLHQW¶VPHGLFLQHFRXOGDOVRDIIHFWWKHFKoice, for example giving advice 
about inhaler technique may be easier in a face-to-face consultation. One 
participant pointed out that: 
µ)DFH-to-IDFHDOORZVPHWRXVHDWUDQVODWLRQVHUYLFHDQG,¶YHJRW
a large proportion of non-(QJOLVKVSHDNLQJSDWLHQWV¶P3 (Male, 
small chain, age 51+ yrs) 
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Therefore it was suggested that having the option to conduct the intervention 
and follow-up consultations by telephone would facilitate the provision of the 
NMS. 
Pharmacist participants reported that as the advice given during NMS 
consultations reflected current practice, the only area they needed training on 
was the logistics of service provision; 
µ,WKLQNWKHRQO\WKLQJ,ZRXOGEHFRQIXVHGDERXWLVKRZ I claim 
SD\PHQWIRULW¶3)emale, large multiple, aged 41-50 yrs) 
Both pharmacist and superintendent participants were positive about the 
accreditation process for the NMS.  For previous services pharmacists have 
had to prove competence in order to become accredited to provide the 
service, a process that takes several months.  The accreditation for the NMS 
requires pharmacists already accredited to provide MURs to self-certify that 
they are competent to provide the service.  This change was welcomed by the 
participants as recognition of pharmacists as professionals: 
µ,think the self-assessment gives us a brain for once where is 
WKH085DFFUHGLWDWLRQZDVDOLWWOHELWULGLFXORXV¶ P13 (female, 
small chain, aged 26-30 yrs) 
µ,WKLQNWKDWFRPHVIURPWKHVOLJKWHWKRVFKDQJHDURXQGWKH
GPhC that as a profession we are allowed to say yes I know I've 
GRQHLWDQG,VWDQGEHKLQGWKDWDQGWKDWVKRXOGEHHQRXJK¶3
(female, large multiple, aged 51+ yrs) 
The self-accreditation process was seen as facilitating the early 
implementation of the service: 
µ7KHUH¶VQRPRUHH[WHUQDODFFUHGLWation with the self-assessment 
VRWKDWZLOOPDNH>WKHVHUYLFH@JHWRIIWKHJURXQGDORWIDVWHU¶ 
SP3 
Participants also felt that self-accreditation was appropriate for this service 
because µLW LV VRPHWKLQJ ZH DUH DOUHDG\ GRLQJ¶ (P3 male, small chain 
pharmacy, aged 51+ yrs) so did not require any up-skilling.   
µ:HDUHQRWEHLQJDVNHGWRGRDQ\WKLQJWKDWZHGRQ
WGR
DOUHDG\DQ\WKLQJWKDWZHQRWSURIHVVLRQDOO\TXDOLILHGWRGR«ZH
can make a statement that we are up to doing this and not be 
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asked to prove it. :HDUHSURIHVVLRQDOVDQGTXDOLILHGWRGRWKLV¶
SP5 
Both pharmacists and superintendent pharmacists saw interview technique 
and communication skills as being important in the successful delivery of the 
NMS but not something requiring further training, with one pharmacist 
commenting: 
µ,W
VDOODERXWFRPPXQLFDWLRQVNLOOVLI\RXFDQ
WVLJQWRVD\WKDW
you have sufficient communication skills, you shouldn't be doing 
WKHMRELQWKHILUVWSODFH¶3IHPDOHODUJHPXOWLSOHDJHG
yrs) 
Superintendent pharmacist opinions on the necessity of training for their 
pharmacists also varied.  Some felt that formal company training was 
unnecessary because their employee pharmacists already possessed the skills 
required and that; 
µ,W¶VWKHPHFKDQLFVDQGWKHSUDFWLFDOLWLHV of the service that I 
QHHGWRFKHFNZLWKHDFKPDQDJHUWKDWWKH\¶UHJRLQJWREHRN
with.¶ SP1 
4.3.4 Potential Barriers to Service Provision 
The study participants perceived general practitioners (GPs) as having a low 
awareness of pharmacy services.  In the case of MURs, there was a feeling 
that most GPs had not accepted them and that GPs were unlikely to accept 
any new services. Similarly, patients were seen as having a poor awareness of 
what pharmacists can offer;  
µ:HMXVWFRXQWWDEOHWVDQGVHOOVKDPSRRV7KDW¶VKRZSHRSOHVHHXV¶ 
SP3 
Both pharmacists and superintendent pharmacists saw GP awareness and 
involvement in the NMS as important; however there was a general feeling 
that GPs were unaware of the NMS despite briefings from Local Medical 
Committees and Primary Care Trusts.  One participant suggested that the 
NMS was unlikely to be a priority for most GPs due to the coincident 
restructuring of the NHS in England: 
µ,I,DPKRQHVW,WKLQNWKH*3VFHUWDLQO\KDYHPDQ\RWKHULVVXHV
at the moment around the changes within the NHS that they are 
83 
 
IDUPRUHFRQFHUQHGDERXW¶ P8 (Male, large multiple, age 31-40 
yrs) 
There is provision in the service for patients to be referred into the service by 
prescribers in primary and secondary care however participants saw patient 
engagement initiated by the pharmacist as the main entry route into the NMS 
due to the perceived low prescriber interest and awareness of the service.   
µ,WVKRXOGEH>WKDW@WKHJHQHUDOSUDFWLWLRQHUVHQGVWKHSDWLHQWWR 
us«EXW,LPDJLQHWKDWRIWKHFRQVXOWDWLRQVDUHJRLQJWREH
LQLWLDWHG E\ WKH SKDUPDFLVW  , GRQ¶W WKLQN ZH¶UH JRLQJ WR JHW
PDQ\SHRSOHUHIHUUHGWRXV¶ SP1 
Participants thought that patients were unlikely to be referred into the service 
from secondary care but were more optimistic about referrals from GPs.   
Local relationships between GPs and pharmacists were seen as being key to 
gaining primary care referrals and good relationships were seen as being 
more likely for pharmacies co-located with GP surgeries: 
µ,WGHSHQGVLI\RXPDQDJHWRJHWWKHULJKWUHODWLRQVKLSZLWK
them. It just depends whether you're getting prescriptions from 
a wide range of surgeries where you can't have a close 
UHODWLRQVKLSRUZKHWKHU\RX
UHLQDKHDOWKFHQWUH¶ P12 (Female, 
large multiple, age 41-50 yrs) 
Participants saw value in pharmacists personally briefing local GP practices in 
order to raise awareness and promote GP involvement but were not 
particularly optimistic about the reception they would receive. 
There were concerns raised by both superintendent pharmacists and 
community pharmacists around the speed of introduction of the NMS and the 
lack of clarity regarding details of service provision.  The wording for the 
consent form was not published until two weeks before implementation and 
the online recording system for national recording of NMS data was not 
released until the day before the implementation of the NMS.  Participants 
were concerned about the administrative requirements for the intervention 
and follow-up consultations.  There was a lot of uncertainty around what the 
recording requirements would look like.  One superintendent pharmacist 
commented: 
84 
 
µ,W¶VSUREDEO\JRLQJWREHSDSHU-bDVHG«DWWKHEHJLQQLQJDJDLQ
like MURs we started that on paper then moved onto computer.  
,W¶VDELWRIDVKDPEOHVUHDOO\ZH¶UHLQQRZD\SUHSDUHGIRULWRQ
the 1st of October.¶63 
The speed of implementation led to some materials being made available 
close to the date for implementation and the final service specification being 
published one month after the introduction of the service.  This was seen as 
potentially hindering the uptake of the service.   
The pharmacists were concerned that the introduction of a new service may 
lead to increased management pressure.  Participants described experiences 
of management pressure to perform MURs and expected pressure to be 
exerted to encourage them to provide the NMS.  This was seen as 
inappropriate as pharmacists felt they had no control over the number of 
eligible patients they would see: 
µ7KHRQO\FRQFHUQWKDWFUHDWHVLV...because I work for a 
company, ZLOO,JHWSUHVVXUHIURPDERYH"«,FDQ
WPDQXIDFWXUH
patients if they are not on a new medicine. If they don't meet 
WKHFULWHULD,FDQ
WPDQXIDFWXUHSHRSOHWRGRLW¶ P12 (Female, 
large multiple, age 41-50 yrs) 
The payment structure raised concerns with both pharmacists and 
superintendent pharmacists.  Pharmacist participants were confused by the 
payment structure and were unclear how they would be remunerated for the 
service.  Pharmacists were concerned that the payment structure could lead 
them to provide services for which they will not be paid: 
µ-XVWSD\XVIRUHYHU\RQHZHGRLW
VMXVWULGLFXORXVWRVD\,FDQ 
GRDQGQRWEHSDLG¶ P9 (Female, large multiple, age 41-50 
yrs) 
Superintendents were less confused by the payment structure but like the 
pharmacists they had serious concerns about what it would mean in practice.  
One superintendent pharmacist was concerned that the payment structure 
could adversely affect the implementation of the service.  Both pharmacists 
and superintendent pharmacists were keen to point out that the payment 
structure would not prevent them offering the service to patients because 
they saw the potential value in the service for patients: 
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µ2EYLRXVO\ZH¶OOSXWWKHLQWHUHVWVRIRXUSDWLHQWVILUVWVRZKHUH
ZHFDQZHZLOORIIHUWKLVVHUYLFH¶P9 (Female, large multiple, 
age 41-50 yrs) 
µ,WKLQNRXUSKDUPDFLVWVZLOOJRIRULW7KH\VHHYDOXe in this 
service and see themselves having a role in helping patients. I 
WKLQNGHVSLWHWKHSD\PHQWVWUXFWXUHZH¶OOPDNHWKLVDVXFFHVV
EXWZHZRQ¶WEHJHWWLQJSDLGLQVRPHLQVWDQFHVZKHUHZHVKRXOG
EHJHWWLQJSDLG$QGWKDW¶VQRWIDLU,W¶VQRWIDLUUHPXneration for 
WKHZRUNZH¶YHSXWLQWRWKLV¶ SP3 
4.4  Discussion 
This chapter H[SORUHVSKDUPDFLVWV¶DQGVXSHULQWHQGHQWSKDUPDFLVWV¶YLHZVRI
the NMS prior to implementation and experiences of preparing to offer the 
service.  Themes emerging from the particiSDQWV¶ UHVSRQVHV LQFOXGHG
participant awareness and understanding of the NMS, benefits of providing 
the NMS, potential facilitators to service provision and potential barriers to 
VHUYLFH SURYLVLRQ  3DUWLFLSDQWV LGHQWLILHG SKDUPDFLVWV¶ SRVLWLYH DWWLWXGHV
towards the NMS, good pharmacist and GP relationships, and the ability to 
conduct the intervention and follow-up stages of the NMS by telephone as 
potential facilitators to the successful implementation of the NMS.  
Participants were concerned that a lack of GP enthusiasm for pharmacy 
services and the payment structure could act as barriers to service 
implementation.  Another potential barrier to the successful implementation of 
the NMS is pharmacist confusion regarding the eligibility criteria for the 
service.  
The superintendent pharmacists in this study agreed that attitudes and beliefs 
about a service are key factors in motivating their pharmacists to provide 
services.  The pharmacist participants held positive attitudes towards the NMS 
and all bar one pharmacist expected to offer the service from the first possible 
GD\3UHYLRXVVWXGLHVKDYHVKRZQWKDWDKHDOWKFDUHSURIHVVLRQDO¶VNQRZOHGJH
of a service and their attitude and confidence towards providing it can affect 
service implementation.109,110  Bradley et al. investigated factors affecting the 
uptake of MURs and found that pharmacists motivated to provide MURs 
facilitated MUR provision.6  This suggests that pharmacists motivated to 
provide the NMS would facilitate the implementation of the service. 
The results from this study suggest that pharmacists have a positive attitude 
to providing services, seeing it as an opportunity to use their clinical skills to 
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benefit patients.  A study exploring the attitudes of pharmacists towards 
MURs found that pharmacists saw them as a chance to make better use of 
WKHLU SURIHVVLRQDO VNLOOV DQG WR KHOS SDWLHQWV¶ PDNH EHWWHU XVH RI WKHLU
medicines.7  My study also suggests that the provision of services is viewed as 
an increasingly important role of the community pharmacist.  This is not 
unique to the UK; a study in New Zealand suggested that pharmacists see 
service provision as crucial to the future of pharmacy as a profession.112  The 
enthusiasm for providing services found in this study is very different to the 
views expressed by Australian pharmacists regarding new roles, where 
pharmacists were hesitant to play a patient-care role despite seeing it as 
important.126   This difference may be explained by participants in this study 
viewing the NMS as a formalisation of advice already provided by pharmacists 
and not a completely new role. 
The study conducted by Clifford et al required pharmacists carrying out 
telephone interviews to receive training that included telephone 
communication skills whereas pharmacists wishing to provide the NMS are not 
required to undergo any training.41  This study found that the participating 
pharmacists felt that they only required training regarding the service 
structure and did not need further training in communication skills, as all 
competent pharmacists should possess good communication skills.    An 
Australian study found that pharmacists perceived training in communication 
skills as less necessary than training in other areas of the provision of 
extended pharmacist roles, supporting the idea that pharmacist see 
themselves as already possessing good communication skills.114  However 
studies investigating pharmacist consultations in England have found that 
pharmacists do not always demonstrate good communications and further 
training may be beneficial specifically in conducting patient-centred 
consultations.113,127 
Several potential barriers to service implementation were identified, the first 
being that pharmacists were confused between the NMS and targeted MUR 
services.  Even those pharmacists who had received training from employers 
on both services immediately prior to the focus groups still appeared 
confused. This was not wholly unexpected as the NMS and changes to MURs 
were introduced concurrently and there are some similarities in eligibility 
criteria for the services, but does raise concerns about how ready the 
pharmacists were to provide both services from October 2011.   
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Participants were concerned that the payment structure for the NMS could act 
as a barrier to service implementation.  Other research in the UK has found 
that inadequate remuneration is viewed as a barrier to service 
implementation.115,116  Since collecting the data for this study, a revised 
payment structure was introduced in May 2012 that addressed many of the 
concerns raised by participants in this study regarding the lack of 
remuneration for service provision.90 
Another potential barrier that participants in this study identified was a lack of 
GP awareness of the service and a lack of interest in the NMS despite 
briefings from the local medical committees.  This seems to be a common 
situation worldwide for pharmacy services.  Studies in Australia and Sweden 
have found low GP awareness and a lack of interest and participation in 
pharmacy services, but where GPs can see benefits to pharmacy services, 
they are more likely to participate and GP involvement with pharmacy 
services leads to an increase in GP-pharmacist collaboration.98-102  This is a 
concern for the implementation of the NMS as Bradley et al found that the 
greatest barrier to the implementation of MURs was a lack of GP 
participation.6   
There are several opportunities to further facilitate the implementation of the 
NMS.  Participants in this study emphasised the importance of making 
pharmacists aware of the benefits to patients that the service can provide in 
order to motivate them to provide the service.  Another concern voiced by 
participants was the lack of awareness or interest in the service held by GPs.  
The findings of this study would suggest that increasing GPs awareness of the 
potential benefits of the NMS to their patients and practice could help 
facilitate the implementation of the service.  Pharmacists need to be proactive 
and work to publicise the service locally to both GPs and patients if the NMS is 
to realise its full potential. 
The results of this study would suggest that pharmacists believe that patients 
are not aware of the expertise of a pharmacist, seeing them as shopkeepers 
more than health professionals.  This is important because the NMS is based 
on the health belief model which was developed by Becker in 1974 and is a 
ZD\ WR SUHGLFW SDWLHQW¶V PHGLFLQH WDNLQJ EHKDYLRXU62 When attempting to 
alWHUDSHUVRQ¶VEHOLHIVDQGWKHUHIRUHDFWLRQV%HFNHUVWDWHV WKDW WKHSDWLHQW
µQHHGVWRKDYHVRPHNLQGRIFXHWRWDNHDFWLRQ¶WKDWLVWKHSDWLHQWQHHGVWR
be prompted before they will take any kind of action.63  He suggests that this 
prompt may be a conveUVDWLRQZLWKD µVLJQLILFDQWSHUVRQ¶,QWKHFDVHRIWKH 
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NMSWKHSKDUPDFLVWZRXOGEHWKHµVLJQLILFDQWSHUVRQ¶FDXVLQJWKHSDWLHQWWR
take action.  This would suggest that the success of the intervention depends 
to an extent on whether the patient views phaUPDFLVWVDVµVLJQLILFDQW¶ 
 
  
89 
 
Chapter 5: Post-Implementation Views and Experiences of Community 
Pharmacists and Superintendent Pharmacists Regarding the New 
Medicine Service 
5.1 Introduction 
This chapter presents the results of a study exploring the views and 
experiences of community pharmacists and superintendent pharmacists 
regarding the implementation of the NMS.  This study follows on from the 
study reported in the previous chapter. 
5.2 Methods 
The views and experiences of the community pharmacists were sought in 
focus groups and interviews.  Focus groups were initially chosen to allow 
discussion of topics and experiences, and the opportunity to participate in 
interviews was offered when a pharmacist was unable to attend a focus group 
session.  It was decided that it would be inappropriate to include 
superintendent pharmacists in the focus groups as their presence may affect 
what their employees said.  In addition the idea of a focus group consisting of 
only superintendent pharmacists was dismissed as commercial sensitivities 
may have affected the discussion.  Therefore superintendent pharmacist 
views and experiences were sought in semi-structured interviews. 
The opportunity to participate in this part of the study was offered to all 
community pharmacists and superintendent pharmacists who participated in 
the earlier study investigating the views of pharmacists regarding the NMS 
prior to the services implementation (Chapter 4). The number of participants 
recruited was limited by a low recruitment rate in the earlier part of my study 
therefore additional participants were recruited through personal contacts. 
The questions used in the focus groups and interviews were developed with 
reference to literature including the provisional service specification and the 
results of the pre-implementation study (Chapter 4). The topic guides and 
interview schedules have been included in Appendices 4 and 5.  The topic 
guide for pharmacists covered the introduction of the NMS, training, patients 
eligible for the service, conducting and recording the service and the payment 
structure. The interview schedule content for superintendent pharmacists was 
similar to the topic guide, covering the preparation for implementing the NMS, 
implementation of the service, the effect the NMS has had, and the payment 
structure. 
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The community pharmacist focus groups and interviews were conducted in 
February and March 2012 with a total of 11 participants.  Two focus groups 
were conducted with three and six participants respectively.  An additional 
two participants were interviewed separately as they were unable to attend 
the focus group sessions.  The average length of focus group sessions was 65 
minutes and the interviews averaged 28 minutes. 
Interviews with six superintendent pharmacists were carried out between 
February and April 2012.  The participants were interviewed individually at 
their place of work or by telephone according to participant preference.  The 
interviews lasted on average 45 minutes. 
The interviews and focus groups were audio-recorded with permission and 
transcribed verbatim.  The transcripts were analysed thematically using the 
method detailed in Chapter 4, and checked by my supervisor as previously.  
The data management software NVivo 9 was used to facilitate the analysis. 
5.3 Results 
Eleven community pharmacists took part in the study and represented a 
range of ages (Table 5.1).  The majority of participants were female and there 
were more employee pharmacists than locums.  The participants represented 
community pharmacies from across the sector including independents, small 
chain pharmacies, large multiples and supermarket pharmacies.    
Six superintendent pharmacists also took part in this study.  Three 
superintendent pharmacists represented independent (1-5 pharmacies) or 
small chain pharmacies (6 or more pharmacies not including the 10 largest 
pharmacy chains in England), and three represented larger chains (the 10 
largest pharmacy chains in England).1 Demographics have not been reported 
to prevent identification of participants. 
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Table 5.1: Demographics of the community pharmacist participants (n=11) 
 Gender Age Employee/Locum 
Male Female 22-25 26-30 31-40 41-50 51+ Locum Employee 
Focus group 1 2 1 - 1 - 1 1 1 2 
Focus group 2 2 4 2 1 1 2 - 3 3 
Interviews - 2 - 1 - 1 - - 2 
Total number of 
participants 
4  7  2  3  1  4  1  4  7  
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This study aimed to explore participants¶ views and experiences of the NMS 
implementation, in order to identify any facilitators and barriers that may 
KDYH DIIHFWHG WKH VHUYLFH¶V LQWURGXFWLRQ  7KLV VWXG\ GLG QRW XVH JURXQGHG
theory therefore data saturation was not required, although some data 
saturation was observed.  Analysis of the focus group and interview data 
produced three main themes; facilitators to NMS implementation, barriers to 
NMS implementation, and the long term impact of the NMS. 
5.3.1 Facilitators to NMS implementation 
Participants reported that a key facilitator to the provision of the NMS was 
positive pharmacist attitude towards the service.  They reported that there 
was an initial enthusiasm to provide the service which helped the early 
implementation of the NMS.  Participants suggested that the NMS gives 
pharmacists an opportunity to use their clinical knowledge to benefit patients 
in a tangible way, and this increased participant job satisfaction.   There was 
a suggestion that because the NMS focuses on one item it is more 
PDQDJHDEOH WKDQ DQ 085 ZKLFK UHYLHZV DOO WKH SDWLHQW¶V PHGLFLQHV DQG
participants felt confident providing advice and support in this way.  Another 
possible contributor to positive pharmacist attitudes was the financial benefit 
gained from providing the service which was seen as µEDVHG RQ ZKDW
SKDUPDFLVWVGRDQ\ZD\¶ (SP5). 
The participants in this study reported there was pressure to provide the NMS.  
A reduction in remuneration for dispensing was reported to create commercial 
pressure to provide services and participants described the strategic 
importance of the NMS as an incentive to provide the service. Community 
pharmacist participants also reported that they had received pressure from 
management to provide the service and the combination of these pressures 
had facilitated the implementation of the NMS. 
Certain pharmacy characteristics were seen as facilitating the provision of the 
service.  Firstly, having adequate consultation space within a pharmacy was 
seen as important.  Participants described a growing demand on the 
consultation room in their pharmacies and multiple consultation rooms per 
pharmacy was seen as desirable; 
µ2QHRISKDUPDFLHVZHKDGWREXLOGDQH[WUDFRQVXOWDWLRQURRP
because the pharmacist couldn't get in WRGR085
V¶ SP1 
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The IT system used within a pharmacy also holds the potential to facilitate 
NMS provision.  Participants using a Patient Medical Record (PMR) system with 
an integrated NMS module that identifies eligible patients and prints consent 
forms found NMS provision easier than those who used a PMR system without 
that facility.  Another pharmacy characteristic that participants reported as 
DIIHFWLQJ106SURYLVLRQZDVWKHSKDUPDF\¶VRSHQLQJKRXUV3DUWLFLSDQWVZKR
worked in pharmacies with opening hours that allowed them to conduct the 
intervention and follow-up stages of the service in evenings or weekends 
UHSRUWHG D JUHDWHU VXFFHVV ZLWK FRQWDFWLQJ SDWLHQWV  /DVWO\ D SKDUPDF\¶V
location was reported as affecting the numbers of NMS eligible patients seen, 
with pharmacies in close proximity to GP practices being reported as having 
more opportunities to provide the service. 
A characteristic of the NMS service that was seen as facilitating the 
implementation of the service was the option for conducting the intervention 
and follow-up stages of the NMS by telephone.  Participants reported that 
most of their NMS interventions and follow-ups were conducted in this way.  
The option for telephone consultations was seen as popular with patients as it 
does not require a visit to the pharmacy and it was also seen as benefitting 
pharmacy as it allows pharmacists to manage their workload by carrying out 
the telephone consultations at the quietest time of the day in the pharmacy. 
µ,QVRPHZD\V,SUHIHUWRGRLWIDFH-to-face, but a combination 
of logistics and patient preference drives most of them towards 
DSKRQHFDOO¶ P19 (Female, independent, 41-50yrs) 
It was reported that staff engaged with the NMS and were involved in 
identifying patients, facilitating the provision of the service in their pharmacy 
by reducing the burden on pharmacists.  Participants suggested that a key 
factor affecting staff attitudes towards the NMS was the training they received 
before the implementation of the service, with a lack of training being 
associated with a lack of staff engagement with the service. 
µ,WKLQNLIWKHVWDIIKDYHEHHQLQIRUPHGDWWKHEHJLQQLQJEHIRUH
WKH ODXQFK DQG \RX FDQ VHH WKH EHQHILWV WKHQ WKH\¶UH PRUH
likely to be on-board and supportive on those, but if they really 
KDYHQ¶WJRWDFOXHWKHQWKH\ZRQ¶WEHERWKHUHG¶ P18 (Female, 
large multiple, 31-40yrs) 
Participants compared the implementation of the NMS with the introduction of 
MURs, suggesting that uptake of NMS had been quicker than the uptake of 
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MURs.  Participants suggested that the experience of providing MURs had 
facilitated the NMS implementation as pharmacists were already familiar with 
providing advanced services, seeing it as a key part of their role as a 
pharmacist.  Participants also reported that they did not require any further 
training to provide NMS consultations as the skills had already been learned in 
order to provide MUR consultations. 
5.3.2 Barriers to NMS implementation 
The pharmacist participants suggested that the timing of the NMS launch may 
have hindered the services uptake as it coincided with the start of flu 
vaccination season and the run up to Christmas, traditionally a busy time for 
pharmacies.  However participants did acknowledge that there would be 
disadvantages to launching a service at any time during the year. 
Both pharmacist and superintendent pharmacist participants described a lack 
of service details as they prepared for the introduction of the NMS.  It was 
suggested that this made the implementation of the service harder and could 
have affected the rate of uptake.  In particular participants reported a lack of 
information about PharmaBase (software for recording the NMS) and a lack of 
clarity around the availability of PMR modules for the service. 
µ:HZHQWOLYH[with PharmaBase] without very much of a trial 
period at all so effectively beta testing was done in situ as we 
were operating and inevitably there are always going to be 
VRPHWHHWKLQJLVVXHV¶ SP4 
Some pharmacist participants described more problems engaging patients 
with the service than the other participants, with one pharmacist reporting 
that up to half of all patients she had invited to take part in the NMS had 
declined, a much higher figure than the other participants described.  This 
could suggest that a pKDUPDFLVW¶V DELOLW\ WR FRPPXQLFDWH WKH SXUSRVH DQG
requirements of a service affects the likelihood of patient engagement.  
Participants also reported a lack of GP engagement with the NMS, despite 
having spoken to practices prior to the launch of the service.  This may be 
another example of pharmacist communication skills acting as a barrier to 
service provision.  
7KH106ZDVGHVFULEHGDVDIIHFWLQJSKDUPDFLVWV¶ZRUNORDGLQVHYHUDOZD\V,W
was suggested that introducing a new service put additional strain on 
pharmacies by increasing the amount of time pharmacists are not available 
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for dispensing and increasing the demand on pharmacies consultation rooms.  
Participants suggested that there was a need to reduce the dispensing burden 
on pharmacists if clinical services are going to be successful.  Some 
participants reported concerns about the increased workload on pharmacists 
potentially affecting the quality and safety of care provided; 
µ$WVRPHSRLQWLQWLPHEHFDXVHRIWKHSUHVVXUHVEHLQJSODFHG
upon pharmacLVWVEHFDXVHRIWKHQHZVHUYLFHV«ZHDUHJRLQJ
to have an accident with somebody.  Somebody will die 
because a pharmacist has been doing a [service] and 
VRPHWKLQJHOVHKDVGURSSHGWKURXJK¶ SP6 
 
In addition to NMS provision adding to the general workload of 
pharmacists, participants reported that the recording required for the 
service was in itself a burden for pharmacists.  Participants reported 
having to record the consultations on paper before transferring the 
information onto PMRs at a later point in time.  Participants using 
PharmaBase had a further step as the information also had to be 
transcribed onto that system.  Therefore whilst participants reported 
that the time spent conducting the NMS consultations was not that 
burdensome, the time spent on recording them was significant. 
 
µ,W¶V D ELW OLNHZLWK WKH SROLFH DQG FULPHDQG UHSRUWLQJ FULPH
You deal with the crime and then you have to fill out a twenty-
ILYH SDJH UHSRUW DQG WKDW¶V KRZ LW IHHOV¶  3 )HPDOH ODUJH
multiple, age 41-50 yrs) 
 
Participants questioned the restrictions on eligible patients stating that some 
patients missed out because the eligibility criteria are too restrictive.  In 
particular participants were concerned that a lot of new asthma medication is 
prescribed for children who cannot consent to the service and the current 
service specification does not allow parents or carers to provide consent.  
Participants also suggested that opening the service to other conditions would 
allow more patients to benefit.  In particular patients newly prescribed anti-
depressants were seen as a group of patients for whom the NMS could make a 
real difference.  Other groups that pharmacists were keen to provide support 
for included pain, rheumatoid arthritis, and high risk medicines. 
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The complexity of the service structure seemed to be causing problems with 
the provision of the NMS.  Participants described the consent form as a 
barrier, questioning the need for some of the statements.  Participants noted 
that patients do not have to provide written consent for consultations with 
other health care professionals and questioned the need for written consent 
for pharmacy consultations.  Participants were also critical of the suggested 
consultation questions and reported that they often create their own 
consultation structure to make it seem more naturalistic: 
µ,VLWGRZQDQGORRNDW[the questions], read through them as a 
refresher, then structure it the way I would speak because I 
GRQ
WIROORZWKDWVRUWRIOLQHZKHQ,VSHDNWRSDWLHQWV¶P3 
(Male, small chain, age 51+ yrs) 
A key barrier to NMS implementation identified by the participants was the 
payment structure.  The complexity of the payment structure meant that the 
pharmacist participants were confused about how many NMS they had been 
paid for and how many they needed to conduct to meet the thresholds.  The 
tiered levels according to dispensed items was specifically described as a 
problem as pharmacies experience fluctuating monthly prescription numbers 
therefore participants felt that it was difficult to predict whether they had met 
the threshold levels for payment.  This uncertainty as to whether a pharmacy 
would receive payment for an NMS conducted led to some pharmacist 
participants opting to provide an MUR instead of an NMS as they were 
guaranteed payment for MURs. 
µ7KHUHKDYHEHHQDFRXSOHRIRFFDVLRQVZKHUH,¶YHKDGWKH
option to do a prescription intervention [MUR] or an NMS and if 
,GRWKHSUHVFULSWLRQLQWHUYHQWLRQ«LW¶VDJXDUDQWHHG:LWK
DQ106LW
VDSRVVLEOHLI\RX
UHOXFN\¶P10 (Male, Locum 
pharmacist, age 26-30) 
A second barrier associated with the payment structure was the assumption 
that 0.5% of all prescription items dispensed in a pharmacy would be eligible 
for the NMS.  Participants reported that the rate of opportunities seemed 
lower in practice and that opportunities varied.  Participants suggested that 
pharmacies located inside or next to GP practices would have more 
opportunities to provide the NMS than pharmacies located on the high street.  
They suggested that this may be due to a combination of better GP-
pharmacist relationships and more newly prescribed items being dispensed.  
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One superintendent pharmacist participant expressed concern that the 
difference in opportunity rates could lead to the NMS only being offered in 
healthcentre pharmacies.  In addition participants were concerned that 
pharmacies that dispensed a high level of Misuse of Drugs Act (MDA) 
prescriptions or prescriptions for care home residents would be 
disadvantaged.  The participants reported that most eligible patients were 
recruited to the service and that the low numbers of NMS opportunities was 
not down to eligible patients not being identified. 
Participants expressed a concern that the problems associated with the 
SD\PHQWVWUXFWXUHFRXOG LPSDFWRQSKDUPDFLVWV¶HQWKXVLDVP IRU WKH VHUYLFH
leading them to become demotivated.  It was suggested that unless the 
payment structure was addressed soon, pharmacists would cease to provide 
the NMS. 
µ0\FRQFHUQLVWKDWSKDUPDFLVWVWKHPVHOYHVZLOOEHFRPH
demotivated... They are not seeing a reward for the provision 
RIWKHVHUYLFH«WKH\VHHWKHLUHPSOR\HULVQ
WEeing paid 
therefore they themselves are not being recognised for the 
service they are providing and as a consequence there is 
SRWHQWLDOIRUGHPRWLYDWLRQLIZHGRQ
WVRUWLWRXWVRRQ¶ SP4 
Participants suggested that this barrier to NMS implementation could be 
removed by changing the payment structure to per item of service 
remuneration.  Participants reported that they would be content with a lower 
amount of remuneration per service if payment was received for every NMS 
provided.  It was suggested that by changing the structure to payment per 
item would make the provision of the NMS more appealing to pharmacists and 
thereby facilitate the implementation. 
5.3.3 Long term impact of NMS 
Participants described the long term impact of the NMS as centred on the 
pharmacist-patient relationship.  It was suggested that by participating in 
clinical services such as the NMS increases patient awareness of the 
professionalism of pharmacists and what they can offer: 
µ,WKDVFKDQJHGVRPHSHRSOH
VSHUFHSWLRQVRIZKDWWKH
pKDUPDFLVWLVFDSDEOHRIDQGLVWKHUHIRU¶ P10 (Male, Locum 
pharmacist, age 26-30) 
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Participants also described the NMS as building trust between pharmacists 
and patients which facilitates discussion of other health related subjects, such 
as smoking cessation: 
µ,WKLQNLW
VUHDOO\EULQJLQJWKHPFORVHUWRWKHSKDUPDFLVWDQG
WKHWHDPFOLQLFDOO\ZKLFKLVJUHDWVRIRULQVWDQFH«LW
VQRWJRLQJ
to be so odd talking to people about stopping smoking because 
they know we're concerned about their health.¶63 
Whilst most participants were enthusiastic about the positive impact the NMS 
was having of the pharmacist-patient relationship, one participant expressed 
concern that introducing clinical services could undermine the informal nature 
of the relationship, which was seen as an advantage for the profession over 
other health care providers.   
5.4 Discussion 
This chapter explores the views and experiences of community pharmacists 
and superintendent pharmacists of the implementation and provision of the 
NMS.  The study identified barriers, facilitators and the long term impact of 
the NMS implementation.  Identified barriers included the complexity of the 
service structure, including the restrictions on eligible patients and the 
SD\PHQW VWUXFWXUH WKH HIIHFW RI WKH 106 RQ SKDUPDFLVWV¶ ZRUNORDG
SKDUPDFLVWV¶ FRPPXQLFDWLRQ VNLOOV DQG WKH ODFN RI GHWDLOV DYDLODEOH WR
pharmacists prior to the launch of the service.  The facilitators identified by 
participants included positive pharmacist attitudes towards the NMS, certain 
pharmacy characteristics, the pressure to provide the service, pharmacy staff 
views and involvement with the service, and the experience of providing 
MURs.  The long term impact of the NMS described by participants focused on 
the effect of NMS provision on building pharmacist-patient relationships. 
A key facilitator to NMS implementation identified by this study was the 
positive attitude towards the service held by pharmacists.  This was identified 
as a potential facilitator in an earlier study (Chapter 4) and supports the idea 
that the attitude towards a service and confidence of a pharmacist to provide 
it can affect the implementation of the service.109-111   There were several 
factors reported by participants as contributing to this positive attitude 
including the perceived benefit to patients and the increased job satisfaction 
associated with using clinical knowledge. Research from MURs showed that 
pharmacists were motivated to provide MURs because it gave them the 
opportunity to use their clinical knowledge to support patients in their 
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medicine taking, supporting the idea that pharmacists are keen to offer 
services that use their knowledge to benefit patients.7 
As predicted by my earlier study, the largest barrier to the NMS 
implementation described in this study was payment structure (Chapter 4).  
The participants suggested that changing the payment structure to a payment 
per item of service would remove this barrier.  In May 2012 a new payment 
structure was introduced ensuring that pharmacies would be remunerated for 
every NMS completed.90  The results from this study suggest that this would 
facilitate the implementation of the NMS by making the provision of the 
service more attractive to pharmacists. 
Participants in this study expressed concern that the introduction of the NMS 
had increased their workload and this had the potential to affect safety in the 
pharmacy.  A review of the literature in 2011 found that dispensing volume 
has increased as well as the number of pharmacies providing non-essential 
services, suggesting the SKDUPDFLVWV¶ZRUNORDGKDVJURZQDQGWKHDGGLWLRQRI
the NMS would have further increased their workload.  However, the review 
did not find robust evidence that that the increased workload had affected 
patient safety but did report that high dispensing volume was associated with 
a decrease in the number of interventions made, suggesting that there is 
potential for dispensing workload to affect patient safety.104  There is no 
consensus regarding the point at which the dispensing volume begins to affect 
patient safety, in the UK it has been suggested that 500 prescriptions per 
pharmacist per 9-hour day is too much, whilst in Australia the threshold for 
the safe dispensing of prescriptions was identified as 150 prescriptions per 
pharmacist in a 9-hour day.105,106  What is agreed is that it is the number of 
prescriptions per pharmacist that is important rather than per pharmacy, 
suggesting that to ensure patient safety, pharmacist staffing levels should be 
examined. 
The participants in this study identified that certain characteristics of a 
SKDUPDF\¶V305V\VWHPKDGWKHDELOLW\WRIDFLOLWDWHWKHSURYLVLRQRIWKH106
by reducing the workload associated with conducting the service.  There 
appears to be very little literature regarding how PMR systems can facilitate 
the provision of pharmacy services, as this appears to be an important 
facilitator to NMS implementation, perhaps further research in this area would 
be beneficial. 
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It was suggested that the combination of commercial and managerial 
pressure to provide the NMS, in addition to the political significance of the 
NMS had facilitated the implementation of the service.  Anecdotal evidence 
regarding MURs suggested that the managerial pressure on pharmacists to 
provide services had was associated with MURs of questionable quality and 
value being carried out.96,119  Therefore whilst the pressure to provide the 
NMS may have facilitated the implementation of the service, it may also have 
adversely affected the quality of the services completed. 
The largest barrier to NMS implementation identified both pre- and post-
implementation was the payment structure.  Concerns were raised that the 
opportunity rate to provide the NMS in practice is much lower than the 
theoretical value of 0.5% of prescription items used to determine the 
remuneration for providing the service.  Therefore the next chapter will detail 
a study conducted in order to determine the actual NMS opportunity rate seen 
in pharmacies. 
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Chapter 6: What Proportion of Prescription Items Dispensed in 
Community Pharmacies are Eligible for the New Medicine Service? 
 
6.1  Introduction 
The findings of earlier studies described in Chapters 3, 4 and 5 suggest that 
the actual opportunity rate to provide the NMS is less than the theoretical 
assumption that 0.5% of prescription items are eligible for the service.  
Therefore this chapter reports the findings of a study conducted examining 
the actual proportion of prescription items dispensed that were eligible to 
receive the NMS. 
6.2  Methods 
This study was carried out in pharmacies in Nottingham belonging to a large 
chain to minimise inter-pharmacy variation.  At least one thousand 
consecutive prescription items were sampled from each pharmacy (a total of 
8005 items) as for most pharmacies this represents several days prescriptions 
and enabled several pharmacies in different locations to be sampled to 
provide a broader picture.   This provided a balance between collecting large 
numbers of prescription items and being more representative of an individual 
pharmacy, and collecting from a wide range of pharmacy location types to be 
more representative of the pharmacy sector.  The sample size software 
nQuery Advisor version 6128 was used to conduct a sample size calculation 
based on the primary outcome to estimate a proportion with 95% confidence 
intervals to a power of 90%.  This showed that 7852 prescription items were 
needed in total to detect a 0.5% difference (a 0.0025% change in prescription 
items eligible for the NMS), allowing for clustering effects, therefore data from 
at least 7852 prescription items would be collected. 
The 17 pharmacies belonging to a large multiple in Nottingham were grouped 
into three distances from GP practices: less than 100 metres, 100-500 metres 
and over 500 metres and the three groups were sampled to reflect as closely 
as possible the distribution of all pharmacies in Nottingham.  These distances 
were chosen in order to distinguish between pharmacies co-located or next to 
GP practices, and pharmacies further away from GP practices.  The distances 
ZHUH FDOFXODWHG E\ HQWHULQJ WKH SKDUPDF\ SRVWFRGH LQWR WKH ³)LQG *3
6HUYLFHV´SDJHRIWKH1+6FKRLFHVZHEVLWHZZZQKVXN 3KDUPDFLHVZHUH
excluded from the study if they dispensed less than 1000 prescription items 
per week (so that data collected in each pharmacy would be sufficient), if the 
SKDUPDF\¶VVWDIILQJOHYHOVUHTXLUHGPRUHWKDQRQHSHUVRQWRUHFHLYHDQGKDQG
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out prescriptions, meaning that more than one researcher would be needed to 
collect the data, or if the pharmacy primarily catered to an atypical 
demographic and were therefore unrepresentative meaning that the results 
from the pharmacy would be unlikely to reflect the average demographics 
seen by pharmacies. One pharmacy was excluded from the study because 
they dispensed less than 1000 items per week.  Two pharmacies were 
excluded from the study because they required more than one person to 
receive and hand out prescriptions. One pharmacy was excluded due to its 
atypical demographic.  This pharmacy was located within a university health 
centre and mainly caters to young people who are less likely to require 
medicines for hypertension, COPD, type 2 diabetes or need anti-platelet 
agents or anticoagulants as these are conditions mainly affecting older 
people.  Therefore this pharmacy could be expected to have a lower 
opportunity rate for the NMS than other pharmacies.  Eight pharmacies were 
sampled from the remaining 12 possible pharmacies reflect the distribution of 
pharmacies in Nottingham according to distance from GP surgery. After 
gaining approval from the head office of the large chain and area managers, 
pharmacies were contacted directly by myself to be invited to participate in 
the study. 
In each pharmacy the data were collected by me taking in and handing out 
prescriptions to patients.  Prescriptions were included in the study if they were 
a NHS prescription, regardless of who collected the prescription, what type of 
NHS prescription it was, or whether the prescription was dispensed as part of 
a care home service.  Prescriptions were only excluded from the study if they 
were private (non-NHS) prescriptions.  A prescription item was eligible to 
receive the NMS if it was newly prescribed for hypertension, type 2 diabetes, 
asthma/COPD or was an anti-platelet or anti-coagulant agent, and the 
medicine was included in the list of medicines eligible for the NMS as specified 
in the service specification.10  In order to determine whether a medicine was 
new, the PMR was checked and each patient was asked if they had been 
prescribed the medicine before.  A prescription item meeting these criteria for 
the NMS was recorded in the study as eligible to receive the service 
regardless of who collected the prescription or whether it was part of a care 
home service.  Therefore the study recorded the number of prescription items 
dispensed that were eligible to receive the NMS as well as actual NMS 
opportunities. 
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For each NHS prescription the researcher recorded the number of items on 
the prescription, whether the patient or a representative collected the 
prescription, if the prescription was delivered, whether the prescription was a 
MDA form or part of a care home service.  Where an item was eligible for the 
NMS, the therapeutic class it fell into was recorded along with whether or not 
the NMS was offered and whether it was declined (and a brief reason why if 
provided by the patient).   This study also recorded instances where items 
which were eligible for the NMS did not translate into an opportunity for the 
pharmacy to provide the service, for example where the patient was a child 
unable to consent to the service, or the patient was a care home resident.  
Data relating to private prescriptions were not recorded as only NHS 
prescriptions are eligible for the NMS.  The data were collected between 
January and May 2013. 
The data collected were inputted into the statistical software SPSS and 
frequency counts with percentages determined.  Proportions were calculated 
for each distance group of pharmacies and for the total number of 
opportunities to provide the NMS.  In order to determine whether there was a 
significant difference between the study results and the estimate that 0.5% of 
prescription items are eligible for the NMS, The difference between the two 
proportions was calculated and the standard error of the difference 
determined.  The standard error was then used to calculate the 95% 
confidence interval of the difference between the proportions, with the 
difference deemed as significant if 0 did not lie within the confidence interval, 
as 0 represents no significant difference.  The difference between the 
proportion of NMS opportunities seen in pharmacies less than 100 metres 
from a GP practice and the proportion in pharmacies located further away was 
calculated in the same way and the significance of the result tested.116 
6.3  Results  
In total 8005 items were recorded in 8 pharmacies in Nottingham (a minimum 
of 1000 items in each pharmacy) and of these 6080 items (76%) were NHS 
prescription items that were not MDA items or for care home residents (Table 
6.1).  Of the 8005 items recorded, 1965 (25%) were delivered to the patient 
or care home, and the remaining 6040 (75%) were collected from the 
pharmacies.  Of the prescription items collected in the pharmacies, 28% 
(n=1720) were collected by patient representatives.   
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Table 6.1:  The types of prescription items included in the data 
collection 
Types of NHS prescription Number of items recorded (%) 
Care home service 1665 (21%) 
MDA 260 (3%) 
Other 6080 (76%) 
Total 8005 
 
In this study 20 prescription items, 0.25% (95% CIs 0.14%-0.36%), were 
eligible for the NMS.  This differs significantly from the assumption that 0.5% 
of prescription items are eligible for the NMS as 0 (representing no difference) 
lies outside the CI. There were 17 opportunities (0.21%, 95% CIs 0.10%-
0.32%) to provide the NMS (Table 6.2) as not all the eligible items translated 
into opportunities to offer the NMS.  Three items were prescribed for the 
treatment of asthma in children who could not consent to the service (Table 
6.3).  The NMS was offered to 16 of the 17 patients that represented 
opportunities to provide the service.  The one opportunity where the service 
ZDVQRWRIIHUHGZDVZKHUHDSDWLHQW¶VUHSUHVHQWDWLYHFROOHFWHGWKHGLVSHQVHG
prescription.   The service was declined by 2 of the 16 patients offered the 
NMS, both of whom had been prescribed an anti-coagulant.  Both patients 
stated the reason for declining the service was that they were receiving a lot 
of support from other health care professionals and felt that the support 
offered by the NMS was not needed.  
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Table 6.2:  The frequency and percentage of NMS opportunities and 
NMS eligible items by distance from nearest GP practice (n=8005). 
Distance of 
pharmacy 
from nearest 
GP practice  
Number 
of items 
collected 
Eligible items  NMS opportunities 
Number 
Percentage with 
95% CIs 
Number 
Percentage with 
95% CIs 
<100m 2002 7 0.35  (0.09-0.61) 6 0.3 (0.06-0.54) 
100-500m 5004 11 0.22 (0.09-0.35) 9 0.18 (0.05-0.31) 
>500m 999 2 0.2 - 2 0.2 - 
Total 8005 20 0.25 (0.14-0.36) 17 0.23 (0.10-0.32) 
 
 
Table 6.3:  The number of NMS eligible items and opportunities to 
provide the service by condition from 8005 prescription items 
dispensed. 
 
Asthma/ 
COPD 
Hypertension 
Type II 
diabetes 
Antiplatelet/ 
Anticoagulant 
Number of NMS eligible items 9 5 1 5 
Number of NMS opportunities 6 5 1 5 
 
There was no significant difference between the proportion of NMS eligible 
items at pharmacies located less that 100 metres from a GP practice 
compared with those further away (more than 100 metres from a GP practice) 
(difference= 0.13%, 95% CIs -0.14% to 0.42%). 
6.4  Discussion  
This study found that 0.25% of prescription items dispensed in community 
pharmacies are eligible for the NMS which is significantly different from the 
'HSDUWPHQWRI+HDOWK¶VWKHRUHWLFDODVVXPSWLRQWKDWRISUHVFULSWLRQLWHPV
would be eligible.  It is possible that in calculating the 0.5% estimate the 
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effect of some factors affecting the number of eligible items, such as 
prescriptions for care home residents, were underestimated, possibly 
explaining the difference between the observed number of eligible prescription 
items and the theoretical estimate. 
Pharmacists were able to earn up to £55m in the first year of the service 
based on pharmacists performing the NMS for 0.5% of their prescription items 
each month.  In order to be remunerated for the NMS conducted, pharmacies 
claim payment each month for completed NMS in the same way that payment 
is claimed for NHS prescriptions dispensed.   The results from this study 
would suggest that pharmacists were not able to access the full potential 
funding as the number of opportunities to carry out the NMS is less than 0.5% 
of their prescription items.  NMS funding is outside the total agreed funding 
for pharmacy contractors, and if it is not earned then contractors are no 
longer able to access it and is not guaranteed to be made available for other 
public health initiatives.  In April 2012 the PSNC communicated that 
theoretical assumption may not reflect the rate of NMS opportunities for all 
pharmacies and has stated that it will be reconsidered in the future.90  This 
study suggests that the actual rate of NMS opportunities is less than the 
theoretical rate which means that it would be possible to widen the scope of 
the NMS by including other conditions eligible for the service to increase the 
number of opportunities a pharmacist has to conduct the NMS and 
consequently the number of patients who could benefit, without exceeding the 
funding limit. 
Studies examining the provision of other UK pharmacy services have found 
that adequate funding is important to the success of a service.7,110,111  This is 
not unique to the UK; research conducted in Finland has also found that 
pharmacies must be adequately reimbursed for providing a service if the 
service is going to be successful long term.112  This study suggests that the 
assumptions used to calculate the funding envelope for the NMS are flawed as 
the actually opportunity rate to provide the service is less than the theoretical 
rate that underpins the potential funding available.  This highlights the 
importance of evidence based methodologies to calculate funding allocation. 
7KH UHVXOWV RI WKLV VWXG\ VXJJHVW WKDW D SKDUPDF\¶V RSSRUWXQLW\ UDWH WR
provide the NMS is less than the number of eligible items dispensed.  In this 
study the reason for this was that eligible items were prescribed to patients 
who were not able to take part in the service because their age prevented 
them from being able to consent.  The service to patients with asthma and is 
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likely to be affected by this more than the other groups as children are less 
likely to have hypertension, type 2 diabetes or require anti-platelet agents or 
anti-coagulants, than asthma.8,85-87,94,122,123 
Of the 17 opportunities to offer the NMS in this study, there was just one 
occasion where the NMS was not offered to the patient, suggesting that the 
pharmacists engaged with the service take most available opportunities to 
provide the service.  This contrasts with the early implementation of Medicine 
Use Reviews (MURs), where a national evaluation found that pharmacies 
offering MURs provided just 13.7% of the maximum number of MURs that 
could have been claimed for, despite this service being available for patients 
with any long term therapy.8   The study carried out before the 
implementation of the NMS suggested that pharmacist engagement and NMS 
uptake would be greater than it was for MURs because when MURs were 
introduced it was seen as a change in direction for pharmacy requiring a 
cultural shift, whereas the NMS was seen as a natural extension of the role of 
community pharmacists (Chapter 4).  
In this study there were 16 occasions when the NMS was offered to patients 
and 2 occasions where the patient declined the service.  The stated reason for 
this was the same in both instances, that the patient felt that they were 
receiving enough support from other health care professionals.  There is 
evidence to suggest that the reason given by patients in a pharmacy for 
declining a service may not be the sole or entire reason the patient did not 
want the service133, however both patients had been prescribed anti-
coagulant agents and were attending anti-coagulant clinics so it is possible 
that the declines in this study indicate that some patients taking anti-
coagulants are content with the existing support provided by other health care 
professionals. 
The most common condition receiving the NMS was asthma/COPD, followed 
by hypertension and anti-platelet agents/anti-coagulants with type 2 diabetes 
being the least common condition.  National data published by the PSNC show 
that the most common NMS condition receiving the service is hypertension 
(54.4%), followed by asthma and COPD (26.4%), then type 2 diabetes 
(11.3%) with anti-platelet agent/anti-coagulant being the least common new 
medicines receiving the NMS (7.9%).92  The likely reason for the difference 
between the study data and the national data is the small numbers of NMS 
recorded in this study.  If the sample size had been greater it is likely that the 
proportions of conditions would reflect the national data. Another possible 
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reason for the difference between the study data and national data is that all 
the pharmacies sampled were in the same geographical location (Nottingham) 
and the demographics could potentially be different to demographics 
nationally.  There is also some sensitivity to seasons with asthma and COPD 
with cold weather causing exacerbations.  This could have affected the results 
of this study as data were collected in winter and spring, whereas the national 
data represents all four seasons. 
In this study 28% of prescription items were collected by patient 
representatives, or proxies. Whilst the proportion of prescriptions collected by 
patient representatives nationally is unknown, it is widely reported that 
around a third of requests for health information and non-prescription 
medicines in pharmacies are made by proxies.134-136  The significance of this 
finding is that proxies are unable to provide consent for patient to receive the 
NMS and represent a barrier to NMS engagement. 
The results of this study did not find a statistical difference between the 
proportions of NMS eligible prescription items dispensed in pharmacies co-
located with GP practices and pharmacies further away.  However, the study 
was not powered to test this so it is possible that with a larger sample size a 
difference may be detected. 
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Chapter 7: Analysis of NMS Service Provision  
 
7.1 Introduction 
This chapter presents the results of a study investigating the uptake and 
impact of the NMS by analysing data recorded in PharmaBase service records 
for one large multiple pharmacy chain.  PharmaBase was a national recording 
system available to all pharmacies in England with a NMS module that allowed 
pharmacies to record NMS registrations and consultations (an updated version 
of the recording system called PharmOutcomes is now available). The records 
in PharmaBase comprised 43% of all NMS consultations claimed for during the 
first year of operation.92  The records were made using tick boxes or selecting 
predefined options to questions.  Using this database was not compulsory 
although the large multiple encouraged its use. 
7.2 Methods 
The data from NMS consultations from October 2011 to September 2012 
(September was a partial month) as recorded using PharmaBase, were 
obtained from one large, national, multiple chain pharmacy.  The data had all 
patient identifiable details removed before the records were received.  The 
data were provided in three parts; registrations, interventions and follow-ups, 
which were merged in SPSS. 
The dataset included the following variables: 
Demographic information: 
x Registration identifier, unique for each new NMS patient registration 
x Patient medicine identifier, unique for each new medicine included in 
the NMS  
x Pharmacy identifier, unique for each pharmacy providing the NMS 
x NMS status (options: completed; completed not claimable) 
x Patient age 
x Patient gender 
x Method of entry into the service (options: pharmacy recruitment; GP 
referral; practice nurse referral) 
x PCT 
x Medicine  
x Pharmacy name 
x Pharmacy address 
110 
 
x Condition (options: antiplatelet/anticoagulants; asthma/COPD; 
hypertension; type 2 diabetes) 
x Dosage 
x Registration date (day, month and year) 
For both intervention and follow-up consultations: 
x Date of consultation (day, month and year) 
x Withdrawal Reason (options: patient could not be contacted; patient 
has withdrawn consent of information sharing; patient has withdrawn 
consent to receive the service; prescriber has stopped new medicine; 
remove erroneous patient registration) 
x Consultation method (options: face to face in the pharmacy; telephone) 
x Matters identified with patient (options for all: Y; blank): 
- Using medicine as prescribed 
- Need for more information about the medicine 
- Side effects 
- Negative feelings about the medicine 
- Uncertainty on whether the medicine is working 
- Concern about remembering to take the medicine 
- Not using medicine as prescribed 
- Not having started the medicine 
- Prescriber has stopped the new medicine 
- Not using the medicine in line with the directions of the prescriber 
- Missing a dose in the past 7 days 
- Difficulty using the medicine due to its form 
x Outcomes of the discussion with the patient (options for all: Y; blank): 
- Information provided: 
o How to manage or minimise side effects 
o Interactions with other medicines 
o Why am I using the medicine/what is it for 
o How to use the medicine 
o Correct dose of the medicine 
o Effect of the medicine on the body/how it works 
o Why should I take the medicine 
o Timing of the dose 
o Interpretation of side effect information 
- Agreed patient actions: 
o Carry on using medicine as prescribed 
o Use medicine as agreed during the intervention  
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o Submit yellow card report to MHRA 
- Actions taken by the pharmacist: 
o Reminder strategies to support use of medicine 
o Change to timing of doses to support adherence 
o Referral 
o Yellow card report submitted to MHRA 
o Reminder chart/MAR chart provided 
- Healthy living advice provided 
o Diet and nutrition 
o Smoking cessation 
o Physical activity 
o Alcohol consumption 
o Weight loss 
o Sexual health 
 
7.2.1 Cleaning the data 
Data were cleaned using Microsoft Excel prior to analysis.  The age data were 
examined for outliers and 631 cases were found to have an age of 999years.  
The ages for these cases were treated as missing data and not included in 
calculating the median age of NMS patients. The medicines were expanded, 
placing the drug name (or brand name) in one column, before converting all 
brand names to generic drug names.  The records for the healthy living advice 
given during consultations were also expanded and converted to six columns, 
one for each of the different types of healthy living advice offered during NMS 
consultations.    
There were some potential limitations in the data; the dates for the NMS 
registrations were not usable (the data did not include the date, just the time 
of registration), however the registration dates were also included in the 
intervention and follow-up records.  Therefore when examining uptake by 
month of the service, the dates were taken from the intervention records.  
The data also appeared to contain input errors as evident in table 7.1. 
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Table 7.1: The frequency of possible input errors when recording the 
dates of the different stages of the NMS 
 
Error 
Frequency 
in records 
Registration date = Intervention date 2213 
Registration date = Completion date 3 
Registration date later than intervention date 116 
Registration date later than completion date 5679 
Registration date is before Oct 1st 2011 2  
Intervention date = Completion date 34 
 
The registration data for the service contained 93,411 cases, and the 
intervention and follow-up consultation data contained 92,978 cases, a 
difference of 433.  When examining the 433 registration cases that were not 
included in the intervention and follow-up data I found that they were cases 
that did not have a registration date recorded.  It is possible that these cases 
were instances where data had been erroneously recorded using PharmaBase 
and did not represent actual NMS provided.  Therefore the 433 cases were 
excluded from analysis.  In addition cases with an intervention withdrawal 
UHDVRQRIµUHPRYHHUURQHRXVSDWLHQWUHJLVWUDWLRQ¶ZHUHDOVRH[FOXGHGDVWKH\
GLGQ¶WUHSUHVHQWYDOLG106UHJLVWUDWLRQV (4 cases). 
7.2.2 Analysis 
In order to investigate the uptake of the NMS and understand the problems 
patients experience and the interventions pharmacists make when providing 
the service, analysis of the data was conducted using the IBM SPSS statistics 
20 software as follows.   
7.2.2.1 Demographics 
Before examining the uptake of the NMS and exploring what problems 
patients experience and the interventions pharmacists make during NMS 
consultations, it was important to describe the data including profiles of the 
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patients receiving the service, the rate of dropout from the service, the 
medicines registered for the NMS and the consultation methods used. 
In order to understand the profile of patients receiving the NMS the data were 
analysed by patient rather than by medicine as some patients had more than 
one medicine registered for the service.  To understand the split between 
genders and conditions, frequency counts with percentages were calculated 
for patients registered for the NMS.  When exploring the average age of 
patients receiving the service, the median age was calculated rather than the 
mean as the age data were not normally distributed (determined visually from 
a histogram with a normal curve plotted).    The interquartile range was 
determined because it provides insight as to the spread of ages. 
The dropout rate (the number of cases where the medicine was registered for 
the NMS but the patient left the service at either the intervention or follow-up 
stage) was calculated because if a patient leaves the service without receiving 
the intervention consultation, the pharmacy cannot claim payment for that 
service.  In addition the dropout rate can provide an indication of whether the 
service is acceptable for patients, with a high dropout rate possibly indicating 
that patients do not like the service.  The data set included withdrawal 
reasons for each registered medicine where the patient did not receive a 
consultation at either the intervention or follow-up stages of the NMS.  
Therefore in order to calculate the dropout rate, the frequencies of the 
different reasons for withdrawal from the service were combined and taken 
away from the number of cases at the previous stage.   
Analysis of the medicines registered for the service involved frequency counts 
being performed for the generic drug data.  The results were grouped by 
condition and also grouped by BNF category in order to understand which 
group of medicines were most frequently registered for the service for each 
condition.  The frequency per 1000 medicines prescribed for condition was 
reported rather than the percentage because the high number of different 
medicines eligible for the service meant that some of the percentages were 
very small. 
In order to understand how the service was conducted, the frequency of each 
consultation method (telephone or face to face in the pharmacy) was 
calculated.   The data are also presented as a percentage of medicines 
registered for the service and as a percentage of medicines for which the 
consultation method was recorded. 
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7.2.2.2 Uptake of the NMS 
The uptake of the NMS was explored by calculating the cumulative number of 
pharmacies providing at least one NMS per month from October 2011 to 
August 2012.  The frequency of medicines registered for the service and the 
frequency of completed NMS were calculated for each month allowing the 
provision of the service over the first year after implementation to be 
understood.  In addition the mean length of time between registration and 
completion of the NMS was determined in order to be able to compare it with 
the time frame set out in the service specification (21-45 days). 
When calculating these figures, cases where registration was recorded as 
having happened before 1st October 2011 or after completion of the service 
were excluded as they represented errors in the data (Table 7.1).  Therefore a 
total of 5681 cases (6%) were excluded from these calculations. 
7.2.2.3 Matters identified with the patient 
In order to understand the interventions pharmacists make when providing 
the service, it was first necessary to understand the problems identified by 
pharmacists in NMS consultations.  This was done by analysing 11 variables 
OLVWHGHDUOLHUXQGHUµPDWWHUVLGHQWLILHGZLWKWKHSDWLHQW¶7KHVHYDULDEOHVZHUH
split into concerns and adherence related problems.  One variable was not 
LQFOXGHGLQDQDO\VLVSDWLHQWµQRWXVLQJPHGLFLQHLQOLQHZLWKGLUHFWLRQV¶DVLW
was not VXIILFLHQWO\ GLIIHUHQW IURP WKH µQRW XVLQJ PHGLFLQH DV SUHVFULEHG¶
variable (frequency of cases where the patient was recorded as not using 
medicine in line with directions = 574, frequency of cases where the patient 
was recorded as not using medicine in line with directions and not using 
medicine as prescribed = 561). 
The intervention and follow-up consultation data were analysed by medicine 
rather than by patient as there were cases where patients were registered for 
the NMS with more than one medicine.  In addition, whilst some of the 
potential problems experienced could be patient specific, there were also 
problems that could be medicine specific (such as experiencing side effects) 
so it was decided that it would be appropriate to analyse the consultation data 
by medicine. 
Analysis of this data involved frequency counts with percentages or frequency 
per 1000 of medicines at intervention and follow-up.  In order to determine 
whether there was a statistical difference between frequencies at intervention 
and follow-up, the proportions of medicines were tested for significance.  The 
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standard error of the difference between the two proportions (SE) was 
established before confidence intervals were calculated.   Differences were 
deemed as significant if 0 did not lie within the confidence interval, as 0 
represents no significant difference.  This method of testing for significance 
was also used to determine whether there was a significant difference 
between conditions. 
7.2.2.4 Outcomes of the discussion with the patient 
To understand the interventions pharmacists make when providing the 
serviceWKHYDULDEOHVOLVWHGDERYHXQGHUµRXWFRPHVRIWKHGLVFXVVLRQZLWKWKH
SDWLHQW¶ ZHUH divided into:  information provided, agreed patient actions, 
actions taken by the pharmacist, and healthy living advice.  As for the matters 
identified with the patient, the outcomes of the discussion with the patient 
were analysed by medicine rather than by patient.  Variables classed as 
µDJUHHG SDWLHQW DFWLRQV¶ ZHUH QRW DQDO\VHG DV WKH\ GLG QRW UHSUHVHQW
interventions made by pharmacists as part of the NMS.  For the remaining 
variable frequency counts and percentages of medicines at intervention and 
follow-up were calculated.  In addition, the frequency and proportion of 
medicines where the patient was provided with support in the form of advice, 
provision of information or referral to their prescriber with information was 
calculated and the frequency and proportion of medicines where the patient 
did not receive any advice, information or a referral to their prescriber was 
determined. 
 
7.3 Results 
After cleaning the data there were 92,973 cases to be analysed.  There were 
records of NMS being conducted in a total of 1,674 pharmacies 
(approximately 75% of the English pharmacies in the chain). 
7.3.1  Demographics 
Of the 92,973 cases, 80,083 (86%) were completed and were claimable, and 
14% (12,890) had been completed but were not claimable.  The 92,973 cases 
translated to 88,656 different patients receiving the NMS as some patients 
were prescribed more than one new medicine at a time.   
7.3.1.1  Rates of drop out from the service 
Figure 7.1 shows the number of registered medicines that did not go on to 
receive both NMS consultations.  Almost three quarters (72%) of medicines 
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registered received both the intervention and the follow-up consultations.  
The proportion of medicines registered that did not lead to the patient 
receiving the intervention was 14%, and 17% of medicines where the patient 
had received the intervention did not lead to the patient receiving the follow-
up stage. 
 
Figure 7.1: Diagram showing the number of medicines that received 
each stage of the NMS and those that did not. 
 
Medicines prescribed for asthma/COPD were associated with a significantly 
higher proportion of patients dropping out of the service than patients with 
other conditions at both intervention and follow-up (95% CI of difference at 
intervention: 0.0316, 0.0423, at follow-up: 0.0249, 0.0373, Table 7.2).  After 
excluding erroneous patient registrations, there were 5 possible options 
available to pharmacists when recording reasons for patients leaving the 
service:  
x Prescriber has stopped the new medicine 
x Patient has withdrawn consent to receive the service 
x Patient has withdrawn consent for information sharing 
x Patient could not be contacted 
x Other  
The most common reason for patients dropping out at either intervention or 
follow-up stages was that the pharmacy was unable to contact the patient 
 
Number of 
medicines 
registered 
92,973 
Received 
intervention 
80,073 
(86%) 
Received 
follow-up 
66,556 
(83%) 
Did not receive 
intervention 
12,900 
(14%)  
Did not receive 
follow-up 
13,518  
(17%) 
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(n=9,342 (10%) at the intervention stage, n=10,435 (13%) at the follow-up 
stage).  The second most common reason that patients dropped out of the 
NMS was that the prescriber had stopped the new medicine (n=2,264 (2%) at 
the intervention stage, n=2,028 (3%) at the follow-up stage). 
 
Table 7.2: Drop out rates at intervention and follow-up stages for 
each condition (n=92,973) 
Condition 
Number of 
registrations 
Frequency of 
drop out at 
intervention 
stage (%) 
Frequency of 
drop out at 
follow-up stage 
(%) 
Hypertension 
 
52,528 
 
7,023 
 
(13%) 
 
7,486 
 
(16%) 
 
Asthma/COPD 
 
23,755 
 
3,950 
 
(17%) 
 
3,807 
 
(19%) 
 
Type 2 diabetes 
 
9,517 
 
1,146 
 
(12%) 
 
1,268 
 
(15%) 
 
Antiplatelet/anticoagulant 
 
7,173 
 
781 
 
(11%) 
 
957 
 
(15%) 
 
 
7.3.1.2  NMS initiation 
The majority of NMS were initiated by pharmacy staff (99.7%) with just 0.3% 
of cases entering the service after a referral from a GP or practice nurse.  
Further analysis of prescriber referrals into the NMS showed that the 192 GP 
referrals were spread out over 172 pharmacies and 89 different PCTs and that 
practice nurse referrals fitted the same pattern.  This suggests widespread 
low prescriber engagement with the NMS. 
7.3.1.3  Profiles of patients receiving the NMS 
Of the 88,656 patients who received the NMS, 55% were female (n=48,548) 
and 45% were male (n=40,108).  The most common condition for which the 
NMS was provided was hypertension (57%), followed by asthma/COPD 
(26%), type 2 diabetes (10%) and lastly antiplatelet/anticoagulant therapy 
(8%).  The median age of patients receiving the NMS was 64 years (minimum 
0 years, maximum 108 years) with an interquartile range of 52-74 years.   
7.3.1.4  Medicines registered for the NMS 
Of the four conditions hypertension has the largest number of medicines 
eligible for the NMS (66 of the 119 medicines listed in the service 
specification).85  The most commonly prescribed new medicine for 
hypertension was amlodipine (26%) followed by ramipril (18%) and losartan 
(10%) (see Table 7.3).  When grouped by BNF category, calcium-channel 
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blockers were most commonly registered for the NMS followed by 
angiotensin-converting enzyme inhibitors (Table 7.3) 
 
Table 7.3:  The frequency of the most common hypertension 
medicines registered for the NMS by BNF catagory (n=52,528) 
BNF 
category 
Drug name Frequency Frequency per 
1000 Medicines 
Prescribed for 
Condition  
Thiazides and related diuretics 6325 120 
  Bendroflumethiazide 3106 59 
  Indapamide 3086 59 
  Chlortalidone 116 2 
  Other 17 <1 
Beta-adrenoceptor blocking drugs 6092 116 
  Bisoprolol 4137 79 
  Atenolol 1011 19 
  Propranolol 560 11 
  Other 384 7 
Vasodilator antihypertensive drugs 48 1 
Centrally acting antihypertensive 
drugs 180 3 
  Moxonidine 114 2 
  Other 66 1 
Alpha-adrenoceptor blocking drugs 1928 37 
  Doxazosin 1891 36 
  Other 37 1 
Angiotensin-converting enzyme 
inhibitors 13971 266 
  Ramipril 9578 182 
  Lisinopril 3171 60 
  Perindopril 925 18 
  Other 297 6 
Angiotensin-II receptor antagonist 7161 136 
  Losartan 5167 98 
  Candesartan 1442 27 
  Irbesartan 232 4 
  Other 320 6 
Renin inhibitors 9 <1 
  Aliskiren 9 <1 
Calcium-channel blockers 16814 320 
  Amlodipine 13487 257 
  Felodipine 1264 24 
  Lercanidipine 739 14 
  Other 1324 25 
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The second largest group of medicines eligible for the NMS belonged to the 
asthma/COPD condition group.  The most commonly prescribed medicine for 
asthma/COPD was salbutamol (35%) followed by beclometasone (21%) and 
tiotropium (10%).  When the medicines are grouped by BNF category 
bronchodilators are most commonly prescribed, followed by corticosteroids 
and other medicines (see Table 7.5).  This reflects the treatment steps for 
asthma and COPD outlined in the guidance for asthma treatment published by 
the British Thoracic Society and Scottish Intercollegiate Guidelines Network.129 
 
Table 7.4:  Frequency of common asthma/COPD medicines registered 
for the NMS by BNF chapter (n=23,749).
 
BNF 
Category 
Drug Name Frequency 
Frequency per 
1000 Medicines 
Prescribed for 
Condition  
Bronchodilators 12,548 528 
  Salbutamol 8,313 350 
  Tiotropium 2,468 104 
  Salmeterol 757 32 
  Other 1,010 43 
Corticosteroids 10,474 441 
  Beclometasone 5,016 211 
  Fluticasone/Salmeterol 2,630 111 
  Budesonide/Formoterol 1,561 66 
  Other 1,267 53 
Cromoglycate and related therapy and 
leukotriene receptor antagonists and 
phophodiesterase type 4 inhibitors 727 31 
  Montelukast 702 30 
  Zafirlukast 17 1 
  Other 8 <1 
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Type 2 diabetes had the third largest group of medicines eligible for the NMS.  
Metformin was the most frequently prescribed medicine (49%), with gliclazide 
(19%) and sitagliptin (14%) coming second and third respectively (Table 
7.5).  When grouped by BNF category Biguanides were the most commonly 
registered medicines for type 2 diabetes.  Insulins were the least commonly 
registered medicines as expected due to them being further down the 
treatment pathway for type 2 diabetes than oral antidiabetic medicines (as 
recommended by the National Institute for Health and Care Excellence 
(NICE)).133 
 
Table 7.5:  The frequency of the most common type 2 diabetes 
medicines registered for the NMS by BNF category (n=9,510). 
BNF 
category 
Drug name Frequency Frequency per 
1000 Medicines 
Prescribed for 
Condition  
Insulins 385 40 
  Lantus 76 8 
  Humulin 75 8 
  NovoMix 63 7 
  Other 171 18 
Sulphonylureas 2,058 216 
  Gliclazide 1,828 192 
  Glimepiride 186 20 
  Glipizide 20 2 
  Other 24 3 
Biguanides 4,653 489 
  Metformin 4,653 489 
Other antidiabetic drugs 2,414 254 
  Sitagliptin 1,374 144 
  Pioglitazone 323 34 
  Saxagliptin 273 29 
  Other 444 47 
 
The smallest group of medicines eligible for the NMS are anti-platelets and 
anti-coagulants.  Aspirin was the most commonly prescribed medicine for the 
antiplatelet/anticoagulant category (35%).  Warfarin was the next most 
frequent medicine (31%) with clopidogrel third (30%).  When grouped by BNF 
category antiplatelet drugs were much more commonly registered for the 
NMS than oral anticoagulant drugs (Table 7.6). 
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Table 7.6:  The frequency of the most common 
antiplatelet/anticoagulant medicines registered for the NMS by BNF 
category (n=7,186). 
BNF category Drug name Frequency Frequency per 
1000 medicines 
prescribed for 
condition  
Antiplatelet drugs 4864 676.87 
  Aspirin 2500 347.90 
  Clopidogrel 2143 298.22 
  Dipyridamole 161 22.40 
  Other 60 8.35 
Oral anticoagulants 2322 323.13 
  Warfarin 2195 305.46 
  Dabigatran 81 11.27 
  Rivaroxaban 29 4.04 
  Other 17 2.37 
 
 
A complete table of all medicines registered for the NMS is included in 
appendix 6. 
7.3.1.5 Consultation Methods 
A majority of records (48,721) did not include the consultation method (Table 
7.7) as recording the method was not mandatory for the full sample period.92  
Where this data was recorded, it could be seen that more consultations were 
conducted by telephone (72% of intervention consultations and 75% of 
follow-up consultations) than in face-to-face consultations in the pharmacy 
(28% of intervention consultations and 25% of follow-up consultations) (Table 
7.7).  These data can give an indication that telephone consultations may be 
the consultation method most commonly used, supported by the intervention 
and follow-up data being very similar, but care must be taken when applying 
the results as so many records did not include these data. 
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Table 7.7:  The frequency of method of consultation being recorded 
(n=80,074). 
Consultation 
Method  
Intervention Follow-up 
Frequency Percentage of 
interventions 
(%) 
Frequency Percentage 
of follow-ups 
(%) 
Not recorded 48,721 61 40,972 62 
Face-to-face in 
the pharmacy 8,628 11 6,299 9 
Telephone 22,725 28 19,285 29 
 
 
7.3.2 Uptake of the NMS 
The cumulative number of pharmacies that have provided at least one NMS by 
month (October 2011 to August 2012) indicates the fast initial uptake of the 
NMS (Figure 7.2).  The number of pharmacies that registered at least one 
NMS for each month has some fluctuation with lower numbers of pharmacies 
recording NMS in April and August, which could be due to those months being 
popular holiday times, however the overall number of pharmacies recording at 
least one NMS using PharmaBase per month remains generally steady (Figure 
7.2).  
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Figure 7.2:  The rate of uptake of the NMS by pharmacies 
The number of medicines registered for the NMS steadily increased in the first 
few months of the service, reaching a peak in February 2012 (Figure 7.3) 
which could be due to the requirement of pharmacies completing 6 NMS 
before March 1st 2012 to be eligible for a one off implementation payment.  
Apart from the first month where the number of completed NMS was low due 
to the NMS taking up to 5 weeks to complete, the frequency of completed 
services each month stays relatively consistent (Figure 7.3).  
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 Figure 7.3:  The frequency of NMS registrations and NMS completions 
by month. 
The mean length of time between registration and completion of the NMS was 
27.3 days (95% CI 27.2-27.5 days).  The maximum length of time recorded 
was 339 days.  The mean length of time between registration and completion 
lies within the range set out in the NMS specification of 21-45 days, although 
47,946 (52%) cases fell outside this range (less than 21 days=39081 cases, 
more than 45 days=8865 cases). 
 
7.3.3 Matters identified with the patient 
The dataset shows that pharmacists identified a total of 30,462 problems at 
the intervention stage of the NMS with 10.1% of medicines having at least 
one problem recorded (medicines receiving intervention=80,074).  At the 
follow-up consultation 13,144 problems were identified with 14.2% of 
medicines having a problem recorded (medicines receiving follow-up=66,556) 
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(Table 7.8).  The problems identified include concerns raised by patients 
about their medicines and adherence related problems. 
At both NMS stages the most common concern identified was that the patient 
was unsure whether the medicine was working (Tables 7.8 and 7.9).  At 
intervention the second most common concern raised was that the patient 
wanted more information about the medicine.  This concern was the third 
most common at follow-up suggesting that patients want information about 
their medicines when they first start taking them and this need decreases 
over time. 
 
Table 7.8: Problems identified in NMS intervention consultations 
(n=80,074). 
Type of 
problem 
Problem Identified 
Frequency 
at 
Intervention 
Frequency at 
intervention 
per 1000 
medicines 
Concerns Need for more information about the 
medicine 
3,162 
 
40 
 
Negative feelings about the medicine 2,775 35 
Uncertainty on whether the medicine is 
working 
4,232 
 
53 
 
Concern about remembering to take the 
medicine 
507 
 
6 
 
Adherence 
issues 
Experiencing side effects 12,117 151 
Not using the medicine as prescribed 4,525 57 
Not having started using the medicine 757 10 
Missing a dose in the last 7 days 995 12 
Difficulty using the medicine due to its form 329 4 
Other Prescriber has stopped the medicine 489 6 
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Table 7.9: Problems identified in NMS follow-up consultations 
(n=66,556) 
 
Type of 
problem 
Problem Identified 
Frequency 
at Follow-
up 
Frequency at 
follow-up 
per 1000 
medicines 
Concerns Need for more information about the 
medicine 
773 
 
12 
 
Negative feelings about the medicine 1,022 15 
Uncertainty on whether the medicine is 
working 
1,544 
 
23 
 
Concern about remembering to take the 
medicine 
197 
 
3 
 
Adherence 
issues 
Experiencing side effects 5,305 80 
Not using the medicine as prescribed 2,651 40 
Not having started using the medicine 112 2 
Missing a dose in the last 7 days 443 7 
Difficulty using the medicine due to its form 126 2 
Other Prescriber has stopped the medicine 683 10 
 
 
Whilst the majority of medicines did not have problems associated with them 
recorded (90% at intervention and 86% at follow-up), some patients 
experienced more than one problem per medicine (Table 7.10).  The number 
of cases where no problems with medicines were recorded is greater than the 
number of cases where the patient was recorded as using their medicine as 
prescribed at both stages of the NMS. 
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Table 7.10:  The number of problems identified per medicine at 
intervention and follow-up (intervention: 80,074 medicines, follow-
up: 66,556 medicines). 
Number of 
problems identified 
per medicine 
Intervention Follow-up 
Frequency  
Frequency of 
problems per 
1000 
Frequency  
Frequency of 
problems per 
1000 
0 72025 899 57135 858 
1 1461 18 7084 106 
2 4553 57 1794 27 
3 1560 19 418 6 
4 357 4 99 1 
5 89 1 19 <1 
6 22 <1 5 <1 
7 6 <1 2 <1 
9 1 <1 0 <1 
 
At the intervention stage there were 65015 cases where patients were 
reported as using their medicines as prescribed (81.2% of medicines at 
intervention).  At the follow-up stage this figure was 48638 cases (73.1% of 
medicines at follow-up).  However this does not mean that patients reported 
as using their medicines as prescribed did not experience problems; 11,955 
concerns were identified at the intervention stage, and 2724 problems 
identified at the follow-up stage, in patients recorded as taking their 
medicines as prescribed (Table 7.11). 
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Table 7.11:  Concerns identified for patients reported as taking their 
medicine as prescribed (intervention: 65,015, follow-up: 48,638). 
 
Concerns Identified 
Frequency at 
Intervention 
Frequency 
per 1000 
medicines 
Frequency 
at Follow-
up 
Frequency 
per 1000 
medicines 
Need for more information about 
the medicine 
6,214 78 648 
10 
Negative feelings about the 
medicine 
1,778 22 674 
10 
Uncertainty on whether the 
medicine is working 
3,597 45 1,263 
19 
Concern about remembering to 
take the medicine 
366 5 139 
2 
Total 11,955   2,724   
 
 
7.3.3.1 Side Effects 
The most common problem identified during NMS consultations was that the 
patient was experiencing side effects of the new medicine (n=12,117 (15%) 
at intervention, n=5,305 (8%) at follow-up) (Table 7.8 and Table 7.9).  A 
higher percentage of medicines for type 2 diabetes or hypertension were 
associated with side effects being reported than antiplatelets/anticoagulants 
or medicines for asthma/COPD (diabetes: 19%, hypertension: 19%, 
asthma/COPD: 7% and antiplatelets/anticoagulants: 10%) (Table 7.12).  The 
proportion of medicines leading to patients experiencing side effects was 
smaller at the follow-up consultation compared to at the intervention 
consultation (Table 7.12). 
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Table 7.12: The frequency of medicines associated with side effects 
and the proportion of medicines for each condition that were 
associated with this problem (n=92,974). 
Condition 
Intervention Follow-up 
Frequency 
Percentage 
of medicines 
within 
condition 
(%) 
Frequency 
Percentage 
of medicines 
within 
condition 
(%) 
Antiplatelet/anticoagulant 638 10 302 6 
Asthma/COPD 1,423 7 591 4 
Type 2 diabetes 1,620 19 686 10 
Hypertension 8,436 19 3,726 10 
Total 12,117 15 5,305 8 
 
 
The reduction in the proportion of medicines reported as causing side effects 
between the intervention and follow-up consultations is significant (95% CI of 
the difference between proportions: 0.0837,0.0911).  This reduction is also 
significant for each of the four therapeutic areas as determined by the CIs 
(antiplatelet/anticoagulant: 0.0026, 0.0042, asthma/COPD: 0.0077,0.0101, 
type 2 diabetes: 0.0006,0.0112, hypertension: 0.0466,0.0521). 
 
7.3.3.2 Patient not using the new medicine as prescribed 
At the intervention consultation 4,525 (6%) medicines were reported as not 
being used by patients as prescribed (Table 7.13).  This figure dropped to 
2,651 (4%) at the follow-up consultation.  The proportion of medicines where 
patients were affected by this problem were similar for hypertension, type 2 
diabetes and antiplatelet/anticoagulant therapy (5.0%, 4.8% and 4.1% at 
intervention, 3.8%, 2.9% and 2.4% at follow-up respectively).   A greater 
proportion of asthma/COPD patients were reported as not using their new 
medicines as prescribed compared to the other conditions at both the 
intervention and follow-up stages (95% CI of difference between proportions 
at intervention: 0.0285-0.0368, CI of difference at follow-up: 0.0180,0.0256) 
(Table 7.13). 
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Table 7.13: The frequency of medicines where the patient is not using 
the medicine as prescribed and the proportion of medicines in each 
condition affected by this problem (n=92,974). 
Condition 
Intervention Follow-up 
Frequency 
Percentage of 
patients with 
condition (%) 
Frequency 
Percentage of 
patients with 
condition (%) 
Antiplatelet/anticoagulant 264 4 31 2 
Asthma/COPD 1,606 8 878 5 
Type 2 Diabetes 401 5 208 3 
Hypertension 2,254 5 1,434 4 
Total 4,525 6 2,651 4 
 
The reduction in the proportion of patients recorded as not using their 
medicines as prescribed between the intervention and follow-up consultations 
is significant as indicated by the 95% CI of the difference between the 
proportions: 0.0145,0.0189. 
 
7.3.3.3 Patient has not started using the new medicine 
Pharmacists reported that patients had not started to take the new medicine 
at the intervention consultation in less than 1% of cases and this number 
dropped further at the follow-up stage (Table 7.14).  In a significantly greater 
proportion of asthma/COPD cases, patients were recorded as not having 
started the new medicine at both the intervention and follow-up consultations 
compared with the other therapeutic groups (95% CI of difference between 
proportions at intervention: 0.0019,0.0051, CI of difference at follow-up: 
0.0011,0.0030).   
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Table 7.14: The frequency of medicines where the patient had not 
started taking it at the time of the consultation, and the proportion of 
medicines in each condition that were associated with patients 
experiencing this problem (n=92,974). 
Condition 
Intervention Follow-up 
Frequency 
Percentage of 
patients with 
condition (%) 
Frequency 
Percentage of 
patients with 
condition (%) 
Antiplatelet/anticoagulant 45 0.7 8 0.2 
Asthma/COPD 277 1.4 52 0.3 
Type 2 Diabetes 64 0.8 5 0.1 
Hypertension 371 0.8 47 0.1 
Total 757 0.9 112 0.2 
 
Although the numbers of patients who had not started the new medicine at 
either consultation were small, the reduction in the proportion of patients 
reported as not having started using the new medicines between the 
intervention and follow-up stages is statistically significant as indicated by the 
95% CI of the difference between proportions: 0.0070,0.0085. 
7.3.3.4 Patient has missed a dose in the last 7 days 
The number of patients recorded as having missed a dose in the 7 days prior 
to the consultation was low with just 1.2% of medicines at intervention 
leading to patients being recorded as having missed a dose (Table 7.15).  At 
the follow-up consultation this figure was lower, with 0.7% of medicines 
leading to pharmacists reporting patients as having missed a dose.  
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Table 7.15: The frequency of a dose being missed in the 7 days prior 
to the consultation, and the proportion of medicines in each condition 
leading to patients experiencing this problem (n=92,974). 
Condition 
Intervention Follow-up 
Frequency 
Percentage of 
patients with 
condition (%) 
Frequency 
Percentage of 
patients with 
condition (%) 
Antiplatelet/anticoagulant 61 1.0 34 0.6 
Asthma/COPD 338 1.7 138 0.9 
Type 2 Diabetes 82 1.0 44 0.6 
Hypertension 514 1.1 227 0.6 
Total 995 1.2 443 0.7 
 
The difference between the proportion of cases where the patient has missed 
a dose in the last 7 days at intervention and follow-up is statistically 
significant (95% CI of the difference between the proportion of cases at 
intervention and follow-up: 0.0048,0.0068).  The proportion of medicines 
where patients had missed a dose in the 7 days prior to the follow-up 
consultation was found to be statistically less than the proportion at 
intervention for each condition (95% CI of the difference in proportions: 
hypertension: 0.0040,0.0066, asthma/COPD: 0.0061,0.0107, type 2 
diabetes: 0.0008,0.0064, and antiplatelets/anticoagulants: 0.0001,0.0065). 
 
7.3.3.5 Patient having difficulty due to form 
The number of medicines that lead to pharmacists recording that patients 
were having problems with their new medicine due to the form of the 
medicine was low just 0.41% of medicines at intervention being reported as 
causing patients difficulty (Table 7.16).  At the follow-up consultation this 
value was 0.19% of medicines.  Despite the low numbers, the difference in 
the number of patients experiencing difficulty due to form at intervention and 
follow-up was found to be significant (95% CI of the difference between the 
proportion of medicines at intervention and follow-up: 0.0017,0.0028). 
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Table 7.16:  The frequency of medicines leading to patients 
experiencing difficulty due to the medicines form, and the proportion 
of each condition affected by this problem (n=92,973). 
Condition 
Intervention Follow-up 
Frequency 
Percentage of 
patients with 
condition (%) 
Frequency 
Percentage of 
patients with 
condition (%) 
Antiplatelet/anticoagulant 15 0.2 11 0.2 
Asthma/COPD 260 1.3 93 0.6 
Type 2 Diabetes 14 0.2 10 0.1 
Hypertension 40 0.1 12 <0.1 
Total 329 0.4 126 0.2 
 
When analysed by condition, asthma/COPD medicines lead to significantly 
more patients experiencing difficult due to form than medicines used for the 
other conditions (95% CI of the difference in proportion of asthma/COPD 
medicines compared to the other conditions at intervention: 0.0104, 0.0136, 
at follow-up: 0.0035, 0.0059).  
 
7.3.4 Outcomes of the discussion with the patient 
67% of intervention records showed the pharmacist providing support to 
patients in the form of advice, provision of information or referral to their 
prescriber.  The data showed that support was not provided in either 
consultation in 25% of records. 
More advice was given and referrals made in intervention consultations 
compared with follow-up consultations (Table 7.17).  This was expected as in 
follow-up consultations patients have already had the opportunity to ask 
questions and receive advice in the intervention consultation.  The most 
frequently given type of advice given was information regarding the purpose 
of the new medicine (at intervention n=20,983 (26%), at follow-up n=7,469 
(11%)), with information about how to take it also being commonly provided 
(at intervention n=18,215 (23%), at follow-up n=6,406 (10%)) (Table 7.17).  
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Table 7.17: Information provided to patients during NMS 
consultations (n=92,974) 
 
Intervention Follow-up 
Information provided Frequency 
Percentage 
of 
Interventions 
(%) 
Frequency 
Percentage 
of Follow-
ups (%) 
How to manage or minimise side 
effects 
10,106 
 
13 
 
4,567 
 
7 
 
Interactions with other medicines 
 
6,292 
 
8 
 
2,934 
 
4 
 
Why am I using the medicine?  
What is it for? 
20,983 26 7,469 11 
How to use the medicine 
 
18,215 
 
23 
 
6,406 
 
10 
Correct dose of the medicine 
 
16,465 
 
21 
 
7,135 
 
11 
 
Effect of the medicine on the 
body, how it works 
15,799 20 5,749 9 
Why should I take the medicine? 
 
14,676 
 
18 
 
5,807 
 
9 
 
Timing of the dose 
 
17,835 
 
22 
 
7,010 
 
11 
 
Interpretation of side effect 
information 
 
12,407 
 
15 
 
5,294 
 
8 
 
 
At intervention a greater proportion of patients taking 
antiplatelet/anticoagulants were provided with information regarding 
interactions with other medicines than patients with the other 3 conditions 
(antiplatelet/anticoagulant=15%, asthma/COPD=4%, type 2 diabetes=6%, 
hypertension=7%, 95% confidence interval of the difference between 
proportions: 0.0811, 0.0980).  This may reflect the high number of medicines 
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that can affect international normalised ratio (INR) levels (a measure of blood 
coagulation used in patients taking anticoagulants). 
A significantly higher proportion of patients with asthma/COPD were provided 
with information regarding how to use the medicine than patients prescribed 
medicines for other conditions (asthma/COPD=27%, 
antiplatelet/anticoagulant=20%, type 2 diabetes=20%, hypertension=16%, 
95% CI of difference between proportions: 0.0890, 0.1013).  This may reflect 
the need for asthma/COPD patients to receive inhaler technique advice, which 
patients with the other conditions do not require. 
In addition a significantly lower proportion of patients with asthma/COPD 
were provided with information regarding the interpretation of side effect 
information (asthma/COPD=9%, antiplatelet/anticoagulant=15%, type 2 
diabetes=15%, hypertension=15%, 95% CI of difference between 
proportions: 0.0525, 0.0615).  This fits with the finding that the proportion of 
asthma/COPD patients affected by side effects was less than the other 
conditions (Table 7.12). 
The records show intervention consultations triggered referrals to prescribers 
in 4.7% of cases (Table 7.18).  This figure was lower in follow-up 
consultations (3.6%), perhaps due to problems developing quickly after 
starting to take the medicine, therefore the problems may have been spotted 
and addressed in intervention consultations.  The number of yellow card 
reports being submitted to the MHRA was low (0.06% of intervention cases 
and 0.05% of follow-up cases) relative to the high numbers of side effects 
reported.  Guidance provided by the MHRA to health care professionals asks 
that all adverse drug reactions be reported for black triangle medicines 
(subject to additional monitoring), all adverse drug reactions in children, and 
all serious adverse drug reactions.131   The relatively low numbers of yellow 
card reports could indicate that pharmacists are following the MHRA guidance 
as most of the medicines included in the NMS have well established side effect 
profiles which do not need reporting. 
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Table 7.18. Actions taken by pharmacists (n=92,974). 
 
Intervention Follow-up 
Actions taken by pharmacist Frequency 
Percentage 
of 
Interventions 
(%) 
Frequency 
Percentage 
of Follow-
ups (%) 
Reminder strategies to support use 
of medicine 
9385 
 
12 
 
5857 
 
9 
 
Change to timing of doses to 
support adherence 
2204 
 
3 
 
825 
 
1 
 
Referral  3760 5 2402 4 
Yellow  card report submitted to 
MHRA 
52 
 
<1 
 
33 
 
<1 
 
Reminder chart/MAR chart provided 
 
53 
 
<1 
 
0 
 
<1 
 
 
Pharmacists also had the opportunity to provide Healthy Living Advice (HLA) 
to patients in intervention and follow-up consultations (Table 7.19).  The 
records show that the most common HLA provided in NMS consultations was 
advice regarding diet and nutrition (n=18,417 (23%) at intervention; 
n=11,075 (17%) at follow-up), followed by physical activity (n=13,030 (16%) 
at intervention; n=7,860 (12%) at follow-up).  Sexual health advice was the 
least common type of HLA provided in NMS consultations, which could be 
explained by the conditions eligible for the service having little effect on 
sexual health.  At intervention pharmacists provided HLA in 28% of cases and 
21% of cases received HLA at the follow-up consultation. 
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Table 7.19.  Healthy living advice provided to patients during NMS 
consultations (n=92,974). 
 
Intervention Follow-up 
Health Living Advice 
Provided 
Frequency 
Percentage of 
Interventions 
(%) 
Frequency 
Percentage 
of Follow-
ups (%) 
Diet and nutrition 18,417 23 11,075 17 
Smoking 7,013 9 3,461 5 
Physical activity 13,030 16 7,860 12 
Alcohol 5,449 7 2,575 4 
Weight loss 4,119 5 2,453 4 
Sexual health  168 <1 117 <1 
 
 
Earlier we saw that some patients who were using their medicines as 
prescribed still experienced problems.  I also found that pharmacists still 
provided information to patients who were not reported as experiencing 
problems with 44% of cases at intervention (n=31269) and 22% of cases at 
follow-up receiving at least on piece of advice.  Advice regarding the purpose 
of the medicine was the most frequent type of advice provided (at 
intervention n=14,834 (21%); at follow-up n=6,030 (7%)) (Table 7.20). 
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Table 7.20: The frequencies of information provided and actions taken 
by pharmacists where the patient is not reported to be experiencing 
problems (at intervention n=71,770, at follow-up n=83555). 
Information provided and 
action taken by pharmacists 
Intervention Follow-up 
Frequency 
Frequency 
per 1000 
medicines Frequency 
Frequency 
per 1000 
medicines 
How to manage or minimise side 
effects 
5,102 
 
71 
 
2,851 
 
34 
 
Interactions with other medicines 4,656 65 2,510 30 
Why am I using the medicine?  
What is it for? 
14,834 207 6,030 72 
How to use the medicine 13,196 184 5,270 63 
Correct dose of the medicine 12,148 169 602 7 
Effect of the medicine on the 
body, how it works 
10,449 
 
146 
 
4,421 
 
53 
 
Why should I take the medicine? 9,921 138 4,518 54 
Timing of the dose 12,916 180 5,794 69 
Interpretation of side effect 
information 
6,882 
 
96 
 
3,394 
 
41 
 
Reminder strategies to support 
use of medicine 
6,734 
 
94 
 
4,956 
 
59 
 
Change to timing of doses to 
support adherence 
1,017 
 
14 
 
521 
 
6 
 
Referral  401 6 473 6 
Yellow  card report submitted to 
MHRA 
8 
 
<1 
 
7 
 
<1 
 
Reminder chart/MAR chart 
provided 
41 
 
1 
 
13 
 
<1 
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The relatively high numbers of cases where the patient was recorded as not 
experiencing problems and information was provided may indicate that either 
patients still want information about their medicines despite not experiencing 
problems, or pharmacists still see value in providing information to patients 
who are not experiencing problems.  In 6% of cases at both intervention and 
follow-up pharmacists referred patients to their prescribers, and at both 
consultations there were cases where it was reported that the pharmacist had 
submitted a yellow card report to the MHRA (at intervention n=8, at follow-up 
n=7) (Table 7.20).  This suggests that in some cases the pharmacist 
identified problems requiring a referral or a yellow card report but did not 
record the problem using PharmaBase.  It is possible that the patients were 
experiencing problems not covered by the options available on PharmaBase, 
or that pharmacists omitted the problems when recording the consultations on 
PharmaBase. 
 
7.4 Discussion 
This study found that the dropout rate of medicines registered for the NMS 
was less than 20% at both intervention and follow-up.  The results show low 
levels of GP and practice nurse engagement with the service as more than 
99% of NMS were initiated by pharmacies.  Where reported, the most 
commonly recorded consultation method was by telephone at both 
consultations.  When examining the uptake and provision of the NMS, it was 
found that the initial uptake of the service happened rapidly with the 
frequency of completed NMS per month quickly becoming consistent.  At 
intervention at least one problem was recorded for 10% of medicines (14% at 
follow-up) with the most common problem reported being the patient 
experiencing side effects.  In the majority of cases it was reported that the 
patient received support from the pharmacist in the form of advice, provision 
of information, or referral to their prescriber.  Pharmacists provided healthy 
living advice in 28% of cases at intervention and 21% of cases at follow-up.  
It was also found that pharmacists provided support to patients who were not 
recorded as experiencing problems which could indicate omissions in 
recording the consultation. 
When comparing the results of this study to an evaluation of the complete 
national PharmaBase (now called PharmOutcomes) NMS data the results are 
similar.92  This study found a very similar split in gender (female: 54.8%, 
male: 45.2%) to that of the national PharmaBase evaluation (female: 53.1%, 
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male: 46.9%).  The percentage of NMS recruited by the pharmacy rather than 
by GPs or practice nurses were also very similar (this study: 99.7%, national 
data: 99.6%), and both studies found that where the consultation method 
was recorded approximately 70% of consultations were conducted by 
telephone.  The split of cases between the four conditions were also very 
similar between the two studies (this study: hypertension=56%, 
asthma/COPD=26%, type 2 diabetes=10%, antiplatelet/anticoagulant=8%; 
PharmaBase evaluation: hypertension=54%, asthma/COPD=26%, type 2 
diabetes=11, antiplatelet/anticoagulant=8%).  This suggests that the data in 
this study is representative of the data collected nationally despite being 
collected from just one pharmacy chain. 
The results of this study found that the uptake of the NMS by pharmacies 
happened rapidly in the first few months of the service before reaching a 
steady number of NMS completed each month.  The study also found that 
after the initial few months the number of pharmacies recording at least one 
NMS per month remained relatively steady.   This is supported by national 
NHS Prescription Services data which shows that the uptake of the service 
happened very quickly before reaching a steady number of NMS conducted 
and number of pharmacies claiming for at least one completed NMS per 
month.92 
The rapid uptake of the NMS is in contrast with the more gradual uptake of 
MURs in 2005.  The national evaluation of the 2005 pharmacy contract 
reported that in the first year (2005-6) just 38% of pharmacies delivered the 
MUR service7 whereas this study found that approximately 75% of the 
pharmacies in the chain provided the NMS between October 2011 and August 
2012 as recorded using PharmaBase.  The actual percentage of pharmacies in 
the chain providing the NMS may be higher than this figure as using 
PharmaBase was not compulsory (although encouraged) therefore some 
pharmacies may have been providing the service but not using PharmaBase 
to record them.  However one must be cautious when comparing these two 
figures as there is evidence to suggest that pharmacy chains have greater 
uptake of services compared to the national pharmacy sector5,7 and therefore 
the results from this study are likely to be higher than the national rate of 
uptake of the NMS. 
This study found that three quarters of pharmacies within the sampled chain 
had used PharmaBase to record NMS consultations.  Whilst the proportion of 
pharmacies in England that used PharmaBase to record NMS consultations 
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has not been published, the national evaluation reported that NMS recorded 
using PharmaBase represented 43% of all NMS claimed for by pharmacies.  
This could suggest that uptake of PharmaBase by the large multiple sampled 
in this study was greater than the national uptake.  It is likely that the greater 
proportion of pharmacies using PharmaBase in this study is due to 
management within the company encouraging its use. 
The results of this study found that 15% of patients were experiencing side 
effects from their medicine at intervention and 7% of patients reported 
experiencing them at follow-up.  These figures seem to be much lower than 
expected as other studies have found that between 33-61% of patients 
experience side effects.16-18  This could reflect omissions in the information 
recorded on PharmaBase by pharmacists or the lower incidence of side effects 
found could be due to patients not reporting them during the NMS 
consultations, or the side effects may not have appeared within the NMS 
timeframe (although this is less likely). 
This study found very low rates of instances where a patient had missed a 
dose in the 7 days prior to the consultation (<2% of patients) and the number 
of medicines that were not being taken as prescribed (<5% of medicines) 
which are indicators of non-adherence.  There has been much research 
conducted examining the levels of non-adherence for long term conditions 
and it is widely accepted that the proportion of medicines prescribed for long 
term conditions not being taken as prescribed is much higher than the results 
of this study would suggest (30-60% of medicines).12,22  In addition the study 
conducted by Clifford that the NMS is based on reported that 10 days after 
the intervention 30% of patients were non-adherent and 4 weeks after the 
intervention 25% of patients were still non-adherent.80,81  This difference may 
be in part due to patients being less willing to report non-adherence to their 
regular pharmacists during the NMS consultations than study participants 
were to pharmacists they did not know in the Clifford study. 
There are several possible reasons for the lower than expected level of non-
adherence found by this study.  One reason is that the data is reliant on the 
patient reporting the problems they have experienced to the pharmacist 
during the NMS consultation.  They may be unwilling to admit to having 
missing doses of their new medicine to the pharmacist and there is much 
evidence that self-reported measures over-estimate adherence.33  Despite 
there being validated self-reported adherence measures available, the 
interview schedule for the NMS consultations was not designed to measure 
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adherence, but instead to highlight any problems the patient may be having 
with their new medicine.  This means that the data recorded by pharmacists 
can be used to give an indication of the number of patients who experience 
problems taking their new medicines, but cannot be used to calculate 
adherence rates.  The study conducted by Clifford used a validated adherence 
measure to calculate rates of non-adherence which may explain why the 
PharmaBase data appears to be so different.41   
A greater proportion of patients with asthma/COPD experienced difficultly 
taking their medicine due to its form than patients with other conditions (at 
intervention: asthma/COPD=1.3%, antiplatelet/anticoagulant=0.2%, type 2 
diabetes=0.2%, hypertension=0.1%).  I would suggest that this may be due 
to the high proportion of asthma/COPD medicines included in the NMS that 
are in inhaler form.  Inhalers require patients to develop good inhaler 
technique skills in a way that oral forms of medicine do not.  This is supported 
by the significantly higher proportion of patients with asthma/COPD who were 
provided with information regarding how to use their medicines compared to 
other conditions (asthma/COPD=27%, antiplatelet/anticoagulant=20%, type 
2 diabetes=20%, hypertension=16%). 
This study indicates that for patients receiving the NMS there is a significant 
reduction in problems reported at the follow-up stage of the service compared 
with the intervention stage.  It is not possible to definitively say if this 
reduction was a result of patients receiving the NMS as there are other factors 
that may have contributed to the reduction.  However it is possible that the 
information provided and actions taken by pharmacists during the service 
played a part in the reduction of adherence related issues.   
This study found that although the frequency of advice provided in follow-up 
consultations was less than at intervention consultations, pharmacists still 
provided information regarding how to use it in 1 in every ten follow-up 
consultations.  This could be interpreted as 10% of patients still being unclear 
about how to take their medicine after the first two stages of the NMS; 
however the results show that just 1% of patients were recorded as needing 
more information about their medicine at follow-up.  Therefore, in this study, 
the advice provided by pharmacists in NMS consultations does not necessarily 
indicate patient demand for information. 
The results show that pharmacists did not only provide support to patients 
who were reported as experiencing problems, but also provided advice and 
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support to patients who were not reported as experiencing problems with 
their medicines. It may be that patients still want information about their 
medicines despite not experiencing problems, or pharmacists still see value in 
providing information to patients who are not experiencing problems.  It 
would suggest that whilst the stated aims of the service are to improve 
adherence and reduce waste, one role of the NMS may be the provision of 
reassurance to patients who have concerns about their medical conditions and 
the new medicines prescribed to them.  The idea that part of the role of a 
pharmacist is to provide reassurance to patients is not a new one; there is 
evidence from studies examining other pharmacy services that patients see 
pharmacists as a source of reassurance about their medicines, especially 
where they do not want to consult their GP fearing a negative reaction to their 
concerns.118,119 
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Chapter 8: Thesis Discussion and Conclusions 
 
8.1 Introduction to thesis discussion 
This chapter will discuss the findings of the five studies conducted in order to 
understand the uptake of the NMS and the barriers and facilitators to the 
VHUYLFH¶V LPSOHPHQWDWLRQ  7KH LPSOLFDWLRQV RI WKHVH ILQGLQJV IRU SROLF\ 
practice and research will be explored and the strengths and limitations of 
each study described. 
8.2  Thesis discussion 
8.2.1  Uptake 
The study investigating the views and opinions of community pharmacists and 
superintendent pharmacists prior to the implementation of the NMS found 
that participants expected the uptake of the new service to be quicker than 
the uptake of MURs had been.  In the post-implementation study, both 
pharmacists and superintendent pharmacists reported that the uptake of the 
NMS had been as fast as expected.  Likewise, the stakeholder interviews 
described the uptake of the NMS as good and faster than the uptake of MURs 
had been. The analysis of PharmaBase records supports this, showing rapid 
uptake of the NMS in the first few months of the service.  In addition the data 
from the evaluation of national PharmaBase records also showed fast uptake 
of the service.92 
A study by Bradley et al found that uptake of MURs was greater in multiple 
pharmacies (chains with 6 or more pharmacies) compared to independent 
pharmacies6.  This trend has been confirmed by other studies8 and several 
reasons suggested.  The MUR service was introduced at the same time as 
major contractual changes for community pharmacy and this may have 
disproportionally affected independent pharmacies as they do not have 
company support for implementing changes8.  In addition it has been 
suggested that company pressure in the form of targets facilitated provision 
of MURs in volumes6,8 although this has been linked to MURs of questionable 
quality119.  The findings from the studies with community pharmacists and 
superintendent pharmacists suggest that the uptake of the NMS may be 
greater in multiple pharmacies as the NMS was introduced at the same time 
as other contractual changes and companies are likely to encourage NMS 
provision by setting targets as they did with MURs.  It is less likely that the 
NMS will experience the same problems with quality as MURs as the eligibility 
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criteria are much narrower (meaning there are far fewer opportunities to 
provide the NMS), and the consultations more focussed. 
8.2.2  Facilitators to NMS implementation 
The studies conducted identified many facilitators to NMS uptake and 
implementation.  A key facilitator identified by both pharmacists and 
stakeholders was the experience of MUR implementation and provision.  
Stakeholders reported that they had aimed to avoid some of the barriers that 
had affected MUR implementation and uptake when they were developing the 
NMS.  A key barrier they wanted to avoid was the accreditation process.  As 
mentioned earlier in the thesis, the accreditation process for MURs took time 
and therefore hindered the uptake of the service.6  By making the 
accreditation requirements for NMS simpler stakeholders hoped to avoid it 
inhibiting the uptake of the service.  Pharmacists and superintendent 
pharmacists agreed that the self-accreditation process for the NMS had 
facilitated implementation and had allowed them to become accredited to 
provide the service from 1st October 2011, facilitating the uptake of the NMS.  
Another barrier experienced during the implementation of MURs that 
stakeholders wanted to avoid was a lack of pharmacist confidence to provide 
the service.6  They consciously chose conditions eligible for the NMS that they 
believed pharmacists would be confident about delivering, as well as 
conditions that would provide the best opportunity for evaluation of the 
service.  This seems to have been successful as the pharmacists that 
participated in the pre- and post-implementation studies reported feeling 
confident that they could counsel patients with the eligible conditions.  This 
confidence in providing the NMS may not stem from the conditions chosen but 
rather the purpose of the service.  Pharmacists and superintendent 
pharmacists reported that counselling patients about new medicines was 
already part of the role of a pharmacist therefore offering the NMS was less of 
a departure from the existing role of a pharmacist than the introduction of 
MURs had been in 2005. 
The confidence that the service was very much a formalisation of what 
pharmacists were already doing appears to have translated into positive 
pharmacist views of the service which was identified as a facilitator to NMS 
implementation.  This supports the findings of other studies investigating the 
factors affecting service implementation that proposed that positive attitudes 
held by health care professionals towards a service can facilitate the 
introduction and uptake of the service.109-111 
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There was concern expressed by stakeholders that pharmacists had been 
under high levels of workload pressure before the introduction of the NMS and 
that pharmacists would see the new service as additional workload that they 
could do without, negatively affecting the uptake of the service.  In addition, 
the pharmacists who participated in the pre-implementation study were 
concerned that they would be put under inappropriate pressure by 
management to provide the NMS, however, in the post-implementation study 
participants reported that the commercial and managerial pressure to provide 
WKH106KDGLQIDFWIDFLOLWDWHGWKHVHUYLFH¶VLPSOHPHQWDWLRQ 
Participants in the post-implementation study reported that the location of a 
pharmacy affected how many opportunities there were to provide the NMS, 
with pharmacies co-located with GP practices seeing a higher proportion of 
prescription items eligible for the service than high street pharmacies.  This 
was supported by the findings of the stakeholder interviews and the results of 
MUR research which found that pharmacies co-located with GP practices 
conducted more MURs than pharmacies further away.7  This finding does not 
match the findings from the study investigating the proportion of prescription 
items that are eligible to receive the NMS which did not find a significant 
difference in the proportion of NMS eligible items between pharmacies at 
different locations (<100m: 0.35%, 100-500m: 0.22%, >500m: 0.2%).  
However, it is important to note that the study was not powered to detect a 
difference in proportions for different locations, and a larger study powered to 
test whether location is associated with the number of eligible items may be 
able to detect a difference. 
Another characteristic of the NMS identified as facilitating the provision of the 
service is the option to conduct the intervention and follow-up consultations 
by telephone.  The results from the stakeholder interviews showed that 
people involved in the development of the NMS were keen that the majority of 
NMS consultations should be conducted face-to-face in the pharmacy, 
however prior to implementation community pharmacists and superintendent 
pharmacists predicted that patients would prefer telephone consultations as it 
would be more convenient for them.  Post-implementation community 
pharmacists and superintendent pharmacists reported that most consultations 
are conducted by telephone, and this was supported by the data from service 
records which showed that where recorded more consultations were 
conducted by telephone than face to face in the pharmacy.  Community 
pharmacists and superintendent pharmacists suggested that patients prefer 
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telephone consultations and that they are easier to fit in with dispensing 
workload within the pharmacy than face to face consultations.  The ability to 
conduct telephone consultations may also improve access to the NMS for 
patients unable to visit their pharmacy in person.   
Whist there are several advantages to conducting consultations by telephone, 
LWLVXQFOHDUZKHWKHUWKH\DUHDVHIIHFWLYHDWPHHWLQJSDWLHQWV¶QHHGVDVIDFH-
to-face consultations.  For example, an important part of supporting patients 
with asthma or COPD is ensuring adequate inhaler technique, however it is 
not possible to check this during a telephone consultation.  Therefore, whilst 
telephone consultations may be suitable for some patients, they may not 
meet the needs of other patients, and pharmacists should consider this when 
arranging the method of conducting NMS consultations. It may also be helpful 
for patients if pharmacists were to use telephone consultations to identify 
patients who would benefit from a face-to-face consultation (such as house-
bound patients with COPD) and offer additional domiciliary visits or 
consultations in the pharmacy. However, the study on which the NMS is based 
conducted consultations by telephone, so whilst there is evidence that 
telephone consultations are effective at improving adherence; it is unknown 
whether face-to-face consultations are as effective. 
8.2.3  Barriers to NMS implementation 
The studies reported in this thesis have identified several barriers affecting 
the implementation of the NMS.  The barrier that caused the greatest amount 
of concern was the payment structure.  There is evidence from other 
pharmacy services that adequate remuneration is an important factor in the 
success or failure of service implementation.6,115,116  The results from the pre-
implementation study showed that the payment structure for the NMS had 
EHHQLGHQWLILHGDVDSRWHQWLDOEDUULHUWRWKHVHUYLFH¶VLPSOHPentation before its 
introduction.  The post-implementation study and the stakeholder interviews 
confirmed that the initial payment structure was not fit for purpose and a new 
payment structure was introduced in May 2012. Whilst some aspects for the 
structure changed, the new structure retained the theoretical assumption that 
0.5% of all prescription items would be eligible for the NMS.  The 
pharmacists, superintendent pharmacists and stakeholders suggested that 
this assumption was not accurate and that the actual opportunity rate was 
lower.  This assumption was tested in the study investigating the proportion 
of prescriptions that are eligible for the service and found that the actual 
opportunity rate for prescription items eligible for the NMS was less than half 
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the theoretical value (actual opportunity rate=0.23% of prescription items, 
theoretical opportunity rate=0.5%).  The implication of this is that pharmacies 
are unable to access the full funding available for the NMS.  Therefore there is 
the potential to change the opportunity rate included in the payment structure 
to further facilitate NMS provision.  Another option would be for additional 
conditions to be included in those eligible for the NMS, increasing the 
opportunity rate for NMS provision.  Neither of these of these options would 
lead to overspend ± something the Department of Health wishes to avoid 
(Chapter 3). 
Before the introduction of the NMS pharmacy remuneration for advanced 
services had been on a per item basis, however the initial payment structure 
for the NMS was very different, with remuneration being linked to dispensing 
volume and thresholds to be met in order to trigger payments.  There are 
several factors that may have led to this change; firstly, stakeholders 
reported that the Department of Health would like pharmacy to move away 
from simplistic per item of service payments and introduce remuneration for 
bundles of care, similar to general practice remuneration for services (Chapter 
3).  Secondly, there were concerns around the per item of service payments 
for MURs, including that pharmacists may have been selecting patients with 
fewer medicines for the service and avoiding potentially complex MURs in 
order to maximise profit (Chapter 3).  The initial NMS payment structure was 
developed to encourage pharmacists to take every opportunity to provide the 
service in order to avoid this pitfall (Chapter3). 
The recording requirements for the NMS were also identified as a barrier to 
service implementation.  The pre-implementation study highlighted that 
pharmacists were uncertain as to the recording requirements prior to the 
introduction of the service which had the potential to hinder the uptake of the 
NMS.  The post-implementation study and the stakeholder interviews also 
identified the recording requirements as a barrier to NMS provision.      
Participants reported that inputting data onto PharmaBase during 
consultations was not possible meaning that pharmacists had to record the 
data twice, doubling their NMS recording workload.  In addition, because 
PharmaBase records were not clinical records and were not integrated into the 
PMR systems used in pharmacies, pharmacists reported that they were having 
to make clinical records of NMS consultations on their PMR systems as well 
which further increased the workload associated with the service.   
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Another barrier pharmacists and superintendent pharmacists reported was 
that there had been early teething issues with PharmaBase.  Analysis of 
service records identified errors in the input of the data which potentially 
supports the idea that pharmacists had problems with recording NMS 
consultations on the database.  Stakeholders reported that there was a lack of 
PMR supplier engagement during the development and prelaunch phase of the 
service.  It is possible that a greater level of PMR supplier involvement could 
have reduced the impact of recording requirements on pharmacist workload.  
Stakeholders also reported that the database had had low uptake which could 
potentially be explained by the extra work that recording NMS consultations 
on PharmaBase created. 
Pharmacist participants were critical of the suggested NMS consultation 
questions and reported that they often create their own consultation structure 
to make it seem more naturalistic (Chapter 4).  However it was found that the 
wording of the consultations had been specifically chosen to make the service 
as similar as possible to the intervention research that the NMS was based on 
and involved a validated question to assess adherence (Chapter 3).  The 
implication of this is that if the pharmacist does not use the adherence 
TXHVWLRQ DV ZULWWHQ WKH\ PD\ QRW JDLQ D YDOLG LQGLFDWLRQ RI SDWLHQWV¶
adherence to new medicines.  However it could be argued that fidelity to the 
question framework used in the RCT is not important provided that the 
concepts are covered during the consultations.  A precise measure of 
adherence is not necessary outside research so long as the questions asked 
by the pharmacist uncover problems patients may be experiencing with their 
new medicines and the service is able to meet its aim to improve adherence. 
Another widely reported barrier to NMS implementation was the lack of GP 
support and engagement.  Studies examining the implementation and 
provision of MURs and other pharmacy services had also identified lack of GP 
support and engagement as a barrier, suggesting that this is not a problem 
unique to the NMS or indeed English pharmacy services.5-7,98-102  This barrier 
was identified as a potential problem prior to the introduction of the service, 
and the post-implementation study and stakeholder interviews confirmed that 
a lack of GP engagement and support for the service had affected the 
implementation of the NMS.  This finding was supported by the analysis of 
PharmaBase records which found a very low rate of GP referrals into the 
service. 
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It would be desirable if there was wider communication between GPs and 
pharmacists generally for the benefit of patients, however the commercial 
environment in which pharmacists work is likely to be a barrier to this.  In 
addition, each pharmacy dispenses prescriptions from a number of GP 
practices and patients from one practice will use many different pharmacies.  
Therefore it might be more beneficial if engagement with pharmacies 
happened at the CCG level rather than the individual practice level. 
Professional pharmacy service provision in Australia may also offer some 
insights into how to improve GP engagement specifically with the NMS.  It has 
been found that collaboration between GPs and pharmacists is minimal for all 
Australian professional pharmacy services except home medicine reviews.101  
A proposed reason for the increased GP engagement with home medicine 
reviews is that the service structure allows GPs to be remunerated for 
engaging with the service in addition to pharmacists receiving payment for 
conducting the consultations, and this allows the service to be sustainable.100  
An examination of the interactions between GPs and pharmacists relating to 
home medicine reviews found that the interactions were mainly administrative 
and suggested that additional remuneration for case discussions after the 
review would further improve GP engagement with the service.100  Another 
factor cited as a possible reason for GP engagement with home medicine 
reviews is that the contribution of each professional to patient care is clearly 
set out in the service protocols.100  These examples from Australia would 
suggest that GP engagement with the NMS in England may be improved if 
GPs received remuneration for referring patients into the service, and 
potentially for communicating with pharmacists regarding patients referred 
back to their prescriber.  In addition, it may help if the NMS service protocol 
clearly describes the roles of GPs and pharmacists in the provision of the 
service. 
8.3  Implications for policy, practice and research 
8.3.1  Implications for policy 
The results from the studies conducted as part of this project suggest that if 
pharmacy stakeholders had been engaged earlier in the development of the 
NMS, some barriers to service implementation and provision may have been 
avoided.  The interviews with policy makers suggested that they had seen the 
electronic recording of NMS consultations as important as it would facilitate 
analysis of service data.  However other studies suggested that the national 
database used to record the service had not had good uptake and that 
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pharmacists had experienced problems associated with that method of 
recording consultations, affecting the quality of data recorded (Chapters 5 and 
7).   
It is possible that had policy makers involved community pharmacists and 
PMR suppliers in the development process, some of these problems could 
have been avoided leading to better quality service data that could be used to 
evaluate the service.  In future I would suggest that policy makers engage 
with pharmacy stakeholders during the development of new services to 
identify potential problems with the practical provision of new services and 
ensure they are addressed before the introduction of the services, and 
therefore avoid them acting as a barrier to service implementation.  I would 
also recommend that when policy makers are developing the recording 
UHTXLUHPHQWV IRU D VHUYLFH WKDW WKH\ FRQVLGHU LWV LPSDFW RQ SKDUPDFLVWV¶
workload.  In addition, with analysis of electronic service records seen by 
policy makers as an important way of assessing the success of a service, it 
would be beneficial if a method of extracting clinical service data from PMR 
systems was developed as this would mean that pharmacists would only need 
to record consultation data once on the PMR system, reducing workload, and 
policy makers would have access to clinical service records for analysis.  
Both prior to and during NMS implementation, the payment structure was 
identified as a key barrier with the assumption underpinning the structure 
(that 0.5% of prescription items are eligible for the NMS) being found to be 
inaccurate (actual opportunity rate: 0.23% of prescription items).  I would 
suggest that this should be addressed if the service is going to continue to be 
funded in the future.  One option would be to change the payment structure 
to include the actual opportunity rate, allowing pharmacists to access the full 
funding available for the service.  Alternatively, it would be possible for policy 
makers to expand the conditions included in the service (and therefore the 
number of opportunities to provide the NMS) without exceeding the funding 
allocated for the service. 
Furthermore it would have been possible to gather information regarding the 
actual rate of opportunities to potentially provide the NMS during the service 
development process, reducing the likelihood of the payment structure 
hindering service implementation.  Given the evidence that adequate 
remuneration is important to the success of a service, I would strongly 
recommend that policy makers base the payment structures for future 
services on robust evidence in order to prevent the structure negatively 
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affecting the implementation of new service.  For example, using GP 
prescribing data to calculate the theoretical opportunity rate for the NMS 
would be more likely to provide accurate numbers of new medicines 
prescribed than using pharmacy PMRs. 
One criticism levelled at stakeholders involved in the development and launch 
of the NMS by pharmacists and superintendent pharmacists was that the 
period between the announcement of the new service and its launch was very 
short and that some important details were not made available until very 
close to the start date for the service.  It was suggested that this could have 
led to pharmacies not being prepared to provide the service immediately, 
affecting the uptake of the NMS.  I would suggest that where possible policy 
makers should provide information in a timely manner and provide a 
timetable for the publication of service details so that pharmacies can plan 
their preparation for any new service accordingly. 
The studies described in this thesis found a widespread lack of GP 
engagement with the service.  Given that this is not a problem unique to the 
NMS but one experienced globally with pharmacy services, I believe that it is 
not enough to rely on individual pharmacists to engage GPs.  I would suggest 
that policy makers need to encourage GPs to support pharmacy services by 
providing incentives to GPs, perhaps in the form of quality and outcomes 
framework (QOF) targets.  I would also suggest that providing a formal route 
of communication between GPs and pharmacists would be helpful, perhaps by 
allowing pharmacists use NMSmail (an email service available to NHS staff). 
8.3.2  Implications for practice 
Participants from the stakeholder interviews and the pre- and post-
implementation studies emphasised the growing importance of clinical 
services to pharmacy as a profession.  This means that good pharmacist 
consultation skills are also becoming more important and some stakeholders 
and superintendent pharmacists reported that community pharmacists could 
benefit from further communication skills training.  A study examining MUR 
consultations suggested that patient centred consultation training could 
improve the quality of MUR consultations, which could potentially improve the 
quality of other pharmacy consultations such as the NMS.113  Health Education 
England (HEE) published practice standards for consultation skills in pharmacy 
practice in March 2014 and in partnership with pharmacy stakeholders has set 
up a website providing training and assessment tool for improving 
SKDUPDFLVWV¶ FRQVXOWDWLRQ VNLOOV (www.consultationskillsforpharmacy.com).137  
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Therefore I would recommend that pharmacists should use these tools to 
evaluate their consultations skills and where appropriate, undergo further 
training in patient centred consultation skills. 
The growing importance of clinical services to the pharmacy business model 
also means that pharmacies should consider changing their characteristics in 
order to facilitate the provision of services.  In the post-implementation study, 
participants suggested that being able to conduct consultations in the 
evenings and at weekends benefited NMS provision.  Participants also 
reported a growing demand on consultation rooms.  Therefore I would 
suggest that if pharmacies are to expand the number of clinical services they 
offer they should consider matching their opening hours to patient need, and 
building further consultation rooms to increase capacity for service provision 
where a pharmacy employs more than one pharmacist. 
Participants in the pre- and post-implementation studies suggested that 
pharmacy support staff had the ability to facilitate service provision by 
HQJDJLQJZLWKWKHVHUYLFHDQGUHGXFLQJSKDUPDFLVWV¶ZRUNORDG IUHHLQJWKHP 
up to conduct consultations. Participants reported that support staff were 
more likely to engage with a new service if they had received training about 
it.  Therefore I would recommend that pharmacy employers provide their non-
pharmacist staff with protected training time in order to learn about new 
services, and ensure that there are adequate staffing levels for pharmacists to 
conduct consultations effectively. 
Research has identified poor GP engagement with pharmacy services globally 
and the studies reported in this thesis found a widespread lack of GP 
engagement with the NMS.5-7,198-102  Participants reported that GP 
engagement was better where good GP-pharmacist relationships already 
existed.  Therefore I believe that pharmacists should pro-actively develop 
their relationships with local GP practices in order to improve GP engagement 
with all pharmacy services, not just the NMS.  Establishing good local 
relationships will also help facilitate the implementation of future services. 
8.3.3  Implications for research 
Conducting this project has highlighted the lack of published information 
available regarding the development and negotiation of new pharmacy 
services due to the closed nature of service negotiations.  This seems to have 
led to frustration that the evidence desired by policy makers is not always 
available.  I believe that it is important that academic researchers should 
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work alongside policy makers, providing the information they need to make 
informed decisions regarding new services.  The stakeholder interviews in this 
project provide some insight into what information policy makers need during 
service development and negotiations, however I believe that further research 
is necessary.  
Policy makers participating in the stakeholder interviews stressed the 
importance of basing new services on robust evidence.  In particular, they 
identified cost effectiveness information regarding interventions as being an 
important factor as to whether the intervention would be developing into a 
pharmacy service.  Therefore I would recommend that economic evaluations 
should be incorporated into evaluations of interventions as a matter of course 
in order for policy makers to have robust evidence to base their decisions on.   
There has been discussion in this thesis about whether pharmacists have the 
necessary consultations skills to provide NMS effectively by telephone.  
Community pharmacists reported that they already have the skills, which 
were developed through MUR provision; however stakeholders and some 
superintendent pharmacists suggested that the skills needed to provide MUR 
consultations may be different to the skills needed for NMS telephone 
consultations.  I believe that this is an area that should be studied as this is 
the first pharmacy service that can be conducted by telephone and may open 
the way for more telephone based services to be introduced. 
This project has also highlighted the ability of information technology (IT) to 
facilitate or hinder service provision. Whist there appears to be very little 
literature about how PMR systems can facilitate the provision of pharmacy 
services, an international study found that IT solutions are important to the 
provision of professional services and that a lack of IT solutions could threaten 
SKDUPDF\¶VUROHLQSDWLHQWFHQWUHGFDUH117  As the presence of a NMS module 
in PMR systems appears to be an important facilitator to NMS implementation, 
perhaps further research in this area would be beneficial. 
 
8.4  Strengths and limitations 
8.4.1  Stakeholder Interviews 
The number of participants in this study is low which could affect the 
generalisability of the results.  However there was a limited pool from which 
to recruit participants due to the closed nature of the negotiations and limited 
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number of stakeholders involved with NMS implementation.  Therefore a 
strength of this study is that participants were recruited from both parties 
engaged in the negotiations for the NMS as well as from each area of 
stakeholder involvement to ensure that the results gained would be as valid 
and reliable as possible.   
8.4.2  Pre-implementation interviews and focus groups 
The participants in this study agreed to take part by responding to invitations.  
They could reasonably be expected to have a greater awareness and interest 
in the service than the general pharmacist population as pharmacists with a 
low awareness or interest in the service might have been less likely to 
respond to the invitation to participate.   
A strength of this study is that both community pharmacists and 
superintendent pharmacists participated, providing insight into the 
introduction of the NMS as experienced on the ground by pharmacists and 
also from the perspective of pharmacy employers. In addition participants 
were recruited from across the pharmacy sector giving a wide range of views 
and experiences of the pharmacy profession regarding the NMS. However the 
number of community pharmacists that participated in this study was limited 
by a low response rate and the short time between the announcement of the 
services and implementation (5 months).  Likewise, the number of 
superintendent pharmacists that participated was also low, but represented 
around 23% of the UK pharmacy market.   
One of the focus groups was conducted with community pharmacists recruited 
at a training day provided by their employer that included some training on 
the NMS.  Due to the training received, awareness and understanding of the 
service were higher than in other focus groups but the views and experiences 
expressed were similar to those expressed in the other focus groups. 
The participants were asked to comment on aspects of the service before the 
NMS had been implemented.  The disadvantage of doing this was that the 
participants were less familiar with the service than they would have been had 
they been providing the NMS, however it was necessary to elicit their views at 
that stage in order to compare the findings with their experiences of 
conducting the NMS which were collected 4 to 6 months after the service had 
been implemented.   
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8.4.3  Post-implementation interviews and focus groups 
Pharmacists and superintendent pharmacists who had previously taken part in 
a study exploring their views of the NMS prior to its implementation were 
invited to take part in this study.  They could reasonably be expected to have 
a greater awareness and interest in the service than the general pharmacist 
population as they had already participated in one study regarding the NMS.  
The number of community pharmacists who participated in this study was 
limited by the number of pharmacists who had participated in the earlier 
study which had experienced a low response rate to invitations to participate.  
Due to some pharmacists not responding, additional participants were 
recruited through personal contacts.   Likewise, the number of superintendent 
pharmacists that participated was also low, although all superintendent 
pharmacists who participated in the pre-implementation study agreed to 
participate in the post-implementation study.  The superintendent 
pharmacists who participated represented around 23% of the UK pharmacy 
market.  A strength of the study is that participants were recruited from 
across the community pharmacy sector; however whilst a range of views were 
expressed, the exploratory nature of the study means that not all opinions 
about the service were expressed in the study.  In addition both community 
pharmacists and superintendent pharmacists participated, providing different 
perspective of the introduction of the NMS.  
8.4.4  Eligibility study 
One limitation of this study is that just 8 pharmacies in Nottingham were 
sampled (out of a total of 97) so it is possible that the study pharmacies 
would not reflect pharmacies locally.  However a strength of this study is that 
it endeavoured to reflect the distribution of all pharmacies in Nottingham 
when sampling pharmacies.  It was not possible to exactly match the 
distribution of pharmacies in Nottingham however, as there were just 2 
pharmacies available in the <100m group that matched the inclusion criteria.   
Another limitation of the study is that all the pharmacies sampled were 
located in Nottingham and belonged to the same large chain, so it is possible 
that the pharmacies did not represent community pharmacy nationally.  In 
addition the study collected 1000 items per pharmacy over a maximum of 6 
days so there is a possibility that the 1000 items collected from each 
SKDUPDF\ GLG QRW UHSUHVHQW D W\SLFDO ZHHN¶V SUHVFULSWLRQ LWHPV IRU WKDW
pharmacy.  However the pharmacies were selected to include a range of types 
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and locations across the Nottingham area and data collection was spread over 
five months in an attempt to minimise these effects.   
In this study pharmacies were excluded if they dispensed less than 1000 
LWHPVSHUZHHNRU LI WKHSKDUPDF\¶V VWDIILQJ OHYHOV UHTXLUHGPRUH WKDQRQH
member of staff to take in and hand out prescriptions as this could have 
introduced potential selection bias.  These demographic exclusions may 
reduce full generalizability and is a limitation of the study. 
The pharmacies in this study were sampled over 5 months which could be a 
limitation as number and type of prescription items can vary over time, 
meaning that the data collected from an individual pharmacy may not reflect 
its long term dispensing patterns.  However, by sampling pharmacies over 5 
months the effect of seasonal prescribing patterns on the whole sample was 
reduced. 
8.4.5  Analysis of PharmaBase records 
This study examined national service data for one pharmacy chain as 
recorded using PharmaBase.  Whilst using national data avoids geographical 
variation and provides a better picture of the national experience of NMS, 
using data from one pharmacy chain may mean that the results do not reflect 
data from across that pharmacy sector, particularly independent pharmacies. 
The study was affected by the limitations of the PharmaBase data.  There was 
evidence of input errors in the data, especially regarding the dates of 
registration, intervention and follow-up, and there was some evidence that in 
some cases the records were not complete.  It is likely that these problems 
occurred partly due to limitation of the PharmBase system as a method of 
recording service data.  PharmaBase was not designed to be a clinical record 
for the NMS and its use was not compulsory.  Therefore using the 
PharmaBase system required pharmacists to record the service in at least two 
places; on the PMR as a clinical record, and on PharmaBase.  It is likely that 
this increased the number of errors and omissions in the PharmaBase data.  
Another limitation of the PharmaBase data, related to it not being a clinical 
record, is that the records were made using tick boxes or selecting predefined 
options to questions.  Therefore the options for pharmacist to select were 
limited and may have led to some data not being recorded.  For example the 
potential problems patients could be recorded as experiencing were limited 
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therefore there may have been additional problems identified during the NMS 
consultations that were not recorded using PharmaBase. 
8.4.6 Reflections on my involvement in the qualitative studies 
My background is that I am a UK qualified community pharmacist and have 
experience providing advanced services.  Personally I am an advocate for 
community pharmacy services, believing that pharmacists are an under-
utilised resource for the NHS and have the potential and clinical knowledge to 
make a greater contribution to patient care than is possible at present.  My 
experience of being a community pharmacist and personal view of pharmacy 
services had the potential to introduce bias into the studies, as I may have 
been looking for results that reflect favourably on community pharmacy. All 
participants in the qualitative studies were made aware that I am a 
pharmacist as some participants already knew.  In an effort to reduce the bias 
I could have introduced, the interview schedules and focus group topic guides 
used open questions and did not include leading questions (Appendices 1-3). 
In addition, my supervisors facilitated the focus groups while I made notes 
(all three supervisors of this project also have experience of practising as 
community pharmacists, although not during the lifetime of this project).  
When analysing the data a conscious effort was made to be objective and to 
derive themes directly from the data, and the coding was validated by a 
supervisor to reduce the likelihood of me introducing bias into the results.  
Whilst efforts were made to reduce the impact of my supervisors and my 
views on the findings of these studies, it is possible that further assessment of 
the plausibility of the results could have been gained by asking participants to 
review the interpretation of the data.  However, this was not possible due to 
concerns regarding confidentiality and the IXQGLQJERG\¶VFRQFHUQVUHJDUGLQJ
commercial sensitivities. 
8.5  Thesis conclusions 
The NMS was developed from an intervention determined to be a cost 
effective way of improving adherence.  When developing the service it was 
important to policy makers that it should be based on evidence, evaluated, 
and stay within a funding envelop without risk of overspend.  The 
implementation of the NMS went well with rapid uptake of the service by 
pharmacies.  There have been several facilitators of NMS implementation 
identified which include positive pharmacist attitudes towards the service, the 
service being a formalisation of current practice, the accreditation procedure, 
pressure to provide the NMS, the experience gained from providing MURs, 
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and certain pharmacy characteristics such as location, and characteristics of 
the service including the option for telephone consultations, as well as other 
pharmacy staff involvement.  The barriers identified as affecting NMS 
implementation include a lack of GP engagement, the restrictions on eligible 
patients, pharmacist communication skills, increased pharmacist workload, 
and the payment structure.  The problems associated with the payment 
structure stemmed mainly from the actual opportunity rate to provide the 
NMS being nearly half of the theoretical rate.  Whilst the changes to the 
payment structure have reduced the importance of the opportunity rate, it is 
still based on the theoretical opportunity rate of 0.5% of prescription items 
and should be reviewed.  During the consultations pharmacists provided 
information about the new medicine in two thirds of cases and provided 
healthy living advice in over a fifth of cases.  Information and advice was not 
just provided to patients experiencing problems, pharmacists also counselled 
patients who were not reported to have any problems with their medicines.  
There was a significant decrease in recorded adherence related problems 
between the intervention and follow-up consultations that may indicate that 
the service has the potential to improve adherence. 
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Appendix 1: Stakeholder Interview Schedule 
 
Development and preparation 
What was your role in the development of the NMS? 
Could you describe to me how the service came about?  What were the 
driving forces behind its development? 
What did your organisation do to prepare for the introduction of the NMS?   
Implementation of the NMS 
How has the roll out of NMS gone?  
± What has gone well and what has gone less well? 
What has the uptake of NMS been like? 
- PharmaBase and non-PharmaBase 
What feedback do you have regarding the numbers of eligible patients 
encountered? 
How does the roll out of NMS compare to the implementation of MURs in 
2005? 
Payment structure 
What are your views about the payment structure for the NMS? 
Has the current payment structure affected the success of the NMS roll out? If 
so How? 
'R\RXNQRZZKDWSURSRUWLRQRIFRPSOHWHG106¶ are reimbursed? 
The Effect of NMS introduction 
How has the introduction of the NMS affected you and your organisation? 
Do you think the NMS has affected the role of the pharmacist, and the 
relationships between patients, GPs and pharmacists? How? 
Has the introduction of the NMS affected other pharmacy activities/services?  
How? 
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When and how did you first hear about the NMS? 
What do you understand the NMS as being? 
Will your pharmacy be offering this service from October 1st? 
How do you think the NMS will affect the role of the pharmacist?  What does 
the new service mean for pharmacists? 
Training and Self-assessment 
What training have you received/will you receive? 
What (if any) training have your staff received/ will your staff receive? 
Is there anything further that the management of your pharmacy could do to 
support you in preparation for the roll out of the NMS? 
What do you think of the self-assessment requirement?  How does it compare 
to the MUR accreditation? 
Eligible conditions 
Do you think the conditions chosen are appropriate for the service?  Why? 
Will the service provided vary between patients with different conditions?  
Why? 
Do you foresee any problems with offering one service for several conditions? 
If you had to choose two more conditions or medicine groups to include, what 
would they be? 
Initiation 
How will you identify eligible patients? 
Are there any problems you foresee with the identification of patients? 
How could these problems be addressed? 
The service specification suggests that patients may be referred to the service 
by prescribers in both primary and secondary care.  Do you see this 
happening?  How? Why? 
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Intervention and follow-up 
The second two parts of the service can be conducted either in face-to-face 
consultations, or by telephone.  What would your preference be? Why? 
The service requires pharmacists to refer patients back to their prescriber if 
there are problems that cannot be dealt with by them.  How do you see this 
happening? 
What do you think about the questions in the interview schedule? 
Service paperwork 
What do you think about the paperwork for the NMS? 
How do you think pharmacists will fill it in? 
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Appendix 3: Pre-Implementation Superintendent Pharmacist 
Interview Schedule 
 
Contractual Changes 
When and how did you first hear about the NMS? 
What will the NMS mean for you, your business and your patients? 
How do you think the NMS will affect the role of the pharmacist, and the 
relationships between patients, GPs and pharmacists? 
The last big contractual changes happened in 2005 with the introduction of 
MURs.  How is the situation now with the introduction of the NMS compare to 
then? 
How did the roll out of MURs in your pharmacies go?  What went well?  What 
could have gone better?  What did you learn from that and how will you put 
that into practise for the roll out of NMS? 
Payment Structure 
What are your views about the payment structure for the NMS? 
The payment for the NMS is very different from the payment for MURs, how 
do you think this will affect the roll out of the new service? 
How do you think the payment structure will work in practise?  For example, 
at what point during the service will payment be claimed for a patient 
receiving the NMS? 
Preparation for the Roll Out 
How has/is your company preparing for the roll out of the NMS? 
What training have your pharmacists received/will your pharmacists receive? 
Are the other members of pharmacy staff receiving training?  How will they be 
involved in providing the service? 
How did you develop the training?  What resources did you use? 
How are you supporting pharmacists in the self-assessment procedure? 
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Appendix 4: Post-Implementation Focus Group Topic Guide 
 
Introduction: 
Is your pharmacy offering the NMS? 
The introduction of the service: 
- Have you had any feedback from patients about the service? What 
have patients told you about the service? (Any anecdotes?) 
- How has the implementation gone from your perspective? Have 
there been things that were easier than expected? Have there been 
things that were harder than expected? 
- What feedback have the staff given you about the service and its 
implementation? 
Has the introduction of the NMS affected your role in the pharmacy? 
Do you think offering the NMS has affected any other services or activities 
you do? 
Training: 
Do you feel the training you received before the introduction of the service 
was adequate?  Did it prepare you to provide the NMS? 
Eligible Patients: 
How many eligible patients does your pharmacy see in an average week? 
(patients who can be signed up i.e. not patient reps) 
What is the most common condition in patients who receive the NMS? 
Do you have a preference for any particular condition/medicine? 
 
Carrying out the service: 
How does your pharmacy identify patients? 
Have you had any patients referred into the service from primary or 
secondary care? 
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When carrying out the intervention and follow-up, do you do more face-to-
face or telephone conversations? 
Have you experienced any difficulty with following up patients?  How common 
is it? 
Do you use the questions provided? 
In your experience, how many patients have experienced problems? 
Recording the service: 
How do you record the consultations?  Do you use a paper-based system or 
an IT program? 
What do you like and dislike about the system you use? 
Payment structure: 
Do you know what band your pharmacy is reaching? (e.g. 20%) 
Do you know how many complete NMS you are reimbursed for compared to 
the number you have carried out? (Do you know what percentage you are 
doing but not being paid for?) 
What do you think about the payment structure?   
It was developed to incentivise pharmacies; do you think it achieves this? 
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Appendix 5: Post-Implementation Superintendent Pharmacist 
Interview Schedule 
 
Development and preparation 
So when we last met we spoke about the build-up and preparation for the 
NMS.  Briefly, how did your pharmacies prepare for the NMS? 
 
Implementation of the NMS 
How has the roll out of NMS gone?  
± What has gone well and what has gone less well? 
- What system do you use to record NMS?  Why did you decide to 
use that system? 
What has the uptake of NMS in your pharmacies been like? 
What feedback do you have regarding the numbers of eligible patients 
encountered in your pharmacies? 
How does the roll out of NMS compare to the implementation of MURs in 
2005? 
 
Payment structure 
What are your views about the payment structure for the NMS? 
Has the current payment structure affected the success of the NMS roll out? If 
so How? 
Do you know what proportion of NM6¶FRPSOHWHGLQ\RXUSKDUPDFLHVDUH
reimbursed? 
 
The Effect of NMS introduction 
How has the introduction of the NMS affected your business? 
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How has the introduction of the NMS affected your patients?  Do you have any 
stories to illustrate that? 
Do you think the NMS has affected the role of the pharmacist, and the 
relationships between patients, GPs and pharmacists? How? 
Has the introduction of the NMS affected other pharmacy activities/services?  
How? 
 
  
182 
 
Appendix 6: A Table of the Complete List of all Medicines Registered 
for the NMS from the Analysis of PharmaBase Data. 
 
Medicines Frequency Percent 
Acarbose 20 0.02 
Acebutolol 3 0.00 
Acenocoumarol 12 0.01 
Adipine 9 0.01 
Aliskiren 9 0.01 
Aminophylline 50 0.05 
Amlodipine 13487 14.51 
Amlodipine/Valsartan 12 0.01 
Apidra 3 0.00 
Aspirin 2500 2.69 
Atenolol 1011 1.09 
Atenolol/Nifedipine 1 0.00 
Bambuterol 1 0.00 
Beclometasone 5016 5.40 
Beclometasone/Formoterol 815 0.88 
Bendroflumethiazide 3106 3.34 
Bisoprolol 4137 4.45 
Budesonide 233 0.25 
Budesonide/Formoterol 1561 1.68 
Candesartan 1442 1.55 
Captopril 2 0.00 
Carvedilol 74 0.08 
Celiprolol 3 0.00 
Chlortalidone 116 0.12 
Ciclesonide 24 0.03 
Clonidine 29 0.03 
Clopidogrel 2143 2.30 
Co-tenidone 14 0.02 
Cyclopenthiazide 1 0.00 
Dabigatran 81 0.09 
Diltiazem 605 0.65 
Dipyridamole 161 0.17 
Dipyridamole/Aspirin 17 0.02 
Doxazosin 1891 2.03 
Enalapril 214 0.23 
Enalapril/Hydrochlorothiazide 3 0.00 
Eprosartan 2 0.00 
Exenatide 78 0.08 
Felodipine 1264 1.36 
Felodipine/Ramipril 4 0.00 
183 
 
Medicines Frequency Percent 
Fluticasone 177 0.19 
Fluticasone/Salmeterol 2630 2.83 
Formoterol 105 0.11 
Fosinopril 4 0.00 
Glibenclamide 9 0.01 
Gliclazide 1828 1.97 
Glimepiride 186 0.20 
Glipizide 20 0.02 
HumaJect 2 0.00 
Humalog 19 0.02 
Humulin 75 0.08 
Hydralazine 27 0.03 
Indacaterol 57 0.06 
Indapamide 3086 3.32 
Indoramin 6 0.01 
Insulatard 21 0.02 
Insulin 18 0.02 
Insuman 9 0.01 
Ipratropium 373 0.40 
Ipratropium/Salbutamol 4 0.00 
Irbesartan 232 0.25 
Irbesartan/Hydrochlorothiazide 14 0.02 
Isradipine 1 0.00 
Labetalol 77 0.08 
Lacidipine 118 0.13 
Lantus 76 0.08 
Lercanidipine 739 0.79 
Levemir 44 0.05 
Linagliptin 85 0.09 
Liraglutide 129 0.14 
Lisinopril 3171 3.41 
Lisinopril/Hydrochlorothiazide 56 0.06 
Losartan 5167 5.56 
Losartan/Hydrochlorothiazide 105 0.11 
Metformin 4653 5.00 
Metformin/Sitagliptin 34 0.04 
Methyldopa 37 0.04 
Metolazone 11 0.01 
Metoprolol 87 0.09 
Minoxidil 7 0.01 
Mometasone 18 0.02 
Montelukast 702 0.76 
Moxonidine 114 0.12 
Nadolol 2 0.00 
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Medicines Frequency Percent 
Nateglinide 2 0.00 
Nebivolol 117 0.13 
Nedocromil 1 0.00 
Nicardipine 2 0.00 
Nifedipine 447 0.48 
NovoMix 63 0.07 
NovoRapid 55 0.06 
Olmesartan 62 0.07 
Olmesartan/Amlodipine 4 0.00 
Olmesartan/Hydrochlorothiazide 5 0.01 
Oxprenolol 2 0.00 
Perindopril 925 0.99 
Perindopril/Indapamide 10 0.01 
Phenindione 1 0.00 
Phenoxybenzamine 1 0.00 
Pindolol 2 0.00 
Pioglitazone 323 0.35 
Pioglitazone/Metformin 9 0.01 
Prasugrel 37 0.04 
Prazosin 9 0.01 
Propranolol 560 0.60 
Quinapril 3 0.00 
Ramipril 9578 10.30 
Repaglinide 22 0.02 
Rivaroxaban 29 0.03 
Roflumilast 3 0.00 
Salbutamol 8313 8.94 
Salmeterol 757 0.81 
Saxagliptin 273 0.29 
Sildenafil 7 0.01 
Sinthrome 4 0.00 
Sitagliptin 1374 1.48 
Sitagliptin/Metformin 16 0.02 
Sitaxentan 2 0.00 
Sodium cromoglicate 4 0.00 
Tadalafil 5 0.01 
Telmisartan 23 0.02 
Telmisartan/Hydrochlorothiazide 2 0.00 
Terazosin 21 0.02 
Terbutaline 335 0.36 
Theophyllin 46 0.05 
Theophylline 39 0.04 
Ticagrelor 6 0.01 
Timolol 2 0.00 
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Medicines Frequency Percent 
Tiotropium 2468 2.65 
Tolbutamide 15 0.02 
Trandolapril 1 0.00 
Valsartan 96 0.10 
Valsartan/Hydrochlorothiazide 7 0.01 
Verapamil 131 0.14 
Vildagliptin 30 0.03 
Vildagliptin/Metformin 19 0.02 
Warfarin 2195 2.36 
Xipamide 5 0.01 
Zafirlukast 17 0.02 
 
